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Summary  
The prediction of adverse outcomes following major non-cardiac surgery is 
complex.  Clinical variables and risk factors, functional status, 
electrocardiography and non-invasive cardiac investigations can all be used to 
assess and stratify the risk of post-operative cardiac morbidity or mortality.  
Multiple factors can be combined into bed-side scoring systems.  Increasingly, 
cardiac biomarkers such as b-type natriuretic peptide (BNP) have been shown to 
predict heart failure and mortality in non-surgical populations.  
In the studies in this thesis, I have investigated the incidence of peri-operative 
cardiac morbidity and mortality in patients undergoing major non-cardiac 
surgery and identified clinical variables that predicted adverse outcomes.  I have 
tested the utility of BNP for prediction of cardiac complications.  I have 
investigated the long-term survival of the patients in the cohort to identify 
predictors of reduced survival.  I have examined the predictive value of the pre-
operative 12-lead ECG for adverse outcomes.  I have also studied the utility of a 
commonly used risk scoring system, the revised cardiac risk index (RCRI), for 
prediction of cardiac events.   
The study was a prospectively performed observational study of consecutive 
patients undergoing major surgery.  The cohort consisted of patients undergoing 
aortic surgery (25.8%), lower limb bypass surgery (29.8%), amputation (25.2%) 
and laparotomy (20.0%).  The patients underwent post-operative screening for 
myocardial infarction; consisting of serial ECG and troponin measurement.  The 
end-points were major adverse cardiac event (MACE), defined as myocardial 
infarction or cardiac death and all-cause mortality.  Long term follow-up was 
performed following discharge.  
Three hundred and forty-five patients were recruited to the trial.  Forty-six 
patients (13.3%) suffered a peri-operative MACE and twenty-seven patients 
(7.8%) died in the post-operative period (six weeks).  Independent predictors of 
peri-operative MACE were pre-operative anaemia, urgent surgery, a history of 
hypertension and age > 70 years.  Pre-operative BNP was significantly higher in 
patients who subsequently went on to have a peri-operative MACE, compared 
with those who did not.  An elevated BNP was an independent predictor of both 
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MACE and peri-operative mortality on multivariate analysis.  A low BNP was 
highly indicative of an uneventful post-operative period, with a negative 
predictive value of 96% for MACE and 95% for all-cause mortality.  Traditional 
clinical markers of heart disease, such as past history of ischaemic heart disease, 
prior myocardial infarction, cerebro-vascular disease or history of cardiac failure 
provided no predictive utility for either MACE or mortality.    
The mortality rate at 1 year was 19.1%.  The median follow-up period was 953 
days (IQR 661-1216 days).  Age > 70 years, diabetes, hypertension, renal 
impairment, a history of left ventricular failure, anaemia and urgent surgery 
were associated with reduced long-term survival.  A BNP concentration of 87.5 
pg/ml provided the best combined sensitivity and specificity for prediction of 
long-term mortality.  Patients with an elevated BNP (>87.5 pg/ml) had a 
significantly reduced survival and BNP >87.5 pg/ml independently predicted 
reduced survival on Cox regression analysis.  Urgent surgery and anaemia were 
also independent predictors of reduced long-term survival. 
An abnormal ECG was observed in 41% of patients recruited.  An abnormal ECG 
was associated with an increased peri-operative MACE and mortality rate.  
Ventricular strain and prolonged QTc (>440ms) were ECG abnormalities that 
predicted MACE on multivariate analysis.  Patients with an abnormal ECG, but no 
prior cardiac history, represent a high risk group that may benefit from 
optimisation. 
The studies in this thesis have identified that BNP, a simple pre-operative blood 
test, provides valuable information regarding the risk of both peri-operative 
morbidity and mortality, and long-term survival after major non-cardiac surgery.  
Improved risk stratification could allow targeted intervention and medical 
optimisation prior to surgery with the aim of modifying the risk of adverse 
outcomes. 
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1 Introduction 
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1.1 Cardiac morbidity and mortality following major non-
cardiac surgery – what is the scale of the problem?  
Peri-operative cardiac events are the commonest cause of peri-operative 
mortality in the Western world.1  Worldwide, it is estimated that over 200 
million major surgical procedures are performed annually, with the majority of 
cases performed in developed countries.2  This number will increase as health 
expenditure rises in developing countries, as will concerns about surgical safety 
peri-operative morbidity and mortality.3  A very conservative estimation of 
between 500,000 and 900,000 patients worldwide will suffer a peri-operative 
cardiac event following non-cardiac surgery (NCS).4  Cardiac morbidity presents 
a significant burden to both patients and healthcare providers.  Furthermore, in 
the setting of an aging population, this will become a more pressing problem in 
the future.   
Numerous studies have presented the rates of peri-operative major adverse 
cardiac events (MACE) and mortality in patients undergoing NCS. The results of 
many of these studies will be individually discussed later in this chapter.  
However, from the larger studies and meta-analyses, the reported incidence of 
major cardiac complications ranges from 1% to 28%.5–8  Unsurprisingly, the 
observed MACE rate is very variable, especially when considering studies 
performed within different surgical subspecialties.  For example, patients 
undergoing major vascular surgery have a high underlying incidence of overt and 
occult heart disease and accordingly a high rate of peri-operative events are 
found.9  In a historical paper from the Cleveland Clinic Foundation, Hertzer and 
colleagues performed percutaneous coronary angiography on 1000 patients prior 
to elective vascular surgery.10  Severe coronary artery disease (CAD), defined as 
coronary artery stenosis >70% in one or more vessel, was present in 60% of cases.  
Only 8% of patients had normal coronary arteries.  A recent review found that 
the incidence of post-operative myocardial infarction (MI) amongst elective 
vascular patients was as high as 26%.11    
The study methodology will also affect the observed MACE rate.  Reporting of 
cardiac events is often higher in prospectively collected cardiac outcome studies 
with active screening for peri-operative cardiac events, than from retrospective 
studies relying on clinical variables and outcomes gathered from databases.12  
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For example, Davenport and colleagues analysed a prospectively collected 
National Surgical Quality Improvement Program (NSQIP) database from 142 North 
American institutions.8  They included over 180,000 patients undergoing a 
variety of surgical procedures, including major abdominal (39%) and vascular 
(16%) surgery, and more minor procedures, such as hernia surgery (25%).  This 
large study revealed a modest 1.29% unscreened cardiac event rate.  
Interestingly, of the patients who suffered an event, 59% went on to die on that 
admission.  This high same admission mortality rate following a peri-operative MI 
has been identified in other studies.4,13  Prospective screening for cardiac events 
post-operatively will inevitable identify a number of ‘silent’ cardiac events.14  
Evidence suggests that clinically unrecognised MI carries a similar prognosis to 
patients with a clinically apparent MI.15         
Large studies examining peri-operative cardiac morbidity and mortality in the 
United Kingdom and, in particular, Scotland are lacking.  National English 
database analysis studies exist that present mortality figures for elective and 
emergency NCS, however little qualitative details about cardiac morbidity can 
be extracted from these studies.16,17  Accurate data regarding the scale of the 
problem locally, and information for clinicians to allow risk stratification, is 
crucial. 
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I have found this literature review of peri-operative cardiac morbidity 
challenging from a number of perspectives.  The following issues were 
encountered frequently while writing this chapter; 
 Diverse study methodology, 
 Variable or unclear endpoints, 
 Heterogeneous populations, 
 Rapidly evolving technologies, both surgical and medical. 
Finally, and perhaps most notable, are the shocking allegations of research fraud 
directed at the chief investigator of one the world’s leading research institutes 
into peri-operative cardiac morbidity.  This will be discussed at the end of this 
chapter. 
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1.2 Pathophysiology of post-operative myocardial 
infarction (PMI) 
A universal definition of myocardial infarction has been published by the joint 
task force from the European Society of Cardiology (ESC), the American College 
of Cardiology (ACC), the American Heart Association (AHA) and the World Heart 
Federation.  The criteria for the diagnosis of acute myocardial infarction are 
detailed in Figure 1.1. 
Figure 1.1  Criteria for diagnosis of acute myocardial infarction   
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria for Acute Myocardial Infarction (MI), adapted from18 
 
The term MI should be used when there is evidence of myocardial necrosis in a 
setting consistent with myocardial ischaemia.  Any of the following criteria meets the 
diagnosis of myocardial infarction. 
 
 Detection of the rise and fall of cardiac biomarkers (preferably troponin) 
together with evidence of myocardial ischaemia with one of the following: 
 Ischaemic symptoms, 
 ECG changes suggesting acute ischaemia (new ST-T changes or new 
left bundle branch block), 
 Development of pathological Q waves on ECG, 
 Imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality. 
 Sudden, unexpected cardiac death, involving cardiac arrest with symptoms 
suggestive of myocardial ischaemia and accompanied by ischaemic ECG 
changes. 
 For patients undergoing percutaneous coronary intervention (PCI) with 
normal baseline troponin, elevations of cardiac biomarkers are indicative of 
necrosis.   Elevations of biomarkers 3x99th percentile of upper reference limit 
(URL) define PCI-related MI . 
 For coronary bypass grafting (CABG) with normal baseline troponin, elevation 
of biomarkers greater than 5x99th percentile of (URL) define CABG-related 
MI. 
 Post-mortem findings of acute myocardial infarction  . 
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The post-operative patient is subjected to a variety of adverse physiological 
events; haemodynamic instability, pro-inflammatory response, deranged 
coagulation, hypothermia and immobility.  Accordingly, it is no surprise that 
these patients are exposed to a higher risk of cardiac events.  Although the peri-
operative period can be likened to the ultimate myocardial stress test, in fact it 
is very unlike a stress test.  Peri-operative stress can be gradual, variable and 
prolonged, with no fixed end-point, rather than the controlled, rapidly 
increasing cardio-respiratory stress of an exercise tolerance test.   
There are no standardised criteria for the diagnosis of post-operative myocardial 
infarction (PMI).  There are 2 suggested mechanisms of evolution for the PMI, 
based on the classification of different types of myocardial infarction.18   
A. Acute coronary syndrome (Type 1 PMI) 
Rupture of an unstable coronary artery plaque due to the systemic inflammatory 
response to surgery leads to thrombus formation and arterial occlusion.18    
B. Oxygen supply-demand imbalance (Type 2 PMI) 
Tachycardia and increased ventricular workload in the presence of pre-existing 
coronary artery disease results in an oxygen supply / demand mismatch leading 
subendocardial hypoperfusion and subsequent infarct.13  These events may be 
potentiated by peri-operative anaemia, arrhythmias and hypotension.19 
The exact aetiology of PMI compared with MI in the non-surgical patient is 
unclear.  Evidence to support type 1 PMI comes from cadaveric data.  A post-
mortem study by Dawood and colleagues found evidence of coronary plaque 
rupture or haemorrhage in 55% of patients, who had suffered a fatal MI within 30 
days of NCS.20  This is confirmed by Cohen and colleagues, who studied the post-
mortem coronary arteries of twenty six patients who had undergone a variety of 
NCS procedures complicated by a fatal MI.21  They demonstrated a 46% rate of 
plaque disruption in this cohort. 
The association between peri- and post-operative ST-segment depression, 
subendocardial ischaemia and PMI was explored by Landesberg and colleagues.22  
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They demonstrated that prolonged periods of ST-segment depression (>2 hours) 
on continuous monitoring was significantly associated with cardiac events, and 
that this preceded 85% of MACE.  Similarly, Fleisher and colleagues performed 
continuous peri-operative ECG monitoring of 145 high risk surgical patients.23  In 
the patients who suffered a PMI, 78% had preceding ST depression that lasted 
longer than 30 minutes.  In this study, ST depression was a stronger predictor of 
MACE than any collected pre-operative variables.    
Bicard and Rodseth have performed a review of the pathophysiology of PMI.24 In 
their review of post mortem studies, pre-operative coronary angiography studies 
and peri-operative myocardial ischaemia trials, they concluded that type 1 PMI 
and type 2 PMI occur with approximately equal frequency.  However, 
hypoperfusion infarcts (type 2 PMI) form the majority of early events (within the 
first 4 days following surgery), while type 2 events are more randomly 
distributed throughout the post-operative period.  Figure 1.2 shows the 
chronological distribution of PMI.  The authors noted that more than 80% of 
hypoperfusion events occur in patients with pre-existing CAD.   
Figure 1.2. Distribution of post-operative myocardial infarction 
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The diagnosis of PMI is further complicated by the masking of the classical 
features of myocardial infarction during the immediate post-operative period by 
wound pain as well as regional anaesthetic techniques and systemic opiate 
therapy.  Mangano and colleagues studied 474 high risk males undergoing NCS.  
They found two thirds of PMIs were clinically undetectable.25  Badner and 
colleagues intensively measured serial post-operative cardiac enzymes (troponin-
T and creatinine kinase) in high risk patients undergoing NCS.14  They found only 
17% of PMI cases had typical chest pain symptoms.     
Several studies have examined the incidence of post-operative serum troponin 
elevation.   Troponins are myofibrillar contractile proteins found in both skeletal 
and cardiac muscle.  The cardiac troponin (cTn) subunits, cTn-I and cTn-T, are 
specific to the myocardium and can be distinguished from skeletal isoforms using 
immunological techniques.26,27   Cardiac troponins are highly sensitive and 
specific markers of myocardial injury.28,29  Patients presenting with acute 
coronary syndrome in the non-operative setting have an increased mortality if 
raised cTn is evident.30  Elevation of cardiac troponins is integral to the diagnosis 
of myocardial infarction.18 
Post-operative troponin elevation is common.  Landesberg and colleagues 
investigated over 500 consecutive high risk patients undergoing vascular surgery 
with serial post-operative serum cTn analysis.31  They identified a raised cTn in 
23.1% of patients, with only 2.3% having a clinically detectable MI (troponin 
elevation and chest pain or ECG changes).  Kim and colleagues demonstrated a 
12% rate of post-operative cTn elevation in an unselected vascular cohort of over 
two hundred patients.32  Similarly, results from the Erasmus Centre at Rotterdam 
have also demonstrated a 14% rate of asymptomatic post-operative cTn 
elevation.33   
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1.3 Implications of post-operative myocardial infarction 
(PMI)  
Patients who suffer a peri-operative MI (PMI) have a poorer outcome than those 
who do not suffer a cardiac event.1 As previously discussed, there are no 
universally accepted criteria for PMI.  Several different definitions of peri-
operative cardiac injury have been used in peri-operative cardiac morbidity 
studies; however, the most commonly used is the definition of a non-fatal MI 
published by The Joint European Society of Cardiology/American College of 
Cardiology Committee34: a typical rise and gradual fall of cTnI with at least one 
of the following: ischaemic symptoms, development of pathological Q waves on 
the ECG, ECG changes indicative of ischaemia (ST segment elevation or 
depression) or coronary artery intervention.     
Studies consistently show that patients suffering a PMI have a poorer post-
operative course,25  and a higher same admission mortality rate.35  For example, 
Devereaux and colleagues showed that PMI was an independent risk factor for 
post-operative mortality (OR 3.45, 95% CI 2.20-5.41).5  Similarly, patients who 
have had a PMI have a higher rate of cardiac morbidity following discharge.  
Mangano and colleagues studied 444 patients undergoing mixed NCS.36  They 
found a 28-fold increase in the incidence of subsequent MACE within 6 months of 
surgery in PMI patients compared with those patients who did not have a PMI.36  
Table 1.1 shows the reported incidence of peri-operative MACE in a selection of 
larger RCTs, observational trials and database analysis studies.   
Vascular patients are at a particularly high risk of PMI.  Sprung and colleagues 
reviewed 8 years of vascular surgery at Cleveland Clinic, Ohio and found that of 
those patients who had a peri-operative MI, 20.6% went on to have a cardiac 
death in the same admission.37  Le Manach and colleagues performed post-
operative troponin surveillance on over one thousand consecutive patients 
undergoing aortic surgery.38  They found a PMI rate of 5%.  Patients who suffered 
a PMI had a significantly higher in-hospital mortality rate than those who did not 
(22% vs. 3%, p<0.001). 
Albaladejo and colleagues reported the results of the RECO study, which 
examined the post-operative outcomes of 1134 patients who had previous 
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percutaneous coronary intervention (PCI) and stent insertion.39  They found that 
despite previous revascularisation the MACE rate was 10.9%, and the 30 day 
mortality in the MACE group was 14.5%.  McFalls and colleagues found that 
patients with evidence of coronary artery disease on angiography, undergoing 
elective vascular surgery, had an 8.4% MACE rate.40  Poldermans and colleagues 
investigated over 400 patients with multiple risk factors for IHD prior to vascular 
surgery.41  Dobutamine stress echocardiography demonstrated extensive 
ischaemia in 101 patients.  The PMI rate in these patients was 32.7%, and the 
one year mortality was 24.7%. 
In summary, there is a considerable variation in the reported incidence of PMI 
depending on the patient group studied and the use or not of post-operative 
screening for MI.
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Table 1.1  Incidence of peri-operative major adverse cardiac events (MACE) in selected randomised control trials, observational 
studies and database analyses published within the last 15 years 
 
Author 
Year of 
Recruiting 
Year of 
Reporting 
Cohort Size Study Population 
Screened 
for MI? 
MACE rate 
Mortality 
Rate 
Randomised Controlled Trials 
Brady42 2001-2004 2005 103 Vascular Surgery Yes 31.1% 3.9% 
Mackey43 2003-2004 2006 236 Vascular Surgery No 17.8% 3.4% 
Devereaux5 2002-2007 2008 8,351 
High risk for IHD, 
mixed NCS 
Yes 6.4% 2.7% 
Dunkelgrun44 2004-2008 2009 1,066 
Intermediate risk for 
IHD, mixed NCS 
No 4.0% 2.3% 
Oscarsson45 2005-2008 2010 220 
High or intermediate 
risk surgery 
Yes 5.4% 2.0% 
Observational Studies 
Lee6 1989-1994 1999 4,315 Mixed NCS Yes 2.9% 
Not 
documented 
Gilbert46 1995-1997 2000 2,035 Mixed NCS No 6.4% 2.4% 
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Author 
Year of 
Recruiting 
Year of 
Reporting 
Cohort Size Study Population 
Screened 
for MI? 
MACE rate 
Mortality 
Rate 
Kumar47 1992-1995 2001 1,121 
Known or suspected 
heart disease - 
mixed NCS 
Yes 8.1% 
Not 
documented 
Boersma48 1996-1999 2001 1,351 Vascular Surgery No 3.3% 
Not 
documented 
Aziz49 1996-2001 2003 365 EVAR N/A 14.2% 2.7% 
Albaladejo39 2007-2009 2011 1,134 
Patients with 
previous coronary 
stents 
No 10.9% 
Not 
documented 
Sabate35 2007-2008 2011 3,387 
Intermediate – high 
risk NCS 
No 4.3% 1.9% 
Orcutt50 2008-2011 2012 1,182 Vascular Surgery No 4.9% 
Not 
documented 
Database Analyses 
Davenport8 2002-2004 2007 183,069 Mixed NCS N/A 1.3% 
Not 
reported 
Kheterpal51 2002-2006 2009 7,740 Mixed NCS N/A 1.1% 
Not 
reported 
Bertges52 2003-2008 2010 10,081 Vascular Surgery N/A 6.3% 
Not 
reported 
 
Abbreviations; MACE - major adverse cardiac event, MI - myocardial infarction, IHD - ischaemic heart disease, NCS - non-cardiac surgery, 
EVAR - endovascular aneurysm repair.
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1.3.1 Raised post-operative cardiac troponin (cTn) 
There are currently over 200 publications examining the incidence and 
significance of peri-operative cTn rise.  Several cardiac markers have been 
studied and a wide variety of study designs have been employed.  For the 
purposes of this chapter, I will discuss a selection of representative studies.  
The implication of asymptomatic cTn elevation was investigated in 297 patients 
undergoing aortic or lower limb vascular surgery, of whom 28 (12%) patients had 
an elevated post-operative cTn-I.32  This was associated with a 6-fold increased 
risk of 6-month all cause mortality (OR 5.9: 95% CI, 1.6-22.4) and a 27-fold 
increase in PMI (OR 27.1; 95% CI, 5.2-142.7).  The authors also noted a dose-
response relationship between cTn-I and outcome.  For example patients with a 
markedly elevated cTn-I (>3.0 ng/ml) had significantly poorer 6 month mortality 
than the group of patients with only a modestly elevated cTn-I (≤0.35 ng/ml) 
(OR, 4.9; 95% CI, 1.3-19.0).   Oscarrson and colleagues studied a group of 211 
patients undergoing urgent NCS (defined as surgery required within 4 days of an 
unplanned admission).53  An elevated post-operative cTn was observed in as 
many 33% of patients, and these patients had a higher 30-day mortality than 
those patients without an elevated cTn (23% vs. 7%, p=0.003). 
Furthermore, cTn elevation remains predictive of poorer outcome when patients 
who have had a peri-operative MACE are excluded.  Lopez-Jimenez and 
colleagues studied the 6-month outcome of 772 patients undergoing major NCS 
(defined as expected hospital stay of >2days).54  Patients with a peri-operative 
MACE were not included in the study.  An asymptomatic cTn elevation was 
observed in 12% of patients.  These patients had a higher rate of MACE during 
the 6 month follow-up period (RR 5.4, 95% CI 2.2-13, p=0.001).     
 Recently, the results of a large prospective multicentre study examining the 
association between raised post-operative cTnT and post-operative outcomes 
have been reported.55  The trial recruited over 15000 patients undergoing NCS 
and demonstrated that peak post-operative cTnT independently predicted 30-
day mortality.  The higher the cTnT value, the higher the risk of mortality; 1.0% 
for cTnT value of <0.01 ng/ml, 4.0% for 0.02 ng/ml, 9.3% for 0.03-0.29 ng/ml 
and 11.6% for cTnT value of >0.30 ng/ml.   
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In summary, elevation in serum cardiac troponin post-operatively is a powerful 
predictor of outcome, and this appears to be the case for both patients who 
meet the criteria for MI, and those with an asymptomatic troponin rise.        
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1.3.2 Long term survival  
Patients suffering a peri-operative cardiac event have poorer long term 
outcomes than those that do not. 
Orcutt and colleagues investigated the long-term outcomes following 1,182 
vascular procedures performed in a single North American institution.50  A peri-
operative cardiac event was associated with a significantly higher long-term 
mortality following multivariate Cox regression analysis (HR 5.30 (95% CI 1.77-
15.96), p=0.003).  Renal disease and COPD were clinical variables that remained 
significant after multivariate analysis.  Similarly, McFalls and colleagues found 
an improved long term survival in patients that did not suffer a peri-operative 
MACE in 115 patients undergoing vascular surgery.56  Virgilio and colleagues 
demonstrated, in patients undergoing EVAR, that a non-fatal MI was associated 
with a significantly shorter median survival (95 days vs. 2265 days, p<0.001).57  
Similarly, Archan and colleagues showed that patients suffering a PMI following 
EVAR had a one year mortality rate of 35.7%.58  At a median follow-up of 2.1 
years, 71.4% of PMI patients had died.    
A raised post-operative troponin also has implications for longer term survival.  
Oscarsson and colleagues prospectively observed 546 elderly patients (>70 years) 
undergoing mixed NCS, and found an elevated cTn-T in 9.7% of patients.59  Only 
11.0% of patients with an elevated cTn-T had clinical signs or symptoms of 
cardiac ischaemia.  At 1-year after surgery, patients with an elevated cTn-T had 
a significantly higher mortality (32.1% vs. 4.6%, p<0.001).  Kertai and colleagues 
demonstrated a significantly higher all cause mortality during a 4-year follow-up 
period in patients with an elevated post-operative cTn-T compared with patients 
without a raised cTn-T (41% vs. 17%, p<0.001).33     
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1.3.3 Implications for health economics 
Cardiac complications have economic implications for health-care providers.  
Fleischmann and colleagues studied nearly 4000 patients undergoing NCS.60  A 
markedly increased hospital stay was seen in patients with peri-operative MACE 
(11 days, 95% CI: 9-12 days) compared with patients without complications (4 
days, 95% CI: 3-4 days).  Likewise, Sabate and colleagues noted a higher ICU 
utilisation (64% vs. 2%) and a longer median length of hospital stay (12 vs. 6 
days) in patients who suffered a MACE compared with those that had no cardiac 
complications.35 
Mackey and colleagues performed a secondary analysis of a pharmacoeconomic 
study of 236 high risk patients undergoing vascular surgery in a North American 
institution.43  A peri-operative MACE rate of 17.8% was observed.  Patients who 
suffered a MACE had a higher mean critical care bed use (6.6 days vs. 3.7 days, 
p=0.009), longer mean length of stay (16.8 days vs. 10.0 days (p<0.001) and 
higher re-admission rate (23.8% vs. 10.3%, p=0.02) compared to patients without 
cardiac complications.  Published in 2006, the authors used a national cost-of-
living index to estimate an increased cost to the healthcare provider of $9980 
per patient who suffered a MACE.  The authors then extrapolated these figures 
to a national level.  They estimated the annual cost of peri-operative cardiac 
morbidity for vascular surgical patients alone at $444 million.    
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1.4 Pre-operative prediction of peri-operative morbidity 
and mortality 
Patient and clinical variables, laboratory tests and pre-operative investigations 
are available to assist the assessment of patients prior to NCS.  Many studies 
have examined the predictive value of these various factors.    
1.4.1 Clinical variables 
1.4.1.1 Age 
The risk of peri-operative MACE and mortality rises with age, as demonstrated 
across many observational studies.  Davenport and colleagues, using NSQIP data 
from over 180,000 patients, showed that the mean age in the MACE group was 
significantly higher than in the non-MACE group (69.3±11.5 years vs. 60.2±14.3 
years, p<0.0001).8 
Polanczyk and colleagues prospectively studied 4315 patients undergoing major 
NCS.61  They grouped patients by age; 50-59, 60-69, 70-79 and 80 years and over 
and found the respective combined mortality and major morbidity were 4.3%, 
5.7%, 9.6% and 12.5% (p<0.001).  Increasing age was significantly associated with 
post-operative heart failure, MI and ventricular arrhythmias.  Similarly, 
Kaafarani and collegues observed a prospectively collected cohort of 1238 
patients undergoing major NCS.62  In patients aged >56 years, they found a 
higher 30-day mortality (0% vs. 1.4%, p=0.0021) and a higher 1-year mortality 
(1.65% vs. 3.89%, p=0.020). 
Fazio and colleagues presented the outcomes of over 5000 patients undergoing 
colorectal resection at the Cleveland clinic.63  Patients age 65-75 had an 
increased rate of mortality (OR 3.28, 95% CI 1.98–5.44, p<0.001) compared with 
patients aged less than 65 years.  Patients older than 85 years had an even 
higher mortality (OR 9.49, 95% CI 4.53–19.90, p<0.001).63    The findings of a 
significant association between increasing age and poor post-operative outcomes 
is supported by numerous other trials.64–67 
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1.4.1.2 Cardiac co-morbidity 
A past history of cardiac disease is a commonly collected clinical variable in the 
assessment of cardiac risk.  Sabate and colleagues have reported the results of 
the ANESCARDIOCAT study.35  They performed a large, multicentre Spanish 
observational study of patients undergoing intermediate-to-high risk surgery, as 
defined by the ACC / AHA guidlines.  They recruited 3387 patients, and observed 
a 4.3% MACE rate.  They found a higher MACE rate in patients with a history of 
CAD (12.5% vs. 3.6%, p<0.0001), previous congestive heart failure (14.0% vs. 
3.6%, p<0.0001) and previous revascularisation (PCI or CABG) (15.9% vs. 4.0%, 
p<0.0001).   
Kheterpal and collegues performed a single centre analysis of NSQIP data for 
7,740 patients.  They found a significantly higher rate of MACE in patients with 
active heart failure (p<0.001), previous cardiac intervention (p<0.001) and 
hypertension requiring medication (p<0.001).  Interestingly, there was no 
association between an MI within the preceding 6 months and peri-operative 
MACE.   
Knowledge of a previous MI, and in particular the timing of the infarction prior 
to surgery, is an important consideration in pre-operative assessment.  Kumar 
and colleagues prospectively studied over a thousand patients with known heart 
disease undergoing mixed major NCS.47  An overall MACE rate of 8.1% was 
observed, although in the aortic surgery subgroup it was 23.8%.  When 
considering a history of previous MI, both recent (<6 months before surgery) and 
earlier (>6 months before surgery) MI were univariate predictors of MACE.  
Likewise, both recent MI (OR 4.9, 95% CI 1.9-12.9) and earlier MI (OR 2.2, 95% CI 
1.4-3.5) remained significant on multivariate analysis.  Recent MI was the 
strongest predictor of an adverse outcome of all the variables studied.  More 
recently, Livhits and colleagues performed an analysis of the Californian Patient 
Discharge Database for orthopaedic, major abdominal and vascular surgery for 
the years 1999 to 2004.68  From the 500,000 patients extracted from the 
database, 2.9% had suffered an MI within the preceding year.  The authors 
subdivided this group into recent MI; 0 to 30 days prior to surgery (13.7%), 31 to 
60 days (13.0%), 61 to 90 days (10.7%), 91 to 180 days (24.8%) and 181 to 365 
days (37.8%).  The overall PMI rate was 1.4%, but of these 32.8% occurred in 
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patients with an MI 0-30 days prior to surgery.  The PMI rate fell as time from 
pre-operative MI increased (31-60 days 17.8%, 61-90 days 6.4% and 91-180 days 
5.3%, p<0.001).  Similarly, the 30 day mortality and 1 year mortality fell as the 
time from pre-operative MI increased.   
Therefore, the American College of Cardioligy and American Heart Association 
(ACC/AHA) guidelines recommend deferral of elective surgery if an MI is present 
within 6 weeks of surgery, and caution within the first 6 months.69     
1.4.1.3 Previous revascularisation 
The role of protective coronary revascularisation in patients undergoing NCS is 
unclear.  In an attempt to answer this question, Eagle and colleagues utilised the 
Coronary Artery Surgery Study (CASS) database, which included 24,959 
participants with suspected coronary disease recruited from 1974 to 1979.  The 
cohort included patients who had received a CABG, and patients who were 
treated medically.  They identified those patients who required NCS during the 
subsequent 10 years.  Nearly 2000 patient had subsequent high risk surgery, 
defined as intra-thoracic, intra-abdominal, head and neck and vascular surgery.  
Patients with prior CABG had reduced PMI rates (0.8% vs. 2.7%, p=0.002) and 
fewer postoperative fatalities (1.7% vs. 3.3%, p=0.03), compared with the 
medically managed group.   
Since this trial, there has been an overwhelming trend towards percutaneous 
coronary intervention (PCI) rather than CABG in patients with unstable CAD.70 
Subsequently, the incidence of patients requiring NCS after coronary stent 
insertion is rising.71 Berger and colleagues performed a secondary analysis of a 
prospectively collected drug eluting stent (DES) registry and found that 4.4% of 
patients underwent major NCS in the year after stent placement.72  Similarly, 
Gandhi and colleagues report their single centre experience of over 800 patients 
following DES insertion.73  They found a 7% incidence of NCS at 1 year, 18% at 2 
years and 22% at 3 year follow-up.    
Subsequently, Hollis and colleagues have published a meta-analysis exploring the 
outcome of patients with previous coronary stenting undergoing NCS.74  They 
examined 28 studies that included patient data regarding previous coronary 
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stent insertion.  Peri-operative MACE rates ranged from 0% to 18% in patients 
with a stent inserted ≤1 year prior to surgery and 0% to 12% in patients >1 year 
following stent insertion.  They concluded that this offered some further 
evidence to support deferring non-urgent surgery for more than one year after 
stent insertion.   
1.4.1.4 Other medical co-morbidities 
It would be expected that diabetes increases the risk of peri-operative cardiac 
events due to increased atherosclerosis, enhanced endothelial dysfunction, 
accentuated systemic inflammatory response and elevated platelet activation.75  
Furthermore, diabetic patients tend to have diffuse, multilevel coronary 
disease.76  The ANESCARDIOCAT study found a higher incidence of MACE in type I 
DM (9.8%) and type II DM (5.1%) than those without diabetes (3.9%, p=0.01).35  
This is in keeping with other studies that have  found diabetes to be an 
independent predictor of MACE.6,77,78  
Renal impairment has been shown to predict MACE.  Lee and colleagues found a 
raised pre-operative serum creatinine (>2mg/dl) was associated with a higher 
rate of post-operative MACE in a cohort of nearly three thousand patients (OR 
3.0, 95% CI 1.4-6.8).6  Similarly, Davenport and colleagues found elevated pre-
operative creatinine was an independent predictor of post-operative MACE in 
over 180,000 patients analysed from a large national database.8   
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1.4.1.5 Functional capacity 
The use of Metabolic Equivalents (METs) allows an assessment of an individual 
patient’s functional capacity.  METs are estimations of the energy cost of a 
certain activity compared with a reference basal metabolic rate.  Hlatky and 
colleagues introduced the concept of an activity status index in 1989.79  A 
subsequent consensus statement from the AHA correlated METs to stages of 
various exercise tolerance tests80 and a simplified MET score for routine 
activities of daily living are now used [Figure 1.3].69 
Figure 1.3  Estimated energy requirements (metabolic equivalents) for 
various activities 
 
 
Can you....  Can you.... 
1 MET Take care of yourself? 
Eat, dress or use the 
toilet? 
4 METs Climb a flight of stairs? 
 
↓ Walk indoors around 
the house? 
 
↓ Run a short distance? 
 
↓ Walk a block on level 
ground? 
 
↓ Do heavy housework 
(scrubbing floors moving 
heavy furniture)? 
 
4 METs Do light housework 
(washing dishes or 
dusting)? 
↓ Participate in moderate 
exercise like golf, 
bowling or dancing? 
 
  >10 METs Participate in strenuous 
activity like swimming 
tennis or football? 
 
 
Reproduced with permission from publisher.69   
Abbreviations; MET - metabolic equivalents. 
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1.4.2 Type of surgery 
The type of surgery performed has implications for the rate or peri-operative 
MACE, with certain procedures carrying a higher risk of an adverse outcome.  
The ACA / AHA guidelines suggest stratification of operative procedures into 
low, intermediate and high risk [Table 1.2].69 
Table 1.2 Risk stratification of non-cardiac surgical procedures 
 
High Risk 
Aortic and major peripheral vascular surgery 
Anticipated prolonged surgical procedure 
Emergency 
Intermediate Risk 
Intra-peritoneal and intra-thoracic surgery  
Carotid endarterectomy 
Head and neck surgery 
Prostate surgery 
Low Risk 
Superficial procedures 
Breast surgery 
Cataract surgery 
Endoscopic procedures 
  
Adapted from Fleisher et al.69   
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1.4.2.1 Expediency of surgery 
Patients undergoing elective surgery have an improved post-operative outcome 
compared with patients having similar surgery performed on a non-elective 
basis.  Several studies have examined the increased risk of MACE and mortality 
associated with unplanned and emergency surgery.  Kumar and colleagues, from 
an observational study of over 1000 mixed NCS, showed that emergency surgery 
(defined as within 72 hours of an unplanned admission) was an independent 
predictor of MACE (OR 2.6, 95% CI 1.2-5.6).47  Slim and colleagues found that in a 
prospectively collected multicentre cohort of 1426 colorectal resections, 
unplanned surgery was the strongest predictor of mortality on multivariate 
analysis.81  Likewise, Tekkis and colleagues reported the mortality rates 
following colonic surgery from the Association of Coloproctology of Great Britain 
and Ireland national database.82  Urgent and emergency surgery was an 
independent predictor of peri-operative mortality in over 8000 patients 
included. 
In high risk populations, urgent surgery increases the risk of adverse events.  In 
over a thousand patients who had previous coronary artery stent insertion 
undergoing NCS, an urgent procedure was an independent risk factor for peri-
operative cardiac complications (OR 3.08, 95% CI 1.74-5.74).39  Results from a 
large English intensive care utilisation database show the overall elective 
mortality following mixed NCS was 0.44%, compared with 5.4% in patients who 
required an emergency operation.16      
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1.4.3 12-lead electrocardiograph 
The use of a resting 12 lead ECG in screening for cardiac disease is controversial.  
No randomised controlled trial has been performed to investigate the benefit of 
screening the general population with an ECG to predict subsequent cardiac 
morbidity and mortality.  Chou and colleagues performed a review of the studies 
investigating the predictive value of an ECG in asymptomatic patients.83  Sixty-
three prospective studies were identified, and the pooled results showed that 
ST-segment or T-wave abnormalities, left ventricular hypertrophy (LVH), left 
axis deviation (LAD) or bundle branch block (BBB) were associated with an 
increased risk of subsequent cardiac morbidity.  Recently, a prospective study of 
an older cohort (aged 70-79 years) was performed.84  It reported a 23% incidence 
of major ECG abnormalities (Q-wave abnormalities, LVH, BBB; atrial fibrillation 
(AF) and major ST-T wave changes) and a 13% incidence of minor abnormalities 
(minor ST changes).  Both major and minor changes were associated with and 
increased incidence of subsequent MACE in the follow-up period.  The authors 
suggest that a screening ECG in more elderly patients improves risk prediction 
above traditional risk factors.  An accompanying editorial, however, cautions 
strong conclusions from this study and points out that an adequately powered 
RCT to investigate the benefits of a screening ECG, even in more elderly 
patients, would require 30,000 patients and 5 years follow-up.85      
Nevertheless, the 12-lead ECG remains a commonly performed pre-operative 
investigation for patients undergoing major surgery.  As with the general 
population, the benefit of routinely performing an ECG has been questioned in 
the peri-operative patient and the predictive value varies widely in published 
studies.86–89  Noordzij and colleagues retrospectively analysed ECGs from over 
20,000 patients undergoing non-cardiac surgery.86  Since this study was 
performed retrospectively, the only endpoint used was cardiac death.  ECG data 
improved risk prediction when combined with clinical variables in high risk 
procedures only.  The authors conclude that an ECG is not necessary in lower 
risk procedures.   
Van Klei and colleagues performed a retrospective secondary analysis of the 
post-operative outcome of over 2000 patients enrolled in a cardiac risk study.87  
The end points were PMI and all cause mortality.  They found that on univariate 
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analysis BBB predicted outcome, but was not significant on regression modelling.  
They concluded that in their study group an ECG did not improve prediction 
beyond other risk factors identified on a careful history.   
Similarly, Lui and colleagues concluded that the preoperative ECG was of limited 
value in a prospective study of more than 500 elderly patients (aged >70).88  
They found a high prevalence of ECG abnormalities (75.2%) and therefore 
suggested that the ECG had no discriminatory value.  Landesberg et al carried 
out a prospective study of 405 patients undergoing vascular surgery.90  They 
carried out rigorous post-operative screening for cardiac events (daily cardiac 
enzymes).  Despite this, they observed a low post-operative MACE rate (4.7%).  
However they did find that LVH and ST segment depression was more predictive 
of poor outcome than standard clinical variables.  Correll et al performed a 
case-control study comparing a cohort of 95 patients with an abnormal pre-
operative ECG, matched to 195 patients without an abnormality.89  They 
concluded that risk factors obtained from a careful history predicted ECG 
abnormalities and therefore questioned the value of the routine ECG. 
Conversely, the ANESCARDIOCAT study found an abnormal ECG, defined as LVH, 
LBBB or ST-T abnormalities, was an independent risk factor for MACE.35  
In summary, while the ECG remains a common pre-operative investigation for 
patients undergoing major NCS, its predictive value for post-operative morbidity 
and mortality is variable.  The incidence of ECG abnormalities in patients in the 
West of Scotland undergoing major NCS is not known. 
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1.4.4 Scoring systems 
The categorisation of patients into defined risk groups is attractive for both 
researchers and clinicians alike.  The derivation of a convenient, reproducible 
and validated scoring system that allows accurate prediction of peri-operative 
risk for individual patients has been attempted by a number of authors.   
1.4.4.1 American Society of Anaesthesiologist (ASA) classification 
The American Society of Anaesthesiology (ASA) scoring system was devised in 
1963 for the standardised reporting of pre-operative functional status.  The ASA 
grade is a simple classification of physical status and is a modification of the 
classification proposed by Dripps and colleagues [Table 1.3].91  The ASA grade is 
universally used in clinical practice.  The ASA classification is now widely used as 
risk stratification tool, although this is not what it was designed for.  Despite 
this, it is often the sole method of medical morbidity stratification in large 
surgical trials.92–94  However, it is often criticised due to its over-simplicity and 
high rate of inter-observer variation.95–97  The ASA grade uses no information 
regarding the intended surgical procedure and should not be considered as an 
accurate tool for risk stratification. 
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Table 1.3  American Society of Anaesthesiologists (ASA) physical status 
classification 
 
Grade Description 
I A normal healthy patient 
II A patient with mild systemic disease 
III A patient with severe systemic disease 
IV Severe systemic disease that is a constant threat to life 
V 
A moribund patient that is not expected to survive without an 
operation 
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1.4.4.2 Multivariate clinical prediction scoring systems 
In a landmark study from 1977, Goldman and colleagues examined the predictive 
value of pre-operative clinical symptoms and signs in 1001 patients undergoing 
major NCS.98  From this, they produced what is considered to be the original 
cardiac risk index.  Nine clinical variables were identified from the multivariate 
analysis and combined to give a 0 to 53 point score [Table 1.4].  The index 
allowed assignment of patients into one of four risk groups [Table 1.5].      
Following the publication of the Goldman’s Cardiac Risk Index, Detsky and 
colleagues investigated 445 consecutive patients that were referred for a 
cardiology opinion prior to major NCS.99  They found that the addition of 
unstable angina and an MI at any time prior to surgery improved the accuracy of 
cardiac morbidity prediction.  Both of these scoring systems are cumbersome 
and difficult to apply to bedside practice.  Also, they proved less accurate out 
with the derivation population, leading to questions about general applicability 
of these indices.46,100   
In 1999, the Cardiac Risk Index was further amended and simplified with 
Goldman as the senior investigator and presented as the Revised Cardiac Risk 
Index.6 
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Table 1.4  Components of Goldman’s Index 
 
Criteria Points Weighting 
Age >70 years 5 
MI within 6 month 10 
Signs of Heart Failure* 11 
Aortic Stenosis 3 
Arrhythmia 7 
5 or more PVCs per minute** 7 
General Medical Co-morbidity*** 3 
Emergency Surgery 4 
Intraperitoneal, Intrathoracic or Aortic 
Surgery 
3 
 
Definitions; 
*Ventricular gallop or raised JVP, ** PVC – Premature Ventricular Complexes, 
***Any one of the following; hypoxia, hypercarbia, acidosis, renal impairment, 
chronic liver disease or bed ridden. Adapted from98. 
 
Table 1.5  Risk of cardiac complications as predicted by the Goldman Index 
 
Points Score Risk of Cardiac Complication 
0-5 1% 
6-12 7% 
13-25 14% 
26-53 78% 
 
Adapted from98. 
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1.4.4.3 Revised Cardiac Risk Index 
The Revised Cardiac Risk Index (RCRI) is a commonly used scoring system for 
assessing cardiac risk in patients undergoing major non-cardiac surgery.6  The 
RCRI scores patients according to 6 equally weighted clinical categories [Table 
1.6].  The RCRI defines Class 1 as no factors present, Class 2 as 1 factor present, 
Class 3 as 2 factors present and Class 4 as 3 or more factors present.  Results 
from the validation cohort of the original study suggest that the risk of a major 
adverse cardiac event (MACE) in Class 1, 2, 3 and 4 was 0.4%, 0.9%, 7% and 11% 
respectively.  The pooled estimated risk of peri-operative MACE is shown in 
Table 1.7.  Risk stratification tools, in particular the RCRI, are now included in 
clinical guidelines produced by the American College of Cardiology/American 
Heart Association (ACC/AHA)69   
Despite the widespread use of the RCRI, few studies have attempted to directly 
validate the performance of the RCRI in different populations.  One study from 
the Erasmus Centre at Rotterdam analysed the post-operative mortality of 
108,593 patients undergoing NCS.101  Due to the retrospective nature of the 
study, all-cause mortality and cardiac mortality were the primary endpoints.  
They found an all-cause mortality rate of 1.7%, and a cardiac mortality rate of 
0.5%.  The RCRI was predictive of mortality; 0.3% for Class 1, 0.7% for Class 2, 
1.7% for Class 3 and 3.6% for Class 4.   The authors improved the performance of 
the scoring system by adding age to the model.   
A similar study by Welten and colleagues retrospectively reviewed the outcome 
of nearly 3000 patients undergoing open vascular surgery.102  They also found 
that the predictive value of the RCRI was improved by an adjustment for age.   
A recent meta-analysis has examined the uses of the RCRI.103  The majority of 
the included studies simply use the RCRI as a stratification tool to display data.  
Only five high quality, prospectively performed studies were found that 
specifically aimed to validate the findings of the RCRI.  The authors concluded 
that the RCRI demonstrated moderate performance in differentiating low and 
high cardiac risk within mixed surgical cohorts.  However, a significantly inferior 
predictive value was found within specific vascular cohorts. 
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Table 1.6  Components of the Revised Cardiac Risk Index (RCRI) 
 
Ischaemic heart disease* 
History of heart failure 
History of cerebrovascular disease 
Diabetes mellitus requiring insulin therapy 
Pre-operative creatinine >2.0mg/dl (176.8umol/l) 
High risk surgery** 
 
Definitions; * Presence of previous myocardial infarction, a positive exercise 
tolerance test, the use of nitrate therapy or the presence of pathological Q-
waves on ECG.  ** Thoracic, abdominal or supra-inguinal bypass surgery. Adapted 
from Lee at el.6 
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Table 1.7  Predicted risk of MACE based on the derivation and validation 
cohorts in the Revised Cardiac Risk Index 
 
Number of Risk Factors Risk of MACE % (95% CI) 
0 0.4 (0.1-0.8) 
1 1.0 (0.5-1.4) 
2 2.4 (1.3-3.5) 
≥3 5.4 (2.8-7.9) 
 
Adapted from Lee et al.6 
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1.4.5 Non-invasive cardiac assessment 
 
Several tools for non-invasive cardiac assessment have been tested in the pre-
operative patient.   
 Transthoracic echocardiography (TTE) provides information about 
ventricular function in the resting subject.  An ejection fraction (EF) of 
<50% has been shown to predict PMI in patients undergoing vascular 
sugery.104  However, not all studies have shown TTE to be a helpful 
predictive tool.  Halm and colleagues prospectively studied 339 high risk 
patients undergoing NCS.105  No echocardiographic variables predicted 
MACE, although an EF of <40% was predictive of a composite of cardiac 
death, PMI, heart failure and ventricular tachycardia (OR 2.5, 95% CI 1.2-
5.0). 
 Pharmacologic stress echocardiography, in particular dobutamine stress 
echocardiography (DSE), allows more accurate assessment of ventricular 
function and inducible new wall motion abnormalities.106  Furthermore, it 
can be performed in patients who are unable to exercise.107  Boersma and 
colleagues performed a predefined secondary analysis of 1351 patients 
recruited in a multicentre Dutch peri-operative cardiac risk trial.48  A 
higher MACE rate was seen in patients with new wall motion abnormalities 
compared with patients without inducible motion abnormalities (13.5% vs. 
1.6%, p<0.001).  The authors recognize the high negative predictive value 
(NPV) of DSE as its main strength.  More recently, Raux and colleagues 
examined the negative predictive value (NPV) of DSE for post-operative 
cTn elevation in over 400 patients undergoing aortic surgery.108  They 
expected a higher frequency of elevated cTn due to the use of a more 
sensitive assay.  Patients with a positive DSE proceeded to angiography.  
Of the patients with a normal DSE, 7% suffered myocardial necrosis 
(defined as any detectable rise in cTn).  The NPV of DSE for necrosis was 
92.7%.  The authors point out that while the observed NPV is still high, it 
is lower than any previously reported value.          
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Several other techniques have been investigated, including  radionuclide 
ventriculography and myocardial perfusion scintigraphy.109,110  These 
investigations all have strengths and weaknesses in cardiac risk prediction.  
Likewise, they have variable availability at the point of care, and many remain 
research tools.  Kertai and colleagues performed a well conducted meta-analysis 
of 58 studies investigating six diagnostic cardiac tests (ambulatory 
electrocardiography, exercise electrocardiography, radionuclide 
ventriculography, myocardial perfusion imaging, DSE and dipyridamole stress 
echocardiography).111  They examined the performance of each test using ROC 
analysis [Figure 1.4] and then compared the respective performance with the 
other tests.  In summary, the only statistically significant superiority was noted 
when comparing DSE with myocardial perfusion scintigraphy, in favour of DSE 
(OR 5.5, 95% CI 2.0-14.9).  DSE trended towards superiority over all other 
investigations, although statistical significance was not reached.  The authors 
concluded that DSE appeared to offer the best predictive performance of the 
imaging modalities studied. 
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Figure 1.4  Graphs showing ROC curves for non-invasive cardiac imaging 
 
 
The horizontal axis represents the false positive rate and the vertical axis the true positive rate.
111
  Reproduced with permission from publisher. 
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1.4.6 Cardiopulmonary Exercise Testing (CPET) 
Whilst non-invasive cardiac investigations specifically assess cardiac function,  
cardiopulmonary exercise testing (CPET) allows a more global assessment of an 
individual patient’s cardio-respiratory response to exercise.112  CPET aims to 
assess functional capacity through an incremental exercise regimen, during 
which a breath-by-breath analysis of oxygen uptake and carbon dioxide 
excretion is performed.113  The oxygen uptake (VO2), and in particular the 
maximum oxygen consumption (VO2max), are calculated.  Increasing aerobic work 
produces a linear response of oxygen consumption and carbon dioxide 
production.  Further increase in work requires additional energy 
supplementation through the anaerobic system.  This leads to the anaerobic 
threshold when a relative increase in carbon dioxide production compared to 
oxygen consumption is observed.  Other variables such as exercise-induced heart 
rate, heart rate recovery, arrhythmia, ischaemia and acidosis can be recorded. 
Hennis and colleagues have performed a review of the trials that examined the 
predictive value of CPET in patients undergoing NCS.114  Twelve studies were 
identified from a variety of surgical cohorts.  The studies were heterogeneous 
with regard to the CPET derived variables studied and endpoints used.  The 
designs of the studies were also variable, and only 3 studies were prospective.  
Broadly speaking, all the studies included were able to demonstrate an 
association between poor performance at CPET and adverse post-operative 
outcome (mortality or major cardio-respiratory morbidity).  However, the 
optimal CPET-derived variable (VO2max or anaerobic threshold) differed between 
trials, as did the optimal cut-off value for each variable.  Finally, the current 
availability of CPET to the general clinician is low, limiting its use in pre-
operative risk stratification.  
In summary, CPET is attractive as a whole body assessment of oxygen uptake, 
utilisation and aerobic / anaerobic capacity.  The test is not a single organ 
assessment, but a multi-organ response to stress.  There are several limitations 
however; not all patients are able to participate, CPET is not universally 
available, the methodology is variable and the optimal measurements are 
unclear.     
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1.4.7 Institutional operative volume 
The outcomes of individual surgeons performing certain types of major surgery 
have been critically reviewed in recent years following the advent of 
subspecialisation.  This has important implications for the procedures that are 
performed in lower volume district general hospitals as opposed to larger 
referral centres.  
The relationship between adverse post-operative outcome and operative volume 
for abdominal aortic aneurysm (AAA) surgery has been investigated by Holt and 
colleagues.115  They performed a meta-analysis of 32 studies and English NHS 
Hospital Episode Statistics (HES) that included over 400,000 patients.  The 
mortality rate fell as institutional operative volume rose.  For elective surgery, 
an OR of 0.66 (95% CI 0.65-0.67) at a threshold of 43 AAA repairs per year was 
found in favour of higher volume hospitals.  For ruptured AAA surgery, an OR of 
0.78 (95% CI 0.73-0.82) at a threshold of 15 repairs per year was found in favour 
of higher volume hospitals.  McPhee and colleagues retrospectively scrutinised 
the US Nationwide Inpatients Sample (NIS) data and found 11 institutions that 
collected individual surgeon outcomes, as well as institutional data.116  They 
found that high individual surgeon activity confers a greater benefit than 
institutional activity for open AAA surgery.  Interestingly, for EVAR, neither 
individual surgeon nor institutional activity predicted post-operative mortality.   
A similar interest in volume related outcomes has been directed towards major 
oesophago-gastric resections.  High volume centres have reduced post-operative 
complications and improved peri-operative survival.117  A recently published 
Cochrane review has examined surgeon and institutional volume in patients 
undergoing surgery for colorectal cancer.  The authors found significantly 
improved stage adjusted 5 year survival in patients treated at high-volume 
hospitals with high volume surgeons.118  This was also true for adverse peri-
operative events and post-operative mortality.  
There is additional research to support the association between improved 
outcomes and higher surgeon / institutional volume for the surgical treatment of 
urological malignancy,119,120 gynaecological malignancy121 and oro-pharyngeal 
malignancy122    
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1.5 Natriuretic peptides  
1.5.1 Basic biology 
The cardiac neurohormone, B-type natriuretic peptide (BNP), has been identified 
as a biological marker of cardiac mortality. Pro-BNP is synthesised predominantly 
within ventricular myocytes in response to cardiac wall stress.  Processing of 
pro-BNP results in the mature BNP molecule and the amino-terminal cleavage 
fragment of its N-terminal pro-BNP (NT-proBNP), both of which enter the 
circulation.123  BNP has an important role in both cardiovascular and renal 
physiology,  reducing  sympathetic tone and blood pressure and maintaining 
circulating volume homeostasis.123 
1.5.2 The evidence from cardiology 
McDonagh and colleagues studied a random sample of asymptomatic patients 
that were previously enrolled in the Glasgow MONICA coronary risk factor 
study.124 In this group of asymptomatic patients, a serum BNP level identified 
patients with LVSD on echocardiography.  They also demonstrated that BNP was 
a better marker of LVSD than atrial natriuretic peptide.  Subsequently, Zaphiriou 
and colleagues examined the use of BNP as a screening tool for patients’ 
referred from primary care with symptoms suggestive of cardiac failure.  This 
multicentre study, performed in Glasgow and London, found evidence of heart 
failure (clinical and radiological) in 34% of patients.  Patients with heart failure 
had significantly higher BNP levels (285pg/ml vs. 51 pg/ml, p<0.001) than 
patients without heart failure.  They concluded that BNP provided an accurate 
‘rule-out’ test for cardiac failure. 
The merits of longer term risk stratification were explored by Wang and 
colleagues.  They recruited 3346 asymptomatic patients who attended for the 
sixth round of surveillance during the Framingham Offspring Study, an 
epidemiological study of cardiovascular risk factors.125   BNP levels were taken, 
and the patients were followed up for a mean of 5.2 years.  High levels of BNP 
predicted death (p=0.009), heart failure (p<0.001) and stroke or TIA (p=0.002) 
during the follow-up period, independent of traditional risk factors. 
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Furthermore, BNP and NT-proBNP can predict the prognosis in patients who 
already have a diagnosis of cardiac failure.  Doust and collegues performed a 
systematic review of 19 studies assessing the prognostic value of BNP.126  In nine 
of these, BNP remained the only significant predictor of mortality on 
multivariate analysis.  More recently, the UK based Heart Protection Study 
Collaborative has reported the results of a large epidemiological study that 
followed over 20,000 patients for an average of 5 years.127  Patients with an 
elevated NT-proBNP had an increased fully adjusted relative risk of MACE (RR 
3.09, p<0.0001) and heart failure (RR 9.23, p<0.0001)  
As demonstrated with the above studies, the predictive value of both BNP and 
NT-proBNP has been studied.  Several trials have included both markers in their 
analysis.128  There appears to be little difference in the predictive value of BNP 
and NT-proBNP, and often local availability dictates the assay used.  
1.5.3 BNP in surgical studies 
Since BNP can detect subclinical cardiac disease and predict outcome in patients 
with known cardiac disease, it is no surprise that BNP is attractive for surgical 
risk stratification.   
Following the start of the research submitted in this thesis, several studies have 
been published examining the predictive value of BNP and NT-proBNP in various 
surgical populations.  Yeh and colleagues observed 190 Taiwanese patients 
undergoing a variety of major NCS procedures.129  They found a 7.9% MACE rate, 
with only age and a NT-proBNP >450 pg/l predicting MACE.  It is worth noting 
that this study included congestive cardiac failure (CCF) in the primary endpoint 
of MACE and CCF contributed to more than half the cases of MACE.  The 
diagnosis of CCF did not require echocardiographical evidence of LVF and could 
be made with clinical findings alone.   
Feringa and colleagues showed that NT-proBNP independently predicted post-
operative MACE in a 170 patient cohort undergoing major vascular surgery (AAA 
or lower limb bypass surgery) at the Erasmus University Medical Centre in 
Rotterdam.130  They used a more robust definition for MACE which consisted of 
non-fatal MI and cardiac death.  A MACE rate of 8% was observed with an NT-pro-
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BNP level of 533 mg/l providing an area under the curve (AUC) of 0.9 on receiver 
operator characteristic (ROC) analysis, with a sensitivity of 85% and specificity of 
91%.  Following this, the Erasmus group showed that the predictive effects of 
NT-proBNP could be extended beyond the short-term follow-up period of 30 
days. At a median follow-up of 14 months, an NT-proBNP of ≥319 pg/l was 
associated with a HR of 4.0 for all-cause mortality (95% CI 1.8-8.9) and of 10.9 
for cardiac events (95% CI 4.1-27.9). 
Gibson and colleagues then published our research groups’ preliminary findings 
of the short term predictive value of a pre-operative BNP level.131  We observed 
a 13.7% MACE rate (defined as non-fatal MI and cardiac death) in 190 patients 
undergoing major vascular or abdominal surgery.  A small derivation cohort (41 
patients) and a larger validation cohort (149 patients) were used during the 
study.  In both the derivation and validation groups, the median BNP was 
significantly higher in patients who had a peri-operative MACE than those that 
did not (210 pg/ml vs. 35 pg/ml, p<0.001 and 351pg/ml vs. 31pg/ml, p<0.001).  
ROC analysis showed that a cut-off of 108.5pg/ml provided the best sensitivity 
and specificity (87% each).  Figure 1.5 shows the relationship between MACE and 
BNP in this study.  
Figure 1.5  Relationship between major adverse cardiac events (MACE) and 
b-type natriuretic peptide (BNP) 
 
Reproduced with permission from publisher.
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Cuthbertson and colleagues have published three studies from Aberdeen Royal 
Infirmary examining the predictive value of BNP.132–134  Firstly, they showed the 
median BNP was significantly higher in patients who died or suffered a cardiac 
event (52.2 vs. 22.2 pg/ml, p=0.001) within the first 3 days after major NCS.132  
They noted a MI rate of 5.8% and a mortality of 0.5% during the 3 day follow-up 
period.  At a median follow-up of 654 days they found a 16% mortality rate.133    
Predictors of mortality were increasing age, post-operative troponin rise and 
elevated BNP.  Cuthbertson and colleagues also examined the predictive value of 
BNP in the setting of emergency surgery.134  They studied 40 patients undergoing 
emergency abdominal or trauma surgery. The primary endpoint was peri-
operative MACE, and the secondary endpoint was 6 month all-cause mortality.  
The MACE rate was high (27.5%) and, as with elective surgery, the median BNP 
was significantly higher in the MACE group (310 pg/ml vs. 82 pg/ml, p+0.001).  
More recently, from the same institution, Rajagopalan and colleagues studied 
the predictive value of NT-proBNP in 136 patients undergoing major vascular 
surgery.135  They found that NT-proBNP was an independent predictor of 
myocardial injury, defined as a post-operative cTn rise.  Interestingly, all the 
cTn elevations were asymptomatic (28 patients) and no patients met the criteria 
for MI.    
Several further studies have confirmed the prognostic use of BNP or NT-proBNP.  
Lebowitz and colleagues showed that in 44 high risk NCS patients BNP was a 
significant predictor of MACE.136  High risk was defined as one of the following; 
previous congestive cardiac failure (CCF), ejection fraction<40% on 
echocardiography or severe aortic stenosis.  Yun and collegues recruited 279 
elderly Korean patients (age >60 years) undergoing a wide variety of 
operations.137  They observed a 9.0% cardiovascular complication rate 
(composite of cardiac death, MI, acute pulmonary oedema and non-fatal stroke).  
A NT-proBNP >201 pg/ml independently predicted post-operative MACE.  
Breidthardt and collegues investigated 270 patients undergoing elective 
orthopaedic surgery.138  They observed a low (1.5%) post-operative cardiac event 
rate; however BNP remained a significant predictor of MACE. 
Thus, an elevated pre-operative BNP level has been shown to predict post-
operative MACE in the following cohorts; major NCS patients, vascular patients, 
high risk cardiology patients, orthopaedic patients and emergency surgical 
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patients.  It should be noted that these studies have been carried out in a 
variety of geographical locations. 
Furthermore, Mahla and collegues have demonstrated that an elevated post-
operative NT-proBNP improves risk stratification in addition to pre-operative 
levels.139  They found that a threshold of 280 pg/ml pre-operatively and 860 
pg/ml post-operatively predicted for MACE.  However on multivariate analysis, 
adjusting for a number of clinical factors, post-operative BNP elevation was the 
only significant predictor of post-operative MACE.   
Goei and collegues from the Erasmus group have shown that the addition of 
highly selective CRP (hs-CRP) to NT-proBNP levels further improves risk 
prediction.140  They observed a large cohort of patient (n=592) undergoing major 
vascular surgery (carotid, aortic and infra-inguinal bypass surgery).  The authors 
defined a raised hs-CRP as >6.5mg/l and a raised NT-proBNP as >350pg/ml.  They 
found that hs-CRP (OR 2.54, 95% CI 1.50-4.30) and BNP (OR 4.78, 95% CI 2.71-
8.42) independently predicted MACE on multivariate analysis.  Furthermore, 
combining both variables improved risk prediction (OR 6.63, 95% CI 3.01-13.25).     
The predictive values of BNP and NT-proBNP have been examined in three meta-
analyses.   Rodseth and colleagues investigated the utility of BNP and NT-proBNP 
in patients undergoing vascular surgery.141  A search of trials published up to 
January 2008 was performed and seven suitable studies were included.  The 
authors found that an elevated BNP and NT-proBNP were predictive of cardiac 
death (OR 7.6, 95% CI 1.3-43.3, p=0.02), non-fatal MI (OR 6.2, 95% CI 1.8-21.4, 
p=0.004) and MACE (OR 17.4, 95% CI3.3-91.2, p<0.001).  The analysis was 
performed at the discriminatory threshold as identified in each individual study.  
The authors concluded that these biomarkers were useful prognostic tests, 
however they were unable to ascertain which marker was preferable and what 
was the optimal cut-off threshold.   
Karthikeyan and colleagues included nine prospective studies investigating the 
short term predictive value of BNP (4 studies) and NT-proBNP (5 studies) in 
patients undergoing a variety of non-cardiac surgical procedures.7  There was an 
overlap of 4 studies examined in the Rodseth analysis.141  Similarly, they 
conclude that both BNP and NT-proBNP are good independent predictors of post-
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operative cardiac events.  However, due to the small number of studies 
included, they were unable to suggest a threshold value for optimal predictive 
utility.   
Ryding and colleagues included 15 studies in their analysis (8 relating to BNP, 7 
to NT-proBNP).142   Similarly, they found that patients with elevated BNP (or NT-
proBNP) had a significantly higher MACE rate than those without.  A pooled odds 
ratios for MACE of 19.77 (95% CI 13.18-29.65, p<0.0001) was found in patients 
with elevated BNP compared with those that did not.  No study to date has 
directly compared BNP with NT-proBNP in a surgical cohort; however all the 
meta-analyses concluded that BNP and NT-proBNP are powerful predictors of 
post-operative cardiac events.  In summary, the predictive value of BNP is 
evident but the best cut-off point is not. 
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1.6 Modification of risk 
The benefit to individual patients of accurate pre-operative risk assessment and 
stratification relies on the availability of therapeutic options that allow 
modification of risk.  Several areas of pre- and peri-operative optimisation have 
been examined. 
1.6.1 Beta-blockers 
The use of peri-operative β-blockers gained popularity in the 1990s following the 
publication of two landmark RCTs.  Firstly, Mangano and colleagues randomised 
200 patients with, or at high risk of, CAD to either orally administered atenolol 
peri-operatively or placebo.143  They showed a significant reduction in mortality 
and cardiac morbidity in the atenolol group during the 2 year follow-up period.  
A Dutch group of researchers (Poldermans and colleagues) then reported the 
results of the DECREASE-I study.144  High risk patients undergoing vascular 
surgery were identified pre-operatively and underwent dobutamine stress 
echocardiography.  One hundred and twelve patients with stress-induced 
ischaemia were randomised to peri-operative bisoprolol and standard care versus 
standard care alone.  Patients in the β-blocker arm of the study had a 
significantly lower rate of cardiac death (3.4% vs. 17%, p=0.02) and non-fatal MI 
(17% vs. 0%, p<0.001).  The differences were not explained by patient 
characteristics, echocardiography results or type of surgery and the authors 
concluded that beta-blockage should be considered routine in high risk patients.   
However, the combined size of these studies (only 312 patients) was small; and 
both studies have been criticised for methodological errors.  The DECREASE-I 
study was unblinded in the setting of a high proportion of silent MIs. The 
Mangano study did not follow an intention to treat protocol.  With these 
concerns in mind, the PeriOperative ISchemic Evaluation (POISE) trial was 
performed.5  This was a large multicentre RCT that recruited over 8000 patients 
undergoing non-cardiac surgery from nearly 200 institutions.  Patients were 
recruited if the they had a history of atherosclerotic disease (CAD, CVD, PVD) or 
if they had one or more risk factor (major intra-abdominal or intra-thoracic 
surgery, diabetes, renal impairment, age >70 years or emergency surgery).  
Patients received pre-operative extended release metoprolol or placebo, given 
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2-4 hours prior to surgery and continued for 30 days.  The authors found a 
statistically significant reduction in the composite end-point of cardiovascular 
death, non-fatal MI and non fatal cardiac arrest in the treatment group (5.8% vs. 
6.9%, p=0.0399).  However, these results were offset by a higher overall 
mortality (3.1% vs. 2.3%, p=0.0317) and higher stroke rate (1.0% vs. 0.5%, 
p=0.0053) in the metoprolol group.  This study used a relatively unselected 
population compared with the DECREASE-I trial, and performed no pre-operative 
cardiac imaging.  Beta-blockade in patients with subclinical LVSD can induce 
bradycardic hypotension, which may explain the higher rate of stroke in the 
treatment arm.  Critics of the POISE study suggest that the study protocol 
resulted in aggressive dosing of metoprolol in patients who had not previously 
been exposed to beta-blockers, just hours before major surgery. 
The smaller UK based Peri-Operative B-Blocker (POBBLE) trial was recruiting in 
parallel to the POISE study.42  One hundred and three patients undergoing infra-
renal vascular surgery were randomised to oral metoprolol from admission to day 
7 post surgery or placebo.  Exclusion criteria included previous MI or positive 
DSE.  Hence a lower risk population was selected.  Despite this, a non-fatal MI 
rate of 8% and unstable angina rate of 9% was noted.  Patients had 72 hour 
Holter monitoring starting at induction of anaesthesia.  A composite end point of 
MI, unstable angina, ventricular tachycardia and stroke was used.  No difference 
in cardiovascular complications was seen between the treatment and placebo 
groups (32% vs. 34%), although median time to discharge was shorter in the 
treatment group (10 days vs. 12 days, p<0.02)     
The Dutch group have subsequently reported the results of the DECREASE-IV 
study.44  They performed a four-armed RCT, with patients assigned bisoprolol, 
fluvastatin, combination therapy or placebo.  Patients considered to be at 
intermediate risk of peri-operative cardiac events were included.  Patients were 
started on the study protocol prior to admission for surgery (median 34 days 
prior to surgery) and the dose was tailored to resting heart rate targets. Patients 
who received bisoprolol had a lower cardiac event rate (2.1% vs. 6.0%, p=0.002).  
No difference in stroke rate was seen.  The authors claim that peri-operative 
beta-blockage is safe, if administered with a careful protocol of dose titration to 
aim for a heart rate of 50-70 beats per minute, and reduces adverse cardiac 
outcomes.   
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In summary, there are conflicting results from the studies examining the benefits 
of peri-operative beta-blockade.  The largest study (POISE) demonstrated a 
significant adverse event rate in the treatment arm.  Smaller studies, with a 
more careful dose-response protocol, have showed benefit with less adverse 
events.  The optimal agent and the timing of beta-blocker commencement prior 
to surgery remain contentious.      
1.6.2 Antiplatelet agents 
Antiplatelet agents (APA) are the cornerstone of best medical therapy in 
patients with, or at high risk of, cardiovascular disease.145 Aspirin and 
clopidogrel inhibit platelet aggregation and therefore prevent thrombosis.146  
Despite the benefits of APA therapy, concerns about peri-operative bleeding 
complications often lead to cessation of anti-platelet therapy prior to surgery.  
This common practice is not based on current evidence for most types of surgical 
procedure.  Furthermore, there is now a recognised acute rebound effect after 
withdrawal of aspirin therapy that leads to a pro-thrombotic state as a result of 
increased thromboxane levels and impaired fibrinolysis.147  This, in combination 
with the pro-thrombotic state produced by the stress of surgical trauma itself, 
leads to a heightened risk of ischaemic events.148  Lastly, with the advent of 
drug eluting stents, withholding APAs peri-operatively may have adverse 
outcomes such as delayed stent occlusion.149   Collet and colleagues investigated 
the use of antiplatelet agents in patients admitted with ACS.150  A small group of 
patients were identified who had recently (<30 days) stopped APA therapy.  Two 
thirds of these patients had the APA stopped for elective surgery.  These patient 
had a higher mortality (21.9% versus 12.4%, P=0.04) than those who did not 
interrupt APA or those who were never on APA therapy.     
Oscarsson and colleagues have performed the only RCT to date examining the 
safety of continuation or discontinuation of aspirin during the peri-operative 
period.45  Patients with high or intermediate risk factors for peri-operative 
MACE, who were already taking aspirin, were randomised to continuation of 
aspirin or placebo.  The study was stopped early, prior to interim analysis due to 
changes in national guidelines regarding the management of high risk 
cardiovascular patients, and increasing evidence that antiplatelet cessation was 
harmful.  The study recruited 220 of an intended 540 patients.  Despite this 
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limitation, the authors were able to demonstrate a significantly improved MACE 
rate in the treatment arm (1.8% vs. 9.0%, p=0.02) and no difference in bleeding 
complications were seen.  Subsequently, Albaladejo and collegues have 
published the results of the RECO study, a large multicentre observational study 
of patients with coronary stents undergoing elective NCS.39  APA was continued 
in 72% of patients, stopped for <5 days in 14% and stopped for ≥5 days in 14%.  A 
significantly higher MACE rate was seen in the group without APA for 5≥days.  
Overall mortality in the MACE group was 14.5% 
A recent meta-analysis has examined 28 studies that recruited patients with a 
history of coronary stents undergoing NCS.74  As previously discussed, a reduced 
MACE rate in patients undergoing NCS greater than one year after stent insertion 
was noted, compared with patients who had a stent placed less than 1 year 
before surgery.  However they also found no improvement in MACE rates in 
patients continued on dual APA therapy compared with those on aspirin only.  In 
particular the authors highlighted the results of a study performed at the 
Erasmus Centre, Rotterdam that investigated the outcomes of 550 patients 
undergoing NCS after stent insertion.151  Of the patients who experienced MACE, 
45% were on single APA, compared with 55% in the dual APA group (p=0.92).  
Significant bleeding complications were higher in the dual APA group compared 
with the single APA group (21% vs. 4%, p<0.001).       
Finally, we await the results of the on-going POISE-II trial which is currently 
randomising APA naïve patients to aspirin, clonidine (α-2 agonist) or placebo.   
In summary, there is a growing body of evidence to support the continuation of 
APAs during the peri-operative period in all but a few select circumstances.  
However, there remains a lack of evidence regarding the safety of dual APA in 
patients undergoing NCS.  
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1.6.3 Lipid-lowering therapy  
The beneficial effects of statins in patients with cardiovascular disease are 
evident.  For example, the MRC/BHF Heart Protection Study randomised over 
20,000 U.K. patients with risk factors for cardiovascular disease to 40mg 
simvastatin or placebo.  There was a significant reduction in the 5 year mortality 
in the treatment group (12.9% vs. 14.7%, p<0.001), predominantly due to a 
reduction in cardiac death (5.7% vs. 6.9%, p<0.0001).152  Similar reductions in 
non-fatal MI and stroke were observed.  Aside from lipid-lowering, statins also 
demonstrate other desirable effects such as plaque stabilisation and reduced 
vascular inflammation, independent of changes in serum cholesterol.153,154   
Accordingly, several studies have demonstrated improved peri-operative 
outcomes with statin therapy.  O’Neil-Callaghan and colleagues retrospectively 
examined the outcome of patients undergoing major vascular surgery over a 2 
year period (1999-2000) in a single centre.78  An adverse outcome was defined as 
death, MI, CCF and ventricular arrhythmia.  Patients receiving a statin had a 
lower adverse event rate than those not on a statin (9.9% vs. 16.5%, p<0.001).  
After adjustment for other significant predictors, statin therapy remains a 
significant protective factor (OR 0.52, 95% CI 0.35-0.77).  Similarly, Lindenauer 
and colleagues presented analysis of a large national US database of discharge 
information and pharmacy prescription from 329 institutions.155  Over 780,000 
patients undergoing mixed major NCS were included.  Unadjusted crude 
mortality was lower in patients prescribed statins (2.13% vs. 3.05%, p<0.001).  
After adjustment for confounding factors, the authors reported a preserved 
protective effect (OR 0.62, 95% CI 0.58-0.67).  Subsequent to these retrospective 
database analyses, Le Manach and colleagues prospectively studied the post-
operative outcome of 1,674 patients undergoing aortic surgery.156  Half the 
patients (52.6%) were receiving chronic statin therapy at the time of surgery.  
Patients treated with statins had a significantly reduced peri-operative mortality 
(OR 0.40; 95% CI 0.28-0.59) and reduced PMI (OR 0.52; 95% CI 0.38-0.71); similar 
reductions in peri-operative stoke and acute kidney injury were observed.     
More recently, Chopra and colleagues have performed a meta-analysis of 15 
RCTs examining the influence of peri-operative treatment with statins.157  
Patients included had not previously received statin therapy.  The majority of 
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trials were in patients undergoing cardiac surgery (11 of 15).  Statin therapy was 
associated with a significantly reduced risk of PMI (RR 0.53; 95% CI 0.38-0.74).  
However, no reduction in peri-operative mortality was observed.  Therefore, 
current evidence supports continuation or commencement of statins prior to 
NCS.     
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1.6.4 Myocardial revascularisation 
The management of patients who are found to have significant CAD is not clear.  
Pre-operative revascularisation, by way of coronary artery bypass grafting 
(CABG) or percutaneous coronary intervention (PCI), adds to the patients’ 
morbidity and mortality and may delay the intended surgical procedure.  
However, as previously discussed, Eagle and colleagues demonstrated a 
significantly improved peri-operative MACE rate and mortality in patients with 
CAD treated with previous CABG compared with those patients treated 
medically.158  
McFalls and colleagues reported the results of the Coronary Artery 
Revascularization Prophylaxis (CARP) study, in which they randomised 510 
patients to revascularisation or standard care prior to AAA or PVD surgery.40  In 
the treatment arm, PCI was performed in 59% of patients and CABG in 41%.  The 
primary endpoint, long term mortality, was similar in the revascularisation group 
compared with placebo (22% vs. 23%, p=0.92).  The secondary outcome of peri-
operative MI was also similar (12% vs. 14%, p=0.37).  
Poldermans and colleagues performed a multicentre RCT, the DECREASE-V trial, 
in which they recruited high risk patients prior to AAA or PVD surgery.41  DSE was 
performed to identify those patients with extensive stress-induced ischaemia.  
One hundred and one patients were randomised to revascularisation (n=49) or no 
revascularisation (n=52).  There was no difference between the revascularisation 
group and the no-revascularisation group for all-cause mortality (22.5% vs. 
11.5%, p=0.14) and a composite of mortality and non-fatal MI (42.9% vs. 32.7%, 
p=0.30).  Alarmingly, 2 patients in the treatment arm died due to a ruptured 
AAA following successful PCI, but prior to vascular surgery.  Also, one patient 
suffered a post-PCI MI that precluded proceeding to vascular intervention.  
Further evidence against the routine use of myocardial revascularisation came 
following the publication of the long-term follow-up results.  At a median of 2.8 
years following randomisation to the DECREASE-V trial, patients in the 
revascularisation group had a similar survival rate than those in the non-
treatment arm (61% vs. 64%, p=0.61).159  There was also no difference when 
considering a composite endpoint of mortality, non-fatal MI and coronary 
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revascularisation.  Only 2 of 52 patients in the no revascularisation arm required 
coronary intervention during the follow-up period. 
Garcia and colleagues performed a subgroup analysis of the long term follow-up 
of the CARP trial, focussing on patients with significant left main coronary artery 
stenosis (>50%).160  Log-rank analysis within this group demonstrated an 
improved survival in the revascularisation group compared with standard care 
(0.84 vs 0.52, p <0.01).  This benefit was not seen in patients with 2 or 3 vessel 
disease without left main coronary stenosis.  
Finally, it is noteworthy that deferral of surgery for cardiac investigation and 
intervention is not without risk, as illustrated by the interval AAA rupture rate 
seen in the DECREASE V trial.  Krupski and colleagues observed 42 patients in 
whom further cardiology assessment was considered necessary prior to vascular 
surgery.  They found a 38% complication rate following cardiac intervention 
(percutaneous or open), including graft infection, pseudoaneurysm formation 
and renal failure.  A median delay to vascular surgery of nearly a month was 
encountered during the study.  Furthermore, 2 patients with reconstructable 
PVD required amputation during the workup period. 
In summary, routine pre-operative revascularisation in patients with CAD does 
not improve post-operative morbidity and mortality and exposes patients to the 
risks and delays of an additional procedure.  However, high risk patients with 
significant left main coronary disease may benefit from intervention.  
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1.6.5 Ventricular assist devices 
The use of left ventricular assist devices (LVAD) is increasing for patients with 
end-stage heart failure (ESHF), and is now considered an alternative to 
transplantation.161  Some authors have described a >50% survival at 2 years 
following LVAD inserion.162  Studies investigating patients with LVAD undergoing 
NCS are limited to case series.  Morgan and colleagues reported on 20 patients 
with ESHF requiring LVAD who underwent elective NCS.163  No mortality, 
thromboembolic complications or device failures were seen and the main 
complications were bleeding related to anticoagulation.  While no studies have 
examined the pre-operative management of ESHF with or without LVAD, the 
anticipated rise in the number of patient with such devices makes them 
noteworthy in this thesis.  
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1.6.6 Enhanced Recover after Surgery (ERAS) 
Enhanced recovery after surgery (ERAS) or ‘fast track surgery’ is a concept first 
described by Henrik Kehlet in the early 1990’s.164  The approach employs a 
multimodal peri-operative care pathway with the aim of attenuating the stress 
response to surgery and accelerating recovery.165  Implementation of enhanced 
recovery protocols has led to improved outcomes across a range of different 
specialties including reductions in surgical morbidity and hospital stay. 166–168  
The primary end-points in most studies examining ERAS versus conventional 
care, particularly in intestinal surgery, are time to discharge, return to normal 
gut function and surgical morbidity.169,170  However, there are certain 
components that are of particular interest from a cardiac morbidity perspective. 
1.6.6.1 Goal directed fluid administration 
Targeted fluid administration during and after surgery, guided by non-invasive 
cardiac output monitoring, is increasingly used within the ERAS pathway.165  
Intra-operative use of Oesophageal Doppler (OD) monitoring aims to reduce 
intra-operative hypotension and allow fluid administration tailored to the 
patient’s cardiac output.171 A meta-analysis of five RCTs studying the use of OD-
monitored fluid administration recruited 420 patients undergoing major NCS.172  
The authors showed a reduced overall complication rate, reduced post-operative 
stay and improved peri-operative cardiac output in the OD group compared with 
the standard care arm. 
How these measures affect high risk patients is unclear.  The ongoing 
optimisation of peri-operative cardiovascular management to improve surgical 
outcome trial (OPTIMISE) may clarify this.  The trial is currently recruiting high 
risk patients undergoing intestinal surgery, with one or more of the following 
inclusion criteria required; emergency surgery, acute or chronic renal 
impairment, DM, age >65 or the presence of a risk factor for cardiac or 
respiratory disease.  Patients are randomised to a goal-directed fluid regime, 
guided by OD, with a fixed dose intra-venous infusion of dopexamine, or 
standard care. 
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1.6.6.2 Minimally invasive surgery 
Many surgical procedures are now performed in a minimally invasive fashion.  In 
the early stages of interest in laparoscopic colorectal surgery, several large RCTs 
were performed to compare outcomes against standard open surgery. The 
COLOR trial was a European multicentre RCT, comparing laparoscopic with open 
colonic resection.92  Over 500 patients were recruited to each arm.  
Disappointingly, there was no improvement in overall, respiratory or cardiac 
complications in either group.  Similarly, the multicentre UK-based MRC CLASSIC 
trial randomised 794 patients to laparoscopic or open colorectal surgery.93  No 
difference in overall complications or cardio-respiratory complications was 
observed.  The US multicentre COST trial randomised 872 patients to 
laparoscopic or open colorectal surgery.173  Again, no improvement in peri-
operative morbidity or mortality was seen.  These finding may be explained by 
the relative inexperience of the operators for laparoscopic surgery compared 
with conventional open surgery.  For example, in the COST trial, participating 
surgeons were only required to have performed 20 laparoscopic colectomies 
before they were able to recruit for the study.  More recently, Feroci and 
colleagues reported a single centre experience of laparoscopic colorectal surgery 
for high risk patients (defined as the presence of respiratory, cardiac or renal 
co-morbidity).174  Cardio-respiratory complications were lower in the 
laparoscopic group compared with the open group (5.8% vs. 15.8%, p=0.003) as 
was mortality less (1.5% vs. 7.5%, p=0.038).       
Endovascular AAA repair (EVAR) is now feasible for certain patients with 
anatomically appropriate aneurysms.175  Brown and colleagues investigated the 
incidence of cardiac morbidity in the year following randomisation to the EVAR 1 
trial.176  This study compared open AAA repair versus EVAR in patients suitable 
for both procedures.  They found a reduced rate of cardiovascular morbidity 
(composite of MI and stroke) in the EVAR group (2.6%) compared with the open 
group (3.2%), although this difference was non-significant (p=0.164).  No 
differences were seen in one year mortality (3.8% vs. 3.6% respectively, 
p=0.674). 
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1.6.7 Post-operative monitoring 
The level of care a patient receives after major NCS has implications for the risk 
of adverse events.  To illustrate this, Pearse and colleagues examined data 
extracted from the Intensive Care National Audit and Research Centre Database 
(ICNARC) from nearly 100 English Institutions over a five year period.16  The 
study included data from over four million operations.  A high risk procedure was 
defined as an operation with an expected mortality of 5% or more.  High risk 
patients comprised only 12.5% over the total cohort, yet 83.8% of the overall 
mortality.  Focused analysis on the high risk group showed that the highest 
elective surgical mortality was in patients that were initially cared for at a 
standard ward level, before escalation to a critical care bed (36.4%) compared 
with patients who were planned admissions to a critical care area immediately 
post-operatively (10.1%).  A limitation of this study was the incomplete 
participation of some institutions.  Therefore, Jhanji and colleagues used the 
ICNARC and HES database to examine this further in a single NHS trust over a 3 
year period.17  They claimed improved data capture, and a more accurate 
reflection of post-operative practice.  The same operative codes to define high 
risk patients were used as in the national trial.  They found that only 35.3% of 
high risk patients were admitted to a critical care bed at any stage post-
operatively.  Only 49.0% of high risk patients that died were admitted to critical 
care areas, and only 25.6% died in a critical care area.  Carlise and colleagues 
identified unplanned critical care bed admission following elective colorectal 
resection as an independent predictor of peri-operative and long term 
mortality.177  Thus, increasing evidence is available to support the elective post-
operative admission of high risk patients to a critical care area.  However, this 
will raise inevitable problems about healthcare resources, particularly in the UK.              
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1.7 Therapeutic intervention for post-operative 
myocardial infarction 
Finally, it is worth noting that there are no randomised trials assessing the 
efficacy of any interventions on patients suffering a PMI.  This is surprising in 
view of the large number of studies in primary (non-operative) infarction, the 
high incidence of PMI in certain populations, and the uncertainty regarding the 
use of many cardiac medications in the immediate post-operative period.  
Overwhelming evidence from therapeutic trials in the non-operative population 
suggests intervention following MI is superior to medical therapy and that the 
timing of intervention is crucial.70  No such information is available in the post-
operative setting.  
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1.8 Current guidelines for the assessment and 
management of cardiac risk in patients undergoing 
non-cardiac surgery (NCS) 
The first well recognised consensus report regarding the assessment and 
management of cardiac risk in NCS was produced jointly by the American College 
of Cardiology (ACC) and the American Heart Association (AHA) in 1996.178  These 
guidelines were updated in 2002179 and then most recently amended in 200769.  A 
framework for the evaluation of patients prior to NCS is presented in Figure 1.6.  
Guidance is also offered for the management of specific peri-operative 
circumstances.  For example, advice about the management of recent PCI is 
provided [Figure 1.7].  Recommendations about the use of beta-blockers, 
statins, pre-operative revascularisation and intra-operative considerations 
(anaesthetic agents, glycaemic control, monitoring) are made. 
More recently, guidelines from the European Society of Cardiology (ESC) and 
endorsed by the European Society of Anaesthesiology have been produced.180  
Broadly speaking, these guidelines follow a similar format to the ACC/AHA 
guidelines.  However some variation is present.  Additional interest is focused on 
optimal methods of non-invasive cardiac imaging.  Reliance on the currently 
available risk stratification scoring systems is questioned and a different strategy 
for pre-operative beta-blockade is suggested.
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Figure 1.6  AHA/ACA Algorithm for cardiac evaluation prior to non-cardiac surgery 
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Figure 1.7  Suggested approach to management of patients with previous 
percutaneous coronary intervention (PCI) 
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1.9   Scientific misconduct and peri-operative research  
The spectre of research fraud has over-shadowed peri-operative medicine in 
recent years, with two noteworthy examples.  Joachim Bolt was a German 
anaesthetist and academic practicing in Rhineland-Pfalz and had published over 
200 peer reviewed studies.  He was considered a leading expert in the field of 
peri-operative intravenous fluid management and his department had produced 
a strong body of research to support the use of colloid for resuscitation during 
surgery, particularly hydroxyethyl starch solution (HeS).181,182  In December 2009, 
a RCT was published in Anaesthesia and Analgaesia by Joachim Boldt studying 
the benefits of colloid versus albumin when used as a pump-priming solution 
during CABG.183  Anaesthesia and Analgaesia’s editor-in-chief, Steven Shafar, 
received correspondence shortly after questioning the study’s amazingly perfect 
results despite a small study size.  Then followed a period of investigation by Dr 
Shafar, culmination in the shocking findings that this study had not received 
ethical approval, no written consent was obtained, no randomisation was 
performed and no follow-up was carried out.  All these omitted steps were 
described by Boldt in the methods section of the paper.   Anaesthesia and 
Analgaesia subsequently published a notice of retraction, which also questioned 
the validity of Boldt’s other work.184  Boldt’s research empire slowly crumbled 
over the following months, and the veracity of his studies were rigorously 
investigated.  This culminated in the publication of a joint statement signed by 
16 editors of anaesthetic journals that had previously published Boldt’s 
papers.185  The editors were unable to find research board and ethical approval 
for 88 of the 102 article investigated and these articles were all retracted.  
Boldt was fired and stripped of his professorship and a criminal investigation is 
ongoing.  Finally, a revised meta-analysis has been published since the scandal, 
which examines the outcomes following the use of HeS compared with other 
fluids for intravenous resucitation.186  They analysed trials with and without 
Boldt’s research included.  Alarmingly, when Boldt’s data was excluded, HeS 
resuscitation was associated with a higher rate of mortality and renal failure 
than other solutions.  This association was not previously observed when Boldt’s 
data was included. 
More directly related to this literature review, though currently less scandalous, 
is the question of ethical misconduct raised against Don Poldermans.  Formerly, 
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Poldermans was head of the department of anaesthetics and peri-operative 
medicine at the Erasmus Medical Centre in Rotterdam.  Poldermans led a well 
respected research group that produced over 500 publications in the field of 
peri-operative medicine, including several seemingly well designed RCTs.  In 
November 2011, a press release from Erasmus MC stated the Poldermans had 
been dismissed for ‘violation of academic integrity’.187  A committee 
investigation found evidence of irregularities of data collection, use of patient 
data without consent and fictitious data use, particularly in relation to the 
DECREASE II, III, IV and V studies.188                
To date, no publications that Poldermans has contributed to have been 
retracted, however some journals have published notices of concern.189,190  Due 
to the large number of studies over many years, investigation of the integrity of 
all Poldermans research contributions is probably impractical. The investigating 
committee published a follow-up report in 2012, highlighting evidence of 
research irregularities and negligence in several studies.191  Furthermore, the 
report states that the lack of record keeping in various databases meant that 
further investigation would be time consuming and likely unsuccessful.   
Poldermans was head of the ESC/ESA guidelines committee for pre-operative 
cardiac risk assessment and peri-operative cardiac management in non-cardiac 
surgery and there are calls for these guidelines to be revised in his abscence.180  
Likewise, his research strongly influenced approaches to non-invasive cardiac 
assessment and peri-operative beta-blockade.  In light of his dismissal, all 
Poldermans studies will now come under suspicion. 
82 
1.10 Aims of the thesis 
The incidence of peri-operative MACE and mortality is variable.  Furthermore, 
numerous methods of risk stratification are available, with variable performance 
in different observed populations. As demonstrated in this chapter, several peri-
operative interventions are available to modify an individual’s risk before, 
during and after major surgery.   Therefore, the aims of this thesis are as 
follows; 
i. To review current literature regarding cardiac risk stratification and 
modification prior to major non-cardiac surgery 
ii. To identify the incidence and clinical predictors of peri-operative MACE 
and mortality in a prospectively collected cohort of patients undergoing 
major non-cardiac surgery in a West of Scotland setting.   
iii. To assess the utility of B-type natriuretc peptide (BNP) in cardiac risk 
prediction.   
iv. To determine whether plasma BNP concentration can predict the long-
term survival of patients following major NCS. 
v. To assess the utility of a pre-operative 12-lead ECG in prediction of post-
operative adverse events and mortality.    
vi. To determine the efficacy of a commonly used risk stratification scoring 
system (RCRI) in our prospectively collected cohort. 
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2 Methods 
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2.1 Patient selection 
A prospective single centre observational cohort study was performed.   
Consecutive patients undergoing major non-cardiac surgery at Gartnavel General 
Hospital between 2003 and 2006 were selected for inclusion in the study.  
Gartnavel General Hospital is a large teaching hospital with vascular, intestinal 
and urological surgery services.  Four groups of patient were included in the 
study;    
1. Aortic surgery.  Both open repair and endovascular aortic aneurysm repair 
(EVAR) procedures were included.   
2. Peripheral vascular disease requiring re-vascularisation surgery.  This 
included femoral artery surgery, femoro-popliteal and femoro-distal 
bypass surgery and extra-anatomical bypass surgery such as axillo-
bifemoral surgery. 
3. Peripheral vascular disease unsuitable for vascularisation requiring lower 
limb amputation.  Both below-knee and above knee amputation were 
included. 
4. Laparotomy for gastro-intestinal or urological pathologies 
2.1.1 Urgency of procedure 
The urgency of surgical intervention was defined as; 
 Elective – following planned admission for surgery 
 Urgent – following un-planned emergency admission requiring same 
admission intervention 
Patients requiring emergency surgery, defined as surgery within 24 hours of an 
un-planned admission, were excluded.    
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2.2 Ethical approval 
Ethical approval for this study (REC reference number 04/193(1)) was provided 
by the West of Scotland Research Ethics Committee.  Participating patients were 
given a patient information sheet and signed a study consent form prior to 
inclusion. This study involved no additional intervention other than an extra 
blood test, which was taken at the time of the routine pre-operative blood tests. 
2.3 Pre-operative clinical assessment 
The presence of risk factors such as diabetes, hyperlipidaemia, previous 
myocardial infarction (MI) and chronic obstructive pulmonary disease (COPD) 
were obtained from the patient’s history and medical records.  Ischaemic heart 
disease was defined as a previous myocardial infarction, a positive exercise 
tolerance test, the use of nitrate therapy or the presence of pathological Q-
waves on ECG.  Left ventricular failure (LVF) was considered present if the 
patient had a prior hospital admission with heart failure or left ventricular 
impairment on previous echocardiography.  Cerebrovascular disease was defined 
as a previous cerebrovascular accident or transient ischaemic attack.  The 
glomerular filtration rate (GFR) was estimated using the Modification of Diet in 
Renal Disease (MDRD) equation.192  Renal impairment was considered present if 
the estimated GFR was <60mls/min.  A patient was considered a smoker if they 
were smoking at the time of admission for surgery.  Hypertension was considered 
present if the patient had a previous medical documentation of hypertension and 
was currently taking antihypertensive medication.  The current medication was 
also recorded, in particular the prescription of anti-platelet agents, statins and 
beta-blockers.   
All patients had standard pre-operative assessment including a 12-lead ECG the 
day before surgery.  Further cardio-respiratory assessment was carried out at 
the discretion of the operating team. 
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2.4 Laboratory investigations 
2.4.1 Haematology 
A 5ml venous blood sample was taken in an ethylenediaminetetraacetic acid 
(EDTA) tube and sent to the haematology laboratory for an analysis of full blood 
count. Another 5ml sample was collected in a citrate tube for a coagulation 
screen. 
2.4.2 Biochemistry  
A 5ml venous blood sample was taken in a lithium-heparin tube and sent to the 
biochemistry laboratory for measurement of serum urea and electrolytes, liver 
function tests, C-reactive protein, non-fasting total cholesterol, triglycerides 
and high-density lipoprotein fraction of cholesterol. 
Serum cardiac troponin-I (cTnI) was measured using the ADVIA Centaur® 
immunoassay (Bayer Diagnostics), which has a sensitivity and assay range of 
0.02-50 ng/ml. 
2.4.3 BNP analysis 
An additional venous blood sample was taken for plasma BNP the evening prior 
to surgery. This was collected in chilled EDTA and aprotinin (Trasylol; 50 IU/ml), 
immediately centrifuged and stored at –25 Celsius.  BNP concentrations were 
measured using a direct radioimmunoassay (Shionoria BNP kit, Shinogi & Co, 
Osaka, Japan).193  The minimum detectable quantity of BNP is 2pg/ml. The 
within-assay and between assay co-efficients of variation are 5.3% and 5.9%, 
respectively.  Batch sample analysis was performed during the study by a 
biochemist blinded to clinical details.  The longest sample storage period was 6 
months. 
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2.5 Post-operative monitoring 
The patients were managed post-operatively in the intensive care unit, the high 
dependency unit or the ward.  Requirement for critical care after surgery was 
determined by the anaesthetic and surgical teams.  Routine laboratory 
investigations (haematology and biochemistry) were performed daily for the first 
3 post-operative days, as per local policy.     
2.5.1 Serial cardiac screening 
Post-operative screening for cardiac events was performed.  This consisted of 
daily clinical assessment and serial ECGs and troponin I measurement on day 2 
and day 5 post-operation.  Patients that were discharged were seen at a clinic 
appointment at 6 weeks.   ECGs and troponin I measurement were repeated at 
this point.  
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2.6 12-Lead electrocardiography 
All electrocardiographs (ECGs) were batch analysed at the end of the study by 
two investigators (general surgeon and cardiologist), blinded to the clinical 
outcomes.  The ECG results were then double checked by a second cardiologist 
and disagreements were resolved by consensus.  ECGs were examined for the 
presence of the following abnormalities; 
 Left ventricular hypertrophy: Sokolow-Lyon voltage criteria (S wave in V1 
and R wave in V5 or V6 > 35mm, or R wave in aVL > 11 mm).194 
 Bundle branch block: The standard morphological appearance of left or 
right bundle branch block, with a QRS duration of >120 ms. 
 Atrial fibrillation: presence or absence. 
 Axis deviation: Using standard QRS axis electrical criteria, left axis 
deviation > -30, right axis deviation > +90. 
 Q-waves: Present of a negative deflection preceding the R wave in two 
contiguous leads with duration of >40ms and amplitude greater than 25% 
of corresponding R wave.   
 Ventricular strain pattern:  Planar ST segment depression ≥ 1mm or T 
wave inversion in V5/V6. 
 Premature ventricular contraction (PVC): presence or absence of broad 
complex ectopic beats.  
An ECG was considered abnormal if one or more of the above characteristics 
were present.  Cumulative abnormalities on individual ECGs were also recorded. 
ECG findings: heart rate (HR), QRS duration and QTc were recorded directly from 
the automated data display on the ECG.  Tachycardia was defined as HR >100, 
broad QRS complex as >130ms and prolonged QTc as >440ms.      
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2.7 Short term endpoints 
2.7.1 Non-fatal myocardial infarction (MI) 
The definition of a non-fatal MI was that used by The Joint European Society of 
Cardiology/American College of Cardiology Committee:34 a typical rise and 
gradual fall of cardiac troponin with at least one of the following: ischaemic 
symptoms, development of pathological Q waves on the ECG, ECG changes 
indicative of ischaemia (ST segment elevation or depression) or coronary artery 
intervention.     
2.7.2 Cardiac Death 
Cardiac death was defined as death secondary to myocardial infarction, 
cardiogenic shock or intractable dysrhythmia.  
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2.8 Long term follow-up 
Patient status was monitored by scrutiny of administrative and inpatient 
databases to identify those patients who had died during the follow-up period.  
The final census point was carried out in the autumn of 2009.  A patient was 
considered alive if they were under active outpatient follow-up or had an 
inpatient admission within the preceding month.  In those patients who had not 
had contact with secondary care, the GP was contacted for current status.  
Where information from the GP was unsatisfactory, the patient was contacted 
directly.  All patients were followed-up for a minimum of 1 year.  
Mortality during the follow-up period was either inpatient or out-of-hospital.  
Medical records were reviewed to confirm death in the case of in-patient 
mortality.  Out-of-hospital death was identified from administrative databases 
and confirmed by direct contact with the GP.    
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2.9 Statistical analysis 
2.9.1 Data handling 
All patient data was entered into a Microsoft Access database.  All patients were 
assigned an individual anonymous patient number, and all patient data was 
stored on a password encrypted file with no identifiable patient factors.   On 
completion of the data collection period, the database was exported into SPSS 
(Version 15) (SPSS, Chicago, IL, USA) for statistical analysis.  
2.9.2 Comparisons of categorical and continuous data 
Categorical data were compared using the Χ2 test or Fisher’s exact tests where 
applicable.  Normally distributed continuous data was described as mean (+/- 
standard deviation) and comparison was performed using an independent 
samples t-test.  Non-parametric data was described as median (interquartile 
range) and comparison was performed using the Mann-Whitney test and Kruskal-
Wallis test as appropriate.  A p value reflects the probability of an event having 
taken place by chance.  For the purposes of this thesis, a p-value of less than 
0.05 was considered significant. 
The performance of individual variables for predicting post-operative outcomes 
was further analysed using receiver operating characteristics (ROC) and the area 
under the curve (AUC) was calculated. 
2.9.3 Univariate and multivariate analysis 
Univariate survival analysis was performed using Kaplan-Meier curves and 
comparisons made using the log rank statistic.  Variables with a p-value of less 
than 0.10 were further evaluated with a multivariate Cox analysis using a 
backward stepwise selection. 
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3 Determinants of an elevated b-type natriuretic 
peptide in patients undergoing major non-
cardiac surgery 
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3.1 Introduction 
B-type Natriuretic peptide (BNP) is a cardiac neurohormone released from 
cardiac myocytes in response to ventricular wall stress.195  BNP has a significant 
role in both cardiovascular and renal physiology.  BNP reduces sympathetic tone, 
blood pressure and circulating volume homeostasis.123  The presence of raised 
plasma BNP is strongly associated with left ventricular systolic dysfunction in the 
general population196,197, and with a poorer prognosis in patients with cardiac 
disease.126  With an aging population, the incidence of heart disease and heart 
failure is rising.198  The European Society of Cardiology estimates that more than 
15 million patients in Europe have symptomatic heart failure, with a similar 
number having asymptomatic or sub-clinical ventricular dysfunction.199  This 
report suggests that the prevalence of heart failure rises to between 10 and 20% 
in patients over the age of 70. 
Biomarkers of heart failure, in particular BNP, are now widely used in the 
diagnosis of heart failure, as well as prognostic indicators of outcome in 
cardiology patients.200    Inevitably, this has generated interest in BNP as a point 
of care marker for patients undergoing surgical intervention.  Early reports of 
the prognostic utility of BNP in the peri-operative period were promising201; 
however the factors associated with a raised BNP are not clear.  Therefore, the 
aim of this study is to identify the incidence and determinants of raised pre-
operative serum BNP in a West of Scotland cohort undergoing major non-cardiac 
surgery. 
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3.2 Methods 
A prospective single centre observational cohort study was performed.   
Consecutive patients undergoing major non-cardiac surgery were selected for 
inclusion in the study.  Operative groups included were aortic surgery, bypass 
surgery for peripheral vascular disease, lower limb amputation and laparotomy.  
The study was approved by the Central Ethics Committee and local Research and 
Development Committee. Patients were given a patient information sheet and 
signed a study consent form prior to inclusion.  The definitions of the clinical 
variables used are described in full in Chapter 2.   
3.2.1 B-type natriuretic peptide analysis 
A venous blood sample was taken for plasma BNP the evening prior to surgery. 
This was collected in chilled EDTA and aprotinin (Trasylol; 50 IU/ml), 
immediately centrifuged and stored at –25 Celsius.  BNP concentrations were 
measured using a direct radioimmunoassay (Shionoria BNP kit, Shinogi & Co, 
Osaka, Japan).193  The minimum detectable quantity of BNP is 2pg/ml. The 
within-assay and between assay co-efficients of variation are 5.3% and 5.9%, 
respectively.  Batch sample analysis was performed during the study by a 
biochemist blinded to clinical detail.  The longest sample storage period was 6 
months. 
3.2.2 Statistical analysis 
Statistical analysis was performed using SPSS version 15 (SPSS, Chicago, IL, USA).  
BNP values are presented as median and interquartile range (IQR).  Comparison 
of the non-parametric data was performed using the Mann-Whitney tests and 
Kruskal-Wallis test as appropriate.  
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3.3 Results 
Three hundred and forty-five patients were included in the study.  The mean age 
was 68.4 years.  Eighty-seven (25.2%) patients underwent lower limb 
amputation, 100 (29.0%) bypass surgery for peripheral vascular disease, 89 
(25.8%) aortic surgery and 69 (20.0%) underwent laparotomy.   
3.3.1 Determinants of a raised b-type natriuretic peptide 
Across the whole group, the median BNP (IQR) was 38 (16-106) pg/ml, and the 
range was 1 to 2009 pg/ml.  The distribution of pre-operative BNP is 
demonstrated in Figure 3.1.  The median BNP (IQR) was higher in patients 
undergoing lower limb amputation (84 (38-214) pg/ml), than those having bypass 
surgery (38 (16-96) pg/ml), aortic surgery (31 (13-84) pg/ml) and laparotomy (28 
(10-78) pg/ml), p<0.001 [Figure 3.2]. 
Pre-operative BNP (IQR) was higher in patients aged ≥70 years compared with 
those aged <70 years (82 (32-186) pg/ml vs. 26 (11-61) pg/ml, p<0.001) [Table 
3.1].  Similarly, BNP was higher in patients with diabetes (p=0.030), 
hypertension (p<0.001), renal impairment (eGFR <60ml/min) (p<0.001), previous 
MI (p=0.001), ischaemic heart disease (p<0.001) and a history of left ventricular 
failure (p=0.007).  Patients who were receiving beta-blockers, antiplatelet 
therapy and a statin had a higher pre-operative BNP (p<0.001, p=0.004, p=0.007 
respectively).
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Figure 3.1  Distribution of pre-operative b-type natriuretic peptide (BNP) in patients undergoing major non-cardiac surgery 
 
 
Figure 3.2  B-type natriuretic peptide concentration (BNP) by operation type 
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 Table 3.1 Clinical variables and b-type natriuretic peptide (BNP) 
concentration 
 
  n BNP (IQR) p* 
Age  ≥70 years 165 82 (32-186) <0.001 
 <70 years 180 26 (11-61)  
Sex Male 217 35 (15-99) 0.070 
 Female 128 55 (18-127)  
Smoker 
Yes 145  40 (16-96) 0.716 
No 200 37 (15-126)  
Diabetes 
Yes 69  69 (20-161) 0.030 
No 276 36 (15-99)  
Hypertension 
Yes 196  60 (19-149) <0.001 
No 149 31 (13-73)  
Renal Impairment † 
 
Yes 142 70 (28-172) <0.001 
No 203 31 (13-81)  
Hyperlipidaemia 
Yes 110  39 (16-105) 0.871 
No 235 38 (15-106)  
Previous MI 
Yes 64  76 (32-174) 0.001 
No 281 35 (15-99)  
Ischaemic Heart 
Disease 
Yes 104  69 (29-167) <0.001 
No 241  32 (14-95)  
History of Left 
Ventricular Failure 
Yes 64  76 (22-205) 0.007 
No 281 36 (15-99)  
Cerebrovascular 
Disease  
Yes 43  54 (22-184) 0.078 
No 302 38 (15-103)  
COPD Yes 49  35 (15-94) 0.661 
 No 296 39 (16-109)  
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β-Blocker Yes 86 82 (28-180) <0.001 
 No 259 33 (15-91)  
APA Yes 179  46 (22-137) 0.004 
 No 166 33 (13-89)  
Statin Yes 175 49 (19-127) 0.007 
 No 170  32 (14-89)  
Operation type Amputation 87 84 (38-214) <0.001** 
 Bypass 100 38 (16-96)  
 Aortic  89 31 (13-84)  
 Laparotomy 69 28 (10-78)  
 
* Mann-Whitney U-test, unless otherwise stated, ** Kruskal-Wallis Test. 
† Defined as eGFR <60mls/min.   
Abbreviations: MI - Myocardial Infarction, COPD - Chronic Obstructive Airways 
Disease, APA - Anti-Platelet Agent. 
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3.4 Discussion 
An elevated BNP is strongly linked to left ventricular systolic dysfunction (LVSD).    
McDonagh and colleagues studied 1252 West of Scotland patients, randomly 
selected from the general population.124  All patients had full clinical 
assessment, natriuretic peptide sampling and trans-thoracic echocardiography. 
LVSD was defined as an ejection fraction of ≤30%.  The median concentration 
BNP (IQR) was significantly higher in patients with LVSD than those with normal 
ventricular function (24(18-33) pg/ml vs. 8(3-13) pg/ml).  Subsequently, 
Zaphiriou and colleagues reported the results of the UK Natriuretic peptide 
study.128  This study was performed between Glasgow and London and 
investigated the diagnostic utility of BNP in patients referred to an open access 
clinic with dyspnoea suspicious of cardiac failure.  Plasma BNP concentrations 
were significantly higher in patients with LVSD, and a BNP of >30pg/ml provided 
a useful ‘rule-out’ test with a NPV of 0.93.  Knudsen and colleagues performed a 
subgroup analysis of patients enrolled into a large multicentre heart failure 
study.202  They studied patients with an elevated BNP, but no evidence of 
current acute heart failure, to identify other determinants of a raised BNP.  
Unsurprisingly, previous CCF predicted a raised BNP.  On multivariate analysis, 
increasing age, atrial fibrillation, cardiomegaly on chest x-ray and anaemia 
predicted a raised BNP.      
The reported incidence of raised pre-operative BNP in research published after 
the start of the present study is variable, depending on which patient group was 
selected for investigation.  For example, Cuthbertson and colleagues studied a 
cohort of over 200 mixed NCS patients from a Scottish centre.132  The median 
BNP (IQR) was 27 (12-50) pg/ml.  Another study from the same institution 
showed the median BNP (IQR) rose to 100 (62-205) pg/ml in patients undergoing 
emergency surgery.134  Bredthardt and collegues recruited 270 patients 
undergoing major orthopaedic procedures.138  They found and median (IQR) BNP 
of 36 (17-82) pg/ml.  Biccard and colleagues found similar results in a vascular 
cohort.203      
This study shows that in a cohort of patients undergoing major NCS, an elevated 
pre-operative BNP is associated with increasing age, several cardiac co-
morbidities (hypertension, IHD, previous MI and previous LVF), renal impairment 
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and diabetes.  Also, patients with severe PVD requiring amputation had a higher 
BNP.  Interestingly, there was no association with a history of cerebrovascular 
disease.   
Unfortunately, most of the subsequently published studies examining the 
prognostic utility of natriuretic peptides in patients undergoing surgical 
procedures do not report the associations between clinical variables and a raised 
BNP.  Bolliger and colleagues examined the predictors of a raised BNP in 133 
clinically stable patients undergoing major vascular surgery.204  Using a cut-off 
point of 50 pg/ml, the authors demonstrated that the group with a high BNP (>50 
pg/ml) were older and had a higher rate of IHD, previous MI, previous cardiac 
failure and hypertension.  However, the presence of diabetes was not associated 
with a raised BNP.  Feringa and colleagues studied 144 Dutch patients 
undergoing major vascular surgery.  They measured NT-proBNP, the  cleavage 
fragment from BNP pro-hormone.  They found an elevated NT-proBNP was 
associated with increasing age, IHD, previous MI, previous cardiac failure, 
diabetes and renal impairment.  These results support the present study’s 
findings.  
This study has shown that a raised pre-operative plasma BNP may act as a 
surrogate marker for a number of medical co-morbidities.  The efficacy with 
which BNP can predict post-operative morbidity and mortality, in particular 
cardiac morbidity, requires a prospective observational study.   
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4 Prediction of peri-operative cardiac morbidity 
and mortality 
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4.1 Introduction 
Post-operative major adverse cardiac events (MACE) occur with varying 
incidence, depending on which patient population is studied.  In cohorts of 
mixed non-cardiac surgery (NCS) operations, including intermediate as well as 
major procedures, MACE rates are less than 3%.6,8,51  However, when cohorts are 
confined to major surgery or high risk patients then observed MACE rates are 
greater than 10%.39,47,68  Post-operative cardiac morbidity has significant 
implications for patients.  Patients suffering a PMI have a higher rate of 
subsequent cardiac events and increased short-term mortality.36,37      
Currently, there is no ‘gold-standard’ method for prediction of risk of cardiac 
morbidity following surgery.  Risk scoring systems may be accurate within 
certain patient groups, but they have limited predictive value when applied to 
cohorts out with their derivation population.103  Non-invasive cardiac imaging 
techniques, such as stress echocardiography, are sensitive predictors of MACE, 
but have limited availability to the general clinician.111      
Scotland, and in particular the West of Scotland, has a high incidence of 
coronary artery disease and a high incidence of asymptomatic heart disease.205  
The use of cardiac biomarkers, in particular BNP, is helpful in the detection of 
subclinical ventricular dysfunction in non-surgical patients.124  The incidence of 
subclinical heart disease in patients attending for surgical procedures, and the 
rate of post-operative MACE in the West of Scotland is not known. 
This study aims to document the incidence of post-operative cardiac morbidity 
and mortality.  Secondly, we aim to identify the prognostic utility of pre- and 
peri-operative clinical variables in the prediction of adverse post-operative 
outcomes, in particular cardiac morbidity and mortality.  Furthermore, we have 
previously shown (Chapter 3) that a single pre-operative serum BNP appears to 
be a surrogate marker for a number of medical co-morbidities.  We aim to 
examine the prognostic utility of BNP for the occurrence of peri-operative 
adverse events. 
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4.2 Methods 
4.2.1 Participants 
A prospective single centre observational cohort study of consecutive patients 
undergoing major non-cardiac surgery was performed.  Emergency patients 
(operated within 24 hours of an unplanned admission) were not included.  This 
left 345 patients that were included in this study.  
All patients had standard pre-operative assessment including clinical history, 
laboratory blood tests and a 12 lead ECG.  Co-morbidities were based on medical 
history and self reporting.  Ischaemic heart disease was defined as a previous 
myocardial infarction, a positive exercise tolerance test, the use of nitrate 
therapy or the presence of pathological Q-waves on ECG.6  Left ventricular 
failure (LVF) was considered present if the patient had a prior hospital admission 
with heart failure or left ventricular impairment on previous echocardiography.  
Cerebrovascular disease was defined as a previous cerebrovascular accident or 
transient ischaemic attack.  The glomerular filtration rate (GFR) was estimated 
using the Modification of Diet in Renal Disease (MDRD) equation.192  Renal 
impairment was considered present if the estimated GFR was <60mls/min.  A 
patient was considered a smoker if they were smoking at the time of admission 
for surgery.  Hypertension was considered present if the patient had a previous 
medical documentation of hypertension and was currently taking 
antihypertensive medication.  The presence of hyperlipidaemia and chronic 
obstructive pulmonary disease (COPD) was extracted from the patient’s primary 
care records and past medical history.  The current medication was also 
recorded, in particular the prescription of anti-platelet agents, a statin and 
beta-blockers.   
An additional venous blood sample was taken for plasma BNP the evening prior 
to surgery. This was collected in chilled EDTA and aprotinin (Trasylol; 50 IU/ml), 
immediately centrifuged and stored at –25 Celsius.  BNP concentrations were 
measured using a direct immunoradiometric assay (Shionoria BNP kit, Shinogi & 
Co, Osaka, Japan).193  The minimum detectable quantity of BNP is 2pg/ml. The 
within-assay and between assay co-efficients of variation are 5.3% and 5.9%, 
respectively.  Batch sample analysis was performed during the study by a 
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biochemist blinded to clinical detail.  The longest sample storage period was 6 
months.   
Post-operative screening for cardiac events was performed.  This consisted of 
daily clinical assessment and serial ECGs and troponin I measurement on day 2, 
day 5 and 6 weeks following surgery.  The primary outcomes were death within 
the post-operative period (6 weeks) and all cause mortality during the follow-up 
period.  Regional ethics committee approval was obtained and all patients gave 
written consent to the study following a verbal explanation and written 
information. 
4.2.2 Statistical analysis 
Statistical analysis was performed using SPSS (Version 15) statistical software 
package (SPSS, Chicago, Illinois, USA).  A p-value of less than 0.05 was 
considered significant.  Comparison of interval data was performed using 
independent samples t-test, Mann-Whitney test and Kruskal-Wallis test as 
appropriate.  Categorical data was compared using the Χ2 test.  Performance of 
continuous variables was analysed used receiver operating characteristics (ROC) 
and the area under the curve (AUC) was calculated.  Variables with a p-value of 
less than 0.10 on univariate analysis were selected for multivariate analysis and 
were entered into a logistic regression model.    
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4.3 Results 
4.3.1 Incidence and clinical predictors of peri-operative major 
adverse cardiac event (MACE)  
MACE occurred in 46 (13.3%) patients during the post-operative period (within 6 
weeks).  The peri-operative MACE rate was higher in patients with hypertension 
(18.4% vs. 6.7%, p=0.002) and patients aged >70 years (19.4% vs. 7.8%, p=0.002) 
[Table 4.1].  Similarly, patients with pre-operative anaemia had a higher MACE 
rate those who were not anaemic (22.2% vs. 7.0%, p<0.001) [Table 4.2].  A 
higher MACE rate was observed following an urgent surgical procedure compared 
with an elective one (20.9% vs. 6.6%, p<0.001).  The presence of cardiac 
variables such as IHD, a previous MI, a previous CVA and a history of CCF did not 
predict MACE.  Patients undergoing lower limb amputation had a higher MACE 
rate (21.8%), compared with patients undergoing lower limb bypass (11.0%), 
aortic surgery (12.4%) and laparotomy (7.2%) (p=0.042) [Table 4.3]. 
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Table 4.1  Pre-operative clinical variables and peri-operative major adverse 
cardiac event (MACE) 
 
  
n = 345 
MACE 
n= 46 
p* 
Sex 
Male 217  30 (13.8%) 0.727 
Female 128 16 (12.5%)  
Age > 70 years 
Yes 165 32 (19.4%) 0.002 
No 180 14 (7.8%)  
Smoker 
Yes 145  20 (13.8%)  0.831 
No 200 26 (13.0%)  
Diabetes 
Yes 69  12 (17.4%)  0.268 
No 276 34 (12.3%)  
Hypertension 
Yes 196  36 (18.4%)  0.002 
No 149 10 (6.7%)  
Renal Impairment 
(eGFR <60) 
Yes 142 25 (17.6%)  0.051 
No 203 21 (10.3%)  
Hyperlipideamia 
Yes 110  14 (12.7%)  0.821 
No 235 32 (13.6%)  
Previous MI 
Yes 64  11 (17.2%) 0.315 
No 281 35 (12.5%)  
Ischaemic Heart 
Disease 
Yes 104  16 (15.4%) 0.462 
No 241  30 (12.4%)  
History of Left 
Ventricular Failure 
Yes 64  11 (17.2%)  0.315 
No 281 35 (12.5%)  
Cerebrovascular 
Disease  
Yes 43  9 (20.9%) 0.147 
No 302 37 (12.3%)  
COPD 
Yes 49  4 (8.2%)  0.363 
No 296 42 (14.2%)  
 
* Χ2 test  
 
Abbreviations: MACE - Major Adverse Cardiac Event, eGFR - estimated 
glomerular filtration rate, MI - myocardial infarction, COPD - chronic obstructive 
pulmonary disease. 
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Table 4.2 Other clinical variables and major adverse cardiac event (MACE) 
 
  n = 345 MACE 
n= 46 
p* 
β-Blocker 
Yes 86 14 (16.3%) 0.354 
No 259 32 12.4%)  
APA 
Yes 179  26 (14.5%) 0.499 
No 166 20 (12.0%)  
Statin 
Yes 175 27 (15.4%) 0.245 
No 170  19 (11.2%)  
Anaemia† 
Yes 144 32 (22.2%) <0.001 
No 201 14 (7.0%)  
Blood Loss >500mls 
Yes 36  7 (19.4%) 0.296 
No 309 39 (12.6%)  
Intra-operative 
hypotension 
Yes 61  11 (18.0%) 0.234 
No 284 35 (12.3%)  
Urgent Surgery 
Yes 163 34 (20.9%) <0.001 
No 182 12 (6.6%)  
 
* Chi-Square Test,  
†
Anaemia defined as haemoglobin <13 g/dl in males and <11g/dl in females. 
 
Abbreviations: MACE - Major Adverse Cardiac Event, APA – Antiplatelet agent 
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Table 4.3  Major adverse cardiac event (MACE) by procedure type 
 
 n 
MACE 
n=46 
p* 
Aortic Surgery 89 11 (12.4%) 
0.042 
 
Bypass Surgery 100 11 (11.0%) 
Amputation 87 19 (21.8%) 
Laparotomy 64 5 (7.2%) 
 
* Χ2 test. 
 
Abbreviations: MACE - Major Adverse Cardiac Event 
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4.3.2 Incidence and clinical predictors of peri-operative mortality 
 
Twenty-seven (7.8%) patients died during the immediate peri-operative period.  
The peri-operative mortality was higher in diabetics (15.9% vs. 5.8%, p=0.005) 
and in patients with renal impairment (11.3% vs. 5.4%, p=0.047) [Table 4.4].  
Similarly, the mortality rate was higher in anaemic patients compared with 
patients that were not anaemic (12.5% vs. 4.5%, p=0.006), and in patients 
undergoing urgent rather than elective surgery (12.3% vs. 3.8%, p=0.004) [Table 
4.5].  There was no significant difference in mortality rates between the 
operative subgroups [Table 4.6].  As with peri-operative MACE, the presence of 
cardiac variables such as IHD, previous MI, previous LVF or cerebrovascular 
disease did not predict peri-operative mortality. 
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Table 4.4  Pre-operative clinical variables and peri-operative mortality 
 
  n = 345 
Mortality 
n=27 
p* 
Sex 
Male 217 19 (8.8%) 0.403 
Female 128 8 (6.3%)  
Age > 70 years 
Yes 165  17 (10.3%) 0.101 
No 180 10 (5.6%)  
Smoker 
Yes 145  10 (6.9%) 0.584 
No 200 17 (8.5%)  
Diabetes 
Yes 69  11 (15.9%) 0.005 
No 276 16 (5.8%)  
Hypertension 
Yes 196  20 (10.2%) 0.059 
No 149 7 (4.7%)  
Renal Impairment 
(GFR <60) 
Yes 142  16 (11.3%) 0.047 
No 203 11 (5.4%)  
Hyperlipideamia 
Yes 110  10 (9.1%) 0.550 
No 235 17 (7.2%)  
Previous MI 
Yes 64  6 (9.4%) 0.609 
No 281 21 (7.5%)  
Ischaemic Heart 
Disease 
Yes 104  8 (7.7%) 0.942 
No 241 19 (7.9%)  
History of Left 
Ventricular Failure 
Yes 64  2 (3.1%) 0.121 
No 281 25 (8.9%)  
Cerebrovascular 
Disease  
Yes 43  4 (9.3%) 0.760 
No 302 25 (8.9%)  
COPD 
Yes 49  7 (14.3%) 0.083 
No 296 20 (6.8%)  
 
* Chi-Square Test 
 
Abbreviations: eGFR - estimated glomerular filtration rate, MI - myocardial 
infarction, COPD - chronic obstructive pulmonary disease. 
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Table 4.5 Other clinical variables and peri-operative mortality 
 
  n = 345 
Mortality 
n=27 
p* 
β-Blocker 
Yes 86 8 (9.3%) 0.556 
No 259 19 (7.3%)  
APA 
Yes 179  11 (6.1%) 0.227 
No 166 16 (9.6%)  
Statin 
Yes 175 13 (7.4%) 0.780 
No 170  14 (8.2%)  
Anaemia† 
Yes 144 18 (12.5%) 0.006 
No 201 9 (4.5%)  
Blood Loss >500mls 
Yes 36  2 (5.6%) 1.000 
No 309 25 (8.1%)  
Intra-operative 
hypotension 
Yes 61  2 (3.3%) 0.192 
No 284 25 (8.8%)  
Urgent Surgery 
Yes 163 20 (12.3%) 0.004 
No 182 7 (3.8%)  
 
  
* Chi-Square Test,  
†
Anaemia defined as haemoglobin <13 g/dl in males and <11 g/dl in females. 
 
Abbreviations: APA – Antiplatelet agent 
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Table 4.6  Mortality by procedure type 
 
 n 
Mortality 
n= 27 
p* 
Aortic Surgery 89 3 (3.4%) 
0.101 
 
Bypass Surgery 100 6 (6.0%) 
Amputation 87 11 (12.6%) 
Laparotomy 64 7 (10.1%) 
 
* Χ2 test 
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4.3.3 Predictive utility of b-type natriuretic peptide in patients 
undergoing major non-cardiac surgery  
The median BNP (IQR) of the 345 patients enrolled in the study was 38 pg/ml 
(16-106 pg/ml).  The determinants of a pre-operatively raised BNP have been 
discussed in Chapter 3.  The median BNP was significantly higher in patients who 
suffered a peri-operative MACE, a peri-operative death and a peri-operative non-
fatal MI [Table 4.7]).  Figure 4.1 demonstrates the distribution of BNP in patients 
with and without a post-operative MACE.  Figure 4.2 demonstrates the 
distribution of BNP in patients with and without post-operative mortality. 
Table 4.7  Median b-type natriuretic peptide (BNP) of patients who suffered a 
peri-operative major adverse cardiac event (MACE), a peri-operative death 
and a peri-operative non-fatal myocardial infarction (MI) 
  
  n BNP (IQR) p* 
Peri-operative 
MACE 
Yes 46 199 (102-430) <0.001 
No 299 33 (15-85)  
Peri-operative 
Mortality 
Yes 27 165 (36-380) <0.001 
No 318 37 (15-95)  
Peri-operative 
Non-fatal MI  
Yes 33 144 (51-379) <0.001 
No 299
†
 33 (15-85)  
 
* Mann-Whitney U Test 
†
 Fatal cardiac event patients removed from denominator 
 
Abbreviations: MACE - Major Adverse Cardiac Event, BNP - B-type natriuretic 
peptide, MI - myocardial infarction. 
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Figure 4.1  Box plot of b-type natriuretic peptide (BNP) concentration and 
peri-operative major adverse cardiac event (MACE) 
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Figure 4.2  Box plot of b-type natriuretic peptide (BNP) concentration and 
peri-operative mortality 
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4.3.4 Best b-type natriuretic peptide (BNP) cut-off point for 
prediction of major adverse cardiac events (MACE) 
The optimal cut-off point for prediction of post-operative MACE was examined 
using ROC curve analysis.  A pre-operative BNP concentration of 107pg/ml had 
the best combined sensitivity (76.1%) and specificity (83.3%), and an AUC of 
0.821 (SE 0.036, 95% CI; 0.751-0.890, p<0.001) [Figure 4.3].  Using this cut-off 
point, the positive predictive value was 41.2% and the negative predictive value 
was 95.8%. 
Using the threshold level of 107 pg/ml, as identified from ROC curve analyses, 
BNP predicted outcome independently of all preoperative risk factors that were 
significant from univariate analysis [Table 4.8]. 
Figure 4.3  ROC curve analysis: BNP concentration and major adverse 
cardiac event (MACE) 
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Table 4.8  Major adverse cardiac events (MACE) by a b-type natriuretic 
peptide (BNP) cut-off point of 107pg/ml and by other risk factors 
 
Characteristic 
 
BNP level 
(pg/ml) 
MACE  p* 
Age >70 <107 8/103 (7.8%) <0.001 
  ≥107 24/62 (38.7%)  
 <70 <107 3/157 (1.9%) <0.001
†
 
  ≥107 11/23 (47.8%)  
Hypertension Yes <107 6/131 (4.6%) <0.001 
  ≥107 30/65 (46.2%)  
 No <107 5/129 (3.9%) 0.004
†
 
  ≥107 5/20 (25.0%)  
Anaemia Yes <107 5/92 (5.4%) <0.001 
  ≥107 27/52 (51.9%)  
 No <107 6/168 (3.6%) <0.001 
  ≥107 8/33 (24.2%)  
Urgent Surgery Yes <107 7/100 (7.0%) <0.001 
  ≥107 27/63 (42.9%)  
 No <107 4/160 (2.5%) <0.001
†
 
  ≥107 8/22 (36.4%)  
 
* Χ2 test unless otherwise stated.
 † 
Fisher’s Exact Test 
Abbreviations: MACE - Major Adverse Cardiac Event, BNP - B-type natriuretic 
peptide. 
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4.3.5 Best b-type natriuretic peptide (BNP) cut-off point for 
prediction of post-operative mortality 
The optimal cut-off point for prediction of post-operative mortality (within 6 
weeks) was examined using ROC curve analysis.  A pre-operative BNP 
concentration of 88pg/ml had the best combined sensitivity (70.4%) and 
specificity (72.3%), and an AUC of 0.720 (SE 0.057, 95% CI; 0.609-0.832, p<0.001) 
[Figure 4.4].  Using this cut-off point, the positive predictive value was 17.7% 
and the negative predictive value was 96.6%. 
Figure 4.4  ROC curve analysis: BNP concentration and post-operative 
mortality 
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4.3.6 Performance of b-type natriuretic peptide (BNP) in 
prediction of major adverse cardiac events (MACE) and 
mortality within operation type subgroup analysis 
The predictive value of a pre-operative BNP concentration was analysed within 
the 4 main subgroups (aortic surgery, lower limb bypass surgery, amputation and 
laparotomy) and by urgency of procedure (elective or urgent).  The median BNP 
was significantly higher in patients who had a MACE compared with those that 
did not, across all subgroups examined [Table 4.9].  Likewise, the median BNP 
was significantly higher in patients who had a MACE compared with those that 
did not following elective and urgent surgery. 
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Table 4.9 Median BNP and peri-operative major adverse cardiac event 
(MACE) by operative subgroup 
 
Operative 
Group 
MACE n BNP (IQR) p* 
Aortic 
Yes 11 144 (31-210) 0.003 
No 78 29 (11-65)  
Bypass 
Yes 11 380 (107-769) <0.001 
No 89 33 (15-80)  
Amputation 
Yes 19 263 (124-582) 0.001 
No 68 70 (33-150)  
Laparotomy 
Yes 5 127 (83-323) 0.004 
No 64 27 (9-60)  
Urgent 
Yes 34 242 (110-622) <0.001 
No 129 59 (26-124)  
Elective 
Yes 12 170 (32-274) <0.001 
No 170 27 (11-55)  
 
*Mann-Whitney U test 
 
Abbreviations: MACE - Major Adverse Cardiac Event 
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4.3.7 Multivariate analysis of predictors of peri-operative major 
adverse cardiac events (MACE) and mortality 
The clinical variables with a p value of <0.10 from univariate analysis of peri-
operative MACE were entered into a logistic regression model.  All four clinical 
factors (age > 70 years, hypertension, urgent surgery and anaemia) that were 
significant on univariate remained significant on multivariate analysis [Table 
4.10].  However, when BNP, at the cut-off point of 107 pg/ml, was added to the 
model, only BNP (OR 9.836, 95% CI 4.443-21.824, p<0.001) and anaemia (OR 
2.357, 95% CI 1.107-5.017, p<0.001) remained significant predictors of MACE 
[Table 4.11].  
 Similarly, the clinical variables with a p value of <0.10 from univariate analysis 
of peri-operative mortality were entered into a logistic regression model.  On 
multivariate analysis, no clinical variable was a significant predictor of peri-
operative mortality [Table 4.12].  When BNP, at a cut-off of 88pg/ml, was added 
to the model, BNP (OR 4.129, 95% CI 1.596-10.683, p=0.003) remained a strong 
predictor of mortality [Table 4.13]. 
123 
Table 4.10  Logistic regression model for prediction of peri-operative major 
adverse cardiac event (MACE) by pre-operative clinical variables 
 
 Univariate Multivariate 
Factor OR (95% CI) p  OR (95% CI) p  
Anaemia 3.816 (1.952-7.460) <0.001 2.693 (1.330-5.450) 0.006 
Urgent Surgery 3.734 (1.860-7.495) <0.001 2.433 (1.165-5.081) 0.018 
Hypertension 3.127 (1.497-6.532) 0.002 2.556 (1.190-5.493) 0.016 
Age >70 years 2.853 (1.462-5.565) 0.002 2.252 (1.117-4.539) 0.023 
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Table 4.11  Logistic regression model for prediction of peri-operative major 
adverse cardiac event (MACE) by b-type natriuretic peptide (BNP) and pre-
operative clinical variables 
 
 Univariate Multivariate 
Factor OR (95% CI) p  OR (95% CI) p  
BNP >107pg/ml 15.845 (7.542-33.293) <0.001 9.836 (4.433-21.824) <0.001 
Anaemia 3.816 (1.952-7.460) <0.001 2.357 (1.107-5.017) 0.026 
Urgent Surgery 3.734 (1.860-7.495) <0.001 1.593 (0.715-3.548) 0.255 
Hypertension 3.127 (1.497-6.532) 0.002 1.692 (0.737-3.884) 0.215 
Age >70 years 2.853 (1.462-5.565) 0.002 1.468 (0.673-3.198) 0.355 
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Table 4.12 Logistic regression model for prediction of peri-operative 
mortality by pre-operative clinical variables 
 
 Univariate Multivariate 
Factor OR (95% CI) p  OR (95% CI) p  
Urgent Surgery 3.497 (1.438-8.503) 0.006 2.462 (0.963-6.296) 0.060 
Diabetes 3.082 (1.359-6.989) 0.007 1.823 (0.749-4.441) 0.186 
Anaemia 3.048 (1.327-6.997) 0.009 2.004 (0.826-4.865) 0.124 
eGFR  <60 2.216 (0.996-4.932) 0.051 2.029 (0.870-4.733) 0.101 
COPD 2.300 (0.917-5.771) 0.076 2.343 (0.877-6.260) 0.089 
 
Abbreviations: eGFR - estimated glomerular filtration rate (mls/min), COPD - 
chronic obstructive airways disease. 
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Table 4.13  Logistic regression model for prediction of peri-operative 
mortality by b-type natriuretic peptide (BNP) and pre-operative clinical 
variables 
 
 Univariate Multivariate 
Factor OR (95% CI) p  OR (95% CI) p  
BNP >88pg/ml 6.207 (2.622-14.696) <0.001 4.129 (1.596-10.683) 0.003 
Urgent Surgery 3.497 (1.438-8.503) 0.006 1.879 (0.714-4.947) 0.201 
Diabetes 3.082 (1.359-6.989) 0.007 1.935 (0.763-4.906) 0.164 
Anaemia 3.048 (1.327-6.997) 0.009 1.681 (0.678-4.170) 0.262 
eGFR  <60 2.216 (0.996-4.932) 0.051 1.477 (0.606-3.601) 0.391 
COPD 2.300 (0.917-5.771) 0.076 2.371 (0.862-6.523) 0.094 
 
Abbreviations: eGFR - estimated glomerular filtration rate (mls/min), COPD - 
chronic obstructive airways disease. 
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4.3.8 Relationship between previous history of cardiac disease, 
medication and MACE 
The rates of prescription of best medical therapy (BMT) for cardiac disease (anti-
platelet agent (APA), a statin and a beta-blocker) were investigated.  Overall, 
prescription rates for APAs were 51.9%, statins 50.7% and beta-blockers 24.9%.  
Prescription rates were significantly higher in patients with IHD for APAs (68.3% 
vs. 44.8%, p<0.001), statins (66.3 vs. 44.0%, p<0.001) and beta-blockers (42.3% 
vs. 17.4%, p<0.001), compared with patients without IHD [Table 4.14].  
Similarly, prescription rates were higher for all three medications groups in 
patients with a previous MI [Table 4.15]. 
 The relationship between BMT, presence of IHD or previous MI and peri-
operative MACE was then investigated.  There was no association between MACE 
rate in patients with IHD with or without prescription of APAs (15.5% vs. 15.2%, 
0.964), statins (15.9% vs. 14.3%, p=0.825) or beta-blockers (11.4% vs. 18.3%, 
p=0.330) [Table 4.16].  Similarly, there was no association between MACE rate in 
patients with a previous MI for all three medication groups [Table 4.17].   
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Table 4.14  Rate of prescription of anti-platelet agents (APA), statin and beta-
blockers by presence or absence of ischaemic heart disease (IHD) 
 
IHD Medication p* 
Yes 
APA 
71/104 (68.3%) 
<0.001 
No 108/241 (44.8%) 
Yes 
Statin 
69/104 (66.3%) 
<0.001 
No 106/241 (44.0%) 
Yes 
Beta Blocker 
44/104 (42.3%) 
<0.001 
No 42/241 (17.4%) 
 
*Chi-squared test. 
Abbreviations: IHD - ischaemic heart disease, MI - myocardial infarction, APA - 
anti-platelet agent. 
 
Table 4.15  Rate of prescription of anti-platelet agents (APA), statin and beta-
blockers by presence or absence of previous myocardial infarction (MI) 
 
Previous MI Medication p* 
Yes 
APA 
45/64 (70.3%) 
<0.001 
No 134/281 (47.7%) 
Yes 
Statin 
49/64 (76.6%) 
<0.001 
No 126/281 (44.8%) 
Yes 
Beta Blocker 
27/64 (42.2%) 
<0.001 
No 59/281 (21.0%) 
 
*Chi-squared test. 
Abbreviations: IHD - ischaemic heart disease, MI - myocardial infarction, APA - 
anti-platelet agent. 
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Table 4.16  Incidence of major adverse cardiac event (MACE) by presence or 
absence of ischaemic heart disease (IHD) and by prescription of anti-platelet 
agents (APA), statin and beta-blockers 
 
IHD Medication MACE p* 
Yes APA 
Yes 11/71 (15.5%) 
0.964 
No 5/33 (15.2%) 
No APA 
Yes 15/108 (13.9%) 
0.542 
No 15/133 (11.3%) 
Yes Statin 
Yes 11/69 (15.9%) 
0.825 
No 5/35 (14.3%) 
No Statin 
Yes 16/106 (15.1%) 
0.270 
No 14/135 (10.4%) 
Yes Beta-blocker 
Yes 5/44 (11.4%) 
0.330 
No 11/60 (18.3%) 
No Beta-blocker 
Yes 9/42 (21.1%) 
0.052 
No 21/199 (10.6%) 
 
* Chi-squared test. 
Abbreviations: MACE - major adverse cardiac event, IHD - ischaemic heart 
disease, APA - anti-platelet agent. 
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Table 4.17  Incidence of major adverse cardiac event (MACE) by presence or 
absence of a history of previous myocardial infarction (MI) and by 
prescription of anti-platelet agents (APA), statin and beta-blockers 
 
Previous MI Medication MACE p* 
Yes APA 
Yes 11/64 (17.2%) 
0.594 
No 7/45 (15.6%) 
No APA 
Yes 19/134 (14.2%) 
0.404 
No 16/147 (10.9% 
Yes Statin 
Yes 7/49 (14.3%) 
0.266 
No 4/15 (26.7%) 
No Statin 
Yes 20/126 (15.9%) 
0.118 
No 15/155 (9.7%) 
Yes Beta-blocker 
Yes 3/27 (11.1) 
0.331
†
 
No 8/37 (21.6) 
No Beta-blocker 
Yes 11/59 (18.6%) 
0.105 
No 24/222 (10.8%) 
 
* Chi-squared test unless otherwise stated.
 † 
Fisher’s Exact Test 
Abbreviations: MACE - major adverse cardiac event, MI - myocardial infarction, 
APA - anti-platelet agent. 
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4.4 Discussion 
This study has three important findings.  Firstly, commonly recorded markers of 
cardiac disease, such as previous MI and IHD, do not predict cardiac morbidity or 
mortality.  Secondly, a number of non-cardiac related variables predict 
morbidity and mortality.  Thirdly, a single pre-operative BNP measurement 
strongly predicts both MACE and mortality. 
4.4.1  Poor performance of cardiac clinical variables 
With the exception of a history of hypertension, none of the recorded cardiac 
variables predicted an adverse post-operative outcome.   There are several 
possible reasons for this.   
The first reason may be the influence of best medical therapy prescription in 
patients with a past cardiac history.  The use of APAs and statins are at the 
heart of primary and secondary prevention of cardiovascular events.145  The use 
of APAs and statins reduces the risk of MI and death in patients with or at high 
risk of cardiovascular disease.206,207  Continuation of APA therapy through the 
peri-operative period appears safe and is likely to be  beneficial in most 
circumstances.45,74,151  The prescription of statins is associated with reduced 
peri-operative MACE and mortality in patients undergoing major NCS.78,155  Peri-
operative administration of beta-blockers have reduced peri-operative cardiac 
morbidity in large RCTs.143,144  The beneficial effects of beta-blockers are not a 
universal finding.  The POISE trial identified a higher stroke and mortality rate in 
patients receiving peri-operative metoprolol.5  Our study demonstrated a higher 
prescription rate for APAs, statins and beta-blockers in patients with IHD or a 
previous MI.  However, we were not able to show an association between 
improved MACE rate and these medications. 
Secondly, the presence of subclinical heart disease may explain the lack of 
difference of MACE rate between patients with cardiac risk factors and those 
without.  A high rate of asymptomatic LVSD has previously been demonstrated in 
the general population in the West of Scotland.205  Therefore, some patients in 
our cohort will present for surgery with ‘latent’ CAD or LVSD.  Also, a proportion 
of our cohort was undergoing vascular surgical procedures.  This group has a 
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notoriously high prevalence of CAD, of which a subgroup will have asymptomatic 
disease.10  Patients with short distance claudication or critical limb ischaemia 
may be unable to perform adequate activity in their daily living to elicit 
symptoms of cardiac disease.208 
Finally, we were, in part, relying on the documentation of cardiac disease in 
patient’s case records and the patients self-reporting of cardiac disease.  Both 
sources of data collection represent a source of error.  We were not able to 
independently corroborate all positive histories of cardiac disease, particularly if 
the diagnosis originated from primary care or historical records.  Nevertheless, 
this limitation reflects the day-to-day experience of assessing patients prior to 
surgery. 
4.4.2 Non-cardiac predictors of MACE and mortality 
We found several clinical variables predicted poor post-operative outcomes. 
4.4.2.1 Patient Age 
We found that elderly patients (defined as age >70 years) had a higher rate of 
MACE than those aged less than 70 years.  Numerous studies have demonstrated 
a similar association with increasing age and a poorer outcome following 
surgery.8,51,61,62  Whilst increasing age is a non-modifiable risk factor for adverse 
post-operative outcome, it is an important factor to consider when stratifying a 
patients risk during and after surgery.  
4.4.2.2 Urgent surgery 
Urgent surgery, defined as surgery performed during an unplanned admission, 
was associated with MACE and mortality on univariate analysis, and remained 
significant on multivariate analysis of clinical variables for MACE.  This finding is 
confirmed by other studies of peri-operative outcomes.39,47  For example, urgent 
surgery was the strongest predictor of mortality on multivariate analysis of a 
prospectively collected multicentre cohort of patient undergoing colorectal 
resection.81  Likewise, urgent and emergency surgery was an independent 
predictor of peri-operative mortality following colonic surgery in over 8000 
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patients analysed from the Association of Coloproctology of Great Britain and 
Ireland national database.82  
4.4.2.3 Anaemia 
Pre-operative anaemia was associated with MACE and mortality on univariate 
analysis, and remained significant on multivariate analysis for MACE.  Since this 
was not anticipated as a major finding of this study, we did not include a more 
detailed assessment of anaemia in our data set, and we have no information 
about chronicity of anaemia, categorisation of anaemia (i.e. haematinic 
assessment) or previous investigations for anaemia.  Therefore, we are unable to 
suggest causes for anaemia in this discussion.  Nevertheless, anaemia appears to 
be a strong marker of poor outcome.  Anaemia limits myocardial oxygenation 
and is poorly tolerated in patients with CAD or LVF.209,210  Analysis of a Canadian 
cohort of >12,000 patients with first presentation LVF identified a 17% incidence 
of anaemia, of which more than half the patients had anaemia of chronic 
disease.211  The group with anaemia and LVF had a higher mortality (HR 1.34, 
95% CI 1.24-1.46) during the follow-up period. 
Anaemia prior to surgery has been recognised as a predictor of adverse outcome.  
Beattie and colleagues studied their single centre experience of patients 
undergoing NCS.212  Nearly eight thousand patients were included, and the 
prevalence of pre-operative anaemia was 39.8%.  Anaemia was associated with 
increased post-operative mortality after multivariate analysis (OR 2.36, 95% CI 
1.57-3.41, p<0.001).  Interestingly, this association was independent of 
requirement for blood transfusion.  Subsequently, Musallam and colleagues used 
NSQIP data for over 200,000 patients undergoing surgery.213  Nearly one third 
(30.4%) were found to be anaemic, and this group had higher 30-day mortality 
(adjusted HR 1.42, 95% CI 1.31-1.54).   
Wu and colleagues performed a larger retrospective analysis of NSQIP data, 
including over 300,000 patients.214  The authors defined anaemia as a pre-
operative haematocrit value of less than 39%.  They examined the association 
with post-operative death and included a secondary endpoint of major cardiac 
events (cardiac arrest or Q-wave MI).  They demonstrated that a fall in pre-
operative haematocrit was associated with increased mortality and cardiac 
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morbidity.  These large database analyses confirm the association between 
anaemia and increased peri-operative mortality, and the present study 
demonstrates an independent association between anaemia and MACE.  
However, the limitations of retrospective database analyses and the limited data 
we prospectively collected regarding the aetiology of anaemia means that it 
remains unclear if anaemia represents a modifiable variable or simply acts as an 
indicator of other chronic diseases.  Therefore, this is a potentially important 
area for future research.   
4.4.3 BNP predicts MACE and mortality  
Serum BNP is a strong predictor of poor outcomes in cardiac patients.126,215  Our 
group published interim results of the predictive utility of BNP for MACE in the 
peri-operative period (6 weeks following NCS).131  Analysis of the initial 149 
patients showed a peri-operative MACE rate of 10.1%, and the median BNP (IQR) 
was higher than in patients who did not have a MACE (351 (127-1034) pg/ml vs. 
31 (11-80) pg/ml, p<0.001).  The final analysis of the entire cohort of 345 
patients confirms that a single pre-operative serum BNP measurement is 
independently associated with increased MACE and increased mortality in 
patients undergoing MACE.  Patients with an elevated BNP had a 10-fold increase 
in peri-operative MACE and a 6-fold increase in peri-operative mortality.   
Following the start of our study, other researchers have reported similar 
associations with raised BNP (or NT-proBNP) and adverse post-operative 
outcomes.  Table 4.18 lists publications examining the prognostic utility of BNP 
(or NT-proBNP) in NCS.  All the published studies have demonstrated a 
significant association between raised post-operative BNP (or NT-proBNP) and 
poor post-operative outcome.  The methodology of these studies has been 
variable, as discussed in Chapter 1.  
The predictive values of BNP and NT-proBNP have been examined in several 
meta-analyses.7,141,142,216   In 2008, Rodseth and colleagues investigated the 
utility of BNP and NT-proBNP from seven studies of patients undergoing vascular 
surgery.141    Karthikeyan and colleagues included nine prospective studies 
investigating the short term predictive value of BNP (4 studies) and NT-proBNP 
(5 studies) in patients undergoing a variety of non-cardiac surgical procedures.7  
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Both studies concluded that both BNP and NT-proBNP are good independent 
predictors of post-operative cardiac events.  However, due to the small number 
of studies included, they were unable to suggest a threshold value for optimal 
predictive utility.  Ryding and colleagues included 15 studies in their analysis, 
published in 2009.142   Similarly, they found that patients with elevated BNP (or 
NT-proBNP) had a significantly higher MACE rate than those without.  A pooled 
odds ratios for MACE of 19.77 (95% CI 13.18-29.65, p<0.0001) was found in 
patients with elevated BNP compared with those that did not.   
More recently, Lurati Buse and colleagues reported their meta-analysis of 23 
studies (published in 2011).  They included cardiac surgery trials and only half 
the number of studies included concerned NCS.  No additional conclusions were 
drawn from this repeat analysis.  Therefore, despite several prospective trials 
and four meta-analyses, several questions remain unanswered.  Firstly, since no 
study to date has directly compared BNP with NT-proBNP in a surgical cohort, 
which marker is superior?  However, evidence suggests (from medical and 
surgical cohorts) that both are similarly powerful predictors of MACE then 
individual institutional availability or personal preference may dictate which 
marker is used.   
Secondly, what is the optimal cut-off point?  In our analysis, BNP performed 
most strongly as a ‘rule-out’ test.  At a cut-off of 88pg/ml, the NPV for MACE 
was 95.8% and at a cut-off of 107pg/ml, the NPV for mortality was 96.6%.  This is 
similar to the pooled analysis from the Lurati Buse paper; they found a NPV for 
all-cause mortality of 99%.  In simple terms, a ‘normal’ BNP is highly suggestive 
of an event-free post-operative course, whereas a raised BNP stratifies patients 
into a high risk group requiring further attention.  Deciding what is ‘normal’ and 
‘abnormal’ is more challenging, and there is no consensus from the surgical 
literature.  Our data suggest a cut-off point at 100 pg/ml would be appropriate.  
This is supported by research from screening studies in non-surgical cohorts 
where a BNP <100pg/ml is considered highly unlikely to be associated with heart 
disease.217,218            
In summary, an elevated pre-operative BNP level predicts post-operative MACE 
in a variety of settings.  However, the optimal cut-off point is not clear.
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Table 4.18  Prognostic utility of BNP and NT-proBNP for peri-operative major adverse cardiac event (MACE) in non-cardiac 
surgery 
 
 
Studies using 
BNP 
       
Author 
Year of 
Reporting 
Cohort 
Size 
Study Population and 
Country  
Screened 
for MI? 
MACE rate 
BNP 
Theshold  
Comments 
Current Study - 345 Mixed NCS, UK Yes 13.3% 88 - 
Gibson131 2007 149 Mixed NCS, UK Yes 10.1% 109 - 
Cuthbertson132 2007 204 Mixed NCS, UK Yes 6.0% 40 
Follow-up limited to 72 
hours. 
Cuthbertson134 2007 40 Emergency NCS, UK Yes 27.5% 170 
58% of cohort had hip 
fracture surgery. 
Leibowitz136 2008 44 
NCS, High cardiac risk,  
Israel 
No 34.1% 165 
High risk - LVF or Aortic 
stenosis. 
Bolliger204 2009 133 
Elective Vascular, 
Switzerland 
Yes 4.5% 50 
Theshold taken from 1 
year MACE rate.  
Secondary analysis. 
Breidthart138 2010 270 Orthopaedic, Switzerland No 1.5% 174 
Low MACE rate.  No 
screening. 
Biccard203 2012 788 
Elective vascular,  
South Africa 
No 17.3% 39 
Only half the cohort had 
BNP measured. 
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Studies using NT-
proBNP 
       
Author 
Year of 
Reporting 
Cohort 
Size 
Study Population and 
Country  
Screened 
for MI? 
MACE rate 
NT-proBNP 
Theshold  
Comments 
Yeh129 2005 190 Mixed NCS, Taiwan No 7.9% 450 
CCF included in MACE 
definition (comprised 73% 
of events). 
Feringa130 2006 170 
Elective vascular, 
Holland 
Yes 7.6% 533 Erasmus study. 
Rajagopalan135 2008 136 Elective vascular, UK Yes 20.6% 308 
Asymptomatic cTn rise 
included within endpoint. 
Yun137 2008 279 
NCS, age >60 years, 
Korea 
Yes 9.0% 201 
Post-op screening only 
performed for 1 day. 
Goei140 2009 592 
Elective vascular, 
Holland 
No 14.0% 350 
Erasmus study.  Endpoint 
included asymptomatic 
cTn rise. 
Chong219 2010 89 
Emergency orthopaedic, 
Australia 
Yes 25.8% 842 
MACE included CCF and 
AF. 
  
 
 
 
 
 
5 BNP as predictor of long-term mortality after 
major non-cardiac surgery 
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5.1 Introduction 
Cardiac death following major non-cardiac surgery is the commonest cause of 
surgical mortality in the Western world.1  Whilst various methods can stratify 
risk on a population basis, accurate individual assessment of cardiac risk 
following major surgery is difficult. Clinical assessment and ECG analysis are 
simple, low cost and routinely available, but have little predictive value87 and 
cardiac scoring systems are notoriously inaccurate.46  Other more specialised 
tests of cardiac structure and function which show promise, such as stress 
echocardiography, may not be widely available and have low positive predictive 
values.111 
Recently, the cardiac neurohormone, B-type natriuretic peptide (BNP), has 
emerged as a biological marker (biomarker) of cardiac mortality. BNP is 
synthesised predominately within ventricular myocytes in response to cardiac 
wall stress.  BNP is a sensitive marker of left ventricular systolic dysfunction 
(LVSD) 124 and is a useful tool in the investigation of patients with suspected 
heart failure.128,197  Furthermore, BNP can predict major adverse cardiac events 
(MACE), defined as cardiac death and myocardial infarction, in acute coronary 
syndrome patients215 and in heart failure.126  
We have previously shown that BNP is an independent predictor of peri-
operative cardiac events in patients undergoing major non-cardiac surgery,131 
and this observation has been confirmed by other groups.132,134,136,220  In order to 
test the long term significance of pre-operative BNP, we aimed to determine if 
plasma BNP concentration also predicted long term survival in patients 
undergoing major non-cardiac surgery.  
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5.2 Methods 
5.2.1 Participants 
A prospective single centre observational cohort study of consecutive patients 
undergoing major non-cardiac surgery between Jan 2004 and August 2006 was 
performed.  Emergency patients (operated within 24 hours of an unplanned 
admission) were not included.  This left 345 patients that were included in this 
study.  
All patients had standard pre-operative assessment including clinical history, 
laboratory blood tests and a 12 lead ECG.  Further cardio-respiratory 
investigations were carried out at the discretion of the operating team.  
Ischaemic heart disease (IHD) was defined as a previous myocardial infarction, a 
positive exercise tolerance test, the use of nitrate therapy or the presence of 
pathological Q-waves on ECG.6  Left ventricular failure (LVF) was considered 
present if the patient had a prior hospital admission with heart failure or left 
ventricular impairment on previous echocardiography.  Cerebrovascular disease 
was defined as a previous cerebrovascular accident or transient ischaemic 
attack.  The glomerular filtration rate (GFR) was estimated using the 
Modification of Diet in Renal Disease (MDRD) equation.192  Renal impairment was 
considered present if the estimated GFR was <60mls/min.  A patient was 
considered a smoker if they were smoking at the time of admission for surgery.  
Hypertension was considered present if the patient had a previous medical 
documentation of hypertension and was currently taking antihypertensive 
medication.  The presence of hyperlipidaemia and chronic obstructive pulmonary 
disease (COPD) was extracted from the patient’s primary care records and past 
medical history.  The current medication was also recorded, in particular the 
prescription of anti-platelet agents, a statin and β-blockers.   
An additional venous blood sample was taken for plasma BNP the evening prior 
to surgery. This was collected in chilled EDTA and aprotinin (Trasylol; 50 IU/ml), 
immediately centrifuged and stored at –25 Celsius.  BNP concentrations were 
measured using a direct immunoradiometric assay (Shionoria BNP kit, Shinogi & 
Co, Osaka, Japan).193  The minimum detectable quantity of BNP is 2pg/ml. The 
within-assay and between assay co-efficients of variation are 5.3% and 5.9%, 
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respectively.  Batch sample analysis was performed during the study by a 
biochemist blinded to clinical detail.  The longest sample storage period was 6 
months.   
Patient follow-up was carried out until the end of 2009.  All patients were 
followed-up for a minimum of 1 year, either at outpatient follow-up, with the 
general practitioner or by direct patient contact.  The primary outcomes were 
death within the post-operative period (6 weeks) and all cause mortality during 
the follow-up period.  Regional ethics committee approval was obtained and all 
patients gave written consent to the study following a verbal explanation and 
written information. 
5.2.2 Statistical Analysis 
Statistical analysis was performed using SPSS (Version 15) statistical software 
package (SPSS, Chicago, Illinois, USA).  A p-value of less than 0.05 was 
considered significant.  Comparison of interval data was performed using 
independent samples t-test, Mann-Whitney test and Kruskal-Wallis test as 
appropriate.  Categorical data was compared using the χ2 test.  Performance of 
continuous variables was analysed used receiver operating characteristics (ROC) 
and the area under the curve (AUC) was calculated.  Survival analysis was 
performed using Kaplan-Meier curves and comparisons made using the log rank 
statistic.  Univariate analysis was performed using Cox regression analysis.  
Variables with a p-value of less than 0.10 were further evaluated with a 
multivariate Cox analysis using a backward stepwise selection.    
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5.3 Results 
5.3.1 Predictors of survival at one year following major non-
cardiac surgery 
All patients recruited to the trial were followed for a minimum 1 year. Of the 
345 patients recruited for the study, 276 (80.0%) patients underwent a vascular 
procedure (aortic surgery 25.8%, lower limb bypass 29.8% and amputation 25.2%) 
and 69 (20.0%) patients underwent a laparotomy.  This reflected the work load 
of the operating unit and to prevent selection bias the results are presented for 
the entire cohort. 
Twenty-seven patients died during the immediate post-operative period (6 
weeks) and a further 39 patients died in the 1 year follow-up period.  In total, 66 
patients (19.1%) died by 1 year post-surgery.   
 The following clinical variables are associated with higher 1-year mortality 
rates; age >70 years (p<0.021), diabetes (p=0.008), hypertension (p=0.004), 
renal impairment (p=0.029), previous MI (p=0.043), previous LVF (p=0.043), 
cerebrovascular disease (p=0.048), anaemia (p<0.001) and urgent surgery 
(p<0.001) [Table 5.1 and Table 5.2].  
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Table 5.1 Clinical variables and 1-year mortality 
 
   n = 345 
Mortality 
n= 66 
p* 
Sex 
Male 217 42 (19.4%) 0.890 
Female 128 24 (18.84%)  
Age > 70 years 
Yes 125  40 (24.2%) 0.021 
No 180 26 (14.4%)  
Smoker 
Yes 145  31 (21.4%) 0.366 
No 200 35 (17.5%)  
Diabetes 
Yes 69  21 (30.4%) 0.008 
No 276 45 (16.3%)  
Hypertension 
Yes 196  48 (24.5%) 0.004 
No 149 18 (12.1%)  
Renal Impairment 
(GFR <60) 
Yes 142  35 (24.6%) 0.029 
No 203 31 (15.3%)  
Hyperlipideamia 
Yes 110  23 (20.9%) 0.566 
No 235 43 (18.3%)  
Previous MI 
Yes 64  18 (28.1%) 0.043 
No 281 48 (17.1%)  
Ischaemic Heart 
Disease 
Yes 104  24 (23.1%) 0.221 
No 241 42 (17.4%)  
History of Left 
Ventricular Failure 
Yes 64  18 (28.1%) 0.043 
No 281 48 (17.1%)  
Cerebrovascular 
Disease  
Yes 43  13 (30.2%) 0.048 
No 302 53 (17.5%)  
COPD 
Yes 49  12 (24.5%) 0.303 
No 296 54 (18.2%)  
 
* Chi-Square Test 
Abbreviations: eGFR - estimated glomerular filtration rate, MI - myocardial 
infarction, COPD - chronic obstructive pulmonary disease. 
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Table 5.2 Other selected clinical variables and peri-operative mortality 
 
  n = 345 
Mortality 
n= 
p* 
β-Blocker 
Yes 86 21 (24.4%) 0.150 
No 259 45 (17.4%)  
APA 
Yes 179  35 (19.6%) 0.836 
No 166 31 (18.7%)  
Statin 
Yes 175 38 (21.7%) 0.216 
No 170  28 (16.5%)  
Anaemia† 
Yes 144 46 (31.9%) <0.001 
No 201 20 (10.0%)  
Urgent Surgery 
Yes 163 53 (32.5%) <0.001 
No 182 13 (7.1%)  
 
  
* Chi-Square Test,  
†
Anaemia defined as haemoglobin <13 g/dl in males and <11 g/dl in females. 
 
Abbreviations: APA – Antiplatelet agent 
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5.3.2 Predictive value of BNP for 1-year mortality  
The median (IQR) of BNP in patients that died during the first year following 
surgery was significantly higher than those patients that survived (158(46-400) 
pg/ml vs. 32 (14-82) pg/ml, p<0.001) 
Receiver operating characteristic (ROC) curve analysis was performed to identify 
the BNP concentration that best predicted mortality at 1 year [Figure 5.1].  In all 
patients, a BNP concentration of 87.5 pg/ml had the best combined sensitivity 
(65.7%) and specificity (78.6%), and the area under the ROC curve (AUC) was 
0.781 (95% C 0.717-0.845, p<0.001).  The AUC for patients undergoing a vascular 
procedure (n=276) was 0.792 (95% CI 0.724-0.861, p<0.001), with the same BNP 
concentration providing the best sensitivity and specificity in this group (67.8% 
and 76.8% respectively).  The one-year mortality rate for patients with a BNP 
>87.5 pg/ml compared with a BNP <87.5 pg/ml was 38.4% vs. 8.5%, p<0.001.   
Figure 5.1  ROC curve analysis: BNP concentration and all-cause mortality 
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5.3.3 Pre-operative clinical variables and the prediction of long 
term survival 
From the study group of 345 patients, there were 27 (7.8%) peri-operative 
deaths (within 6 weeks) and 84 (24.3%) deaths within the subsequent follow-up 
period.  The median follow-up period was 953 days (IQR 661-1216 days).  
Survival curve analysis showed that mean survival was shorter in association with 
the following variables; age >70 years (991 days vs. 1229 days, p<0.001), 
diabetes (925 days vs. 1163 days, p=0.002), hypertension (1036 days vs. 1214 
days, p=0.006), renal impairment (1028 days vs. 1173 days, p=0.045), a history 
of LVF (914 days vs. 1152 days, p=0.020), anaemia (883 days vs. 1266 days, 
p<0.001) and urgent surgery (885 days vs. 1298 days, p<0.001) [Table 5.3]. 
In order to examine the predictive value of variables in the longer term only and 
to remove any bias attributed directly to surgical mortality, the survival curve 
analysis was repeated after exclusion of patients who died during the peri-
operative period (within 6 weeks).  The only associations that became non-
significant following this analysis were diabetes and renal impairment [Table 
5.4].  Therefore, age>70 years, hypertension, a history of LVF, anaemia and 
urgent surgery were associated with a higher long term mortality.   
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Table 5.3  Kaplan-Meier survival analysis for clinical variables and long-term 
follow-up 
 
  n=345 
Mean Survival (days) 
(95% CI) 
p 
Sex 
Male 217 1099 (1018-1179) 0.838 
Female 128 1120 (1014-1226)  
Age > 70 years 
Yes 165 991 (894-1088) <0.001 
No 180 1229 (1148-1311)  
Smoker 
Yes 145 1136 (1033-1238) 0.587 
No 200 1103 (1020-1186)  
Diabetes 
Yes 69 925 (771-1079) 0.002 
No 276 1163 (1092-1234)  
Hypertension 
Yes 196 1036 (946-1126) 0.006 
No 149 1214 (1128-1299)  
Renal Impairment 
(eGFR <60) 
Yes 142 1028 (925-1131) 0.045 
No 203 1173 (1091-1254)  
Hyperlipdidaemia 
Yes 110 1095 (978-1212) 0.589 
No 235 1122 (1045-1199)  
Previous MI 
Yes 64 986 (840-1132) 0.171 
No 281 1136 (1065-1207)  
Ischaemic Heart 
Disease 
Yes 103 1071 (950-1192) 0.450 
No 242 1130 (1054-1205)  
History of Left 
Ventricular Failure 
Yes 64 914 (766-1061) 0.020 
No 281 1152 (1082-1221)  
Cerebrovascular 
Disease 
Yes 43 926 (751-1100) 0.102 
No 302 1139 (1070 -1207)  
COPD 
Yes 49 955 (794-1115) 0.125 
No 296 1137 (1068-1206)  
Anaemia
†
 
Yes 144 883 (781-984) <0.001 
No 170 1266 (1192-1339)  
Urgent Surgery 
Yes 163 885 (782-999) <0.001 
No 182 1298 (1226-1369)  
 
*Log-rank test, 
†
Anaemia defined as haemoglobin <13 g/dl in males and <11 g/dl 
in females. 
Abbreviations: eGFR - estimated glomerular filtration rate, MI - myocardial 
infarction, COPD - chronic obstructive pulmonary disease. 
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Table 5.4  Kaplan-Meier survival analysis for clinical variables and long-term 
follow-up, after exclusion of patients who died in the peri-operative period 
 
  n=345 
Mean Survival (days) 
(95% CI) 
p 
Sex 
Male 198 1202 (1129-1275) 0.800 
Female 120 1192 (1092-1292)  
Age > 70 years 
Yes 148 1103 (1011-1195) 0.002 
No 170 1300 (1226-1374)  
Smoker 
Yes 135 1218 (1122-1314) 0.747 
No 183 1203 (1128-1279)  
Diabetes 
Yes 58 1097 (952-1243) 0.069 
No 260 1233 (1167-1299)  
Hypertension 
Yes 176 1151 (1066-1236) 0.038 
No 142 1271 (1194-1349)  
Renal Impairment 
(eGFR <60) 
Yes 126 1156 (1062-1251) 0.255 
No 192 1240 (1162-1314)  
Hyperlipdidaemia 
Yes 100 1202 (1093-1310) 0.761 
No 218 1208 (1137-1280)  
Previous MI 
Yes 58 1085 (948-1223) 0.196 
No 260 1226 (1160-1291)  
Ischaemic Heart 
Disease 
Yes 96 1164 (1050-1277) 0.421 
No 222 1223 (1153-1292)  
History of Left 
Ventricular Failure 
Yes 62 943 (796-1089) <0.001 
No 256 1262 (1200-1324)  
Cerebrovascular 
Disease 
Yes 39 1018 (850-1186) 0.094 
No 279 1231 (1168-1293)  
COPD 
Yes 42 1110 (971-1250) 0.472 
No 276 1217 (1153-1283)  
Anaemia
†
 
Yes 126 1007 (908-1105) <0.001 
No 192 1323 (1257-1390)  
Urgent Surgery 
Yes 143 1007 (904-1110) <0.001 
No 175 1347 (1284-1412)  
 
*Log-rank test, 
†
Anaemia defined as haemoglobin <13 g/dl in males and <11 g/dl 
in females. 
Abbreviations: eGFR - estimated glomerular filtration rate, MI - myocardial 
infarction, COPD - chronic obstructive pulmonary disease. 
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5.3.4 Predictive utility of BNP for long term mortality after major 
non-cardiac surgery 
For the entire cohort, the median (IQR) pre-operative BNP concentration was 
higher in patients who died during follow-up than in those who did not (95 pg/ml 
(37-310) vs. 29 pg/ml (13-75), p<0.001).  Furthermore, analysis of the 318 
patients who survived beyond the peri-operative period showed that BNP was 
higher in those patients who died compared with those who survived (147 pg/ml 
(44-407) vs. 32 pg/ml (14-83), p<0.001).   
The BNP cut-off point identified at ROC curve analysis for prediction of 1 year 
mortality was used for long-term analysis.  The mean survival of patients with a 
BNP >87.5 pg/ml compared with a BNP <87.5 pg/ml was 732 days (95% CI 613.6-
850.2) vs. 1285 days (95% CI 1219.3-1350.0), p <0.001 [Figure 5.2].  When 
survival analyses are restricted to patients who survived the post-operative 
period (6 weeks), patients with an elevated BNP (>87.5 pg/ml) had a reduced 
survival (887 days (95% CI 764.9-1008.2) vs. 1328 days (95% CI 1267.7-1388.3), 
p<0.001 [Figure 5.3]. 
Subgroup analysis by type of procedure showed that the mean survival of 
patients with an elevated BNP (>87.5 pg/ml) was significantly lower in all groups 
(aortic surgery (800 days vs. 1461 days, p<0.001), lower limb bypass (860 days 
vs. 1180 days, p=0.021), amputation (506 days vs. 1086 days, p<0.001) and 
laparotomy (877 days vs. 1212 days, p=0.009).   
Similarly, when stratified for the presence of IHD, patients with an elevated BNP 
(>87.5pg/ml) had a lower mean survival in the group with IHD (769 days vs. 1269 
days, p<0.001) and the group without IHD (700 days vs. 1289 days, p<0.001).  
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Figure 5.2  Kaplan-Meier survival curve according to BNP level 
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Figure 5.3  Kaplan-Meier survival curve according to BNP level in patients 
who survived the peri-operative period 
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5.3.5 Multivariate analysis of clinical variables and long-term 
survival 
Cox regression analysis was performed to examine the value of the clinical 
variables for the prediction of long-term survival.  For the entire cohort, urgent 
surgery (p<0.001), anaemia (p<0.001), age >70 years (p=0.001), diabetes 
(p=0.003), hypertension (p=0.007), a history of LVF (p=0.021) and renal 
impairment (p=0.047) were associated with increased mortality on univariate 
analysis [Table 5.5].  Only urgent surgery (HR 2.485, 95% CI 1.631-3.785, 
p<0.001) and anaemia (HR 2.106, 95% CI 1.406-3.156, p<0.001) were associated 
with increased mortality on multivariate analysis.   
The analysis was repeated excluding the patients that died within the peri-
operative period (6 weeks).  Urgent surgery (p<0.001), anaemia (p<0.001), a 
history of LVF (p<0.001), age >70 years (p=0.003) and hypertension (p=0.040) 
were associated with increased mortality on univariate analysis [Table 5.6].  
Only urgent surgery (2.573, 95% CI 1.604-4.127, p<0.001), a history of LVF (HR 
2.360, 95% CI 1.451-3.535) and anaemia (HR 2.240, 95% CI 1.419-3.535, p=0.001) 
were associated with increased mortality on multivariate analysis.    
Since urgent surgery is such a strong predictor of mortality, the analysis was 
repeated for patients undergoing elective surgery only.  Only anaemia (p<0.001) 
and age > 70 years (p=0.038) were significant on univariate analysis.  Both 
factors remained significant on multivariate analysis [Table 5.7].  Interestingly, 
diabetes became significant on multivariate analysis (HR 2.948, 95% CI 1.256-
6.916, p=0.013). 
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Table 5.5  Cox regression analysis of clinical variables for all cause mortality 
during long term follow-up 
 
 Univariate Multivariate 
Factor HR (95% CI) p  HR (95% CI) p  
Urgent Surgery 3.348 (2.236-5.012) <0.001 2.485 (1.631-3.785) <0.001 
Anaemia 2.848 (1.936-4.189) <0.001 2.106 (1.406-3.156) <0.001 
Age >70 years 1.945 (1.329-2.847) 0.001   
Diabetes 1.870 (1.239-2.821) 0.003   
Hypertension 1.732 (1.163-2.580) 0.007   
History of LVF 1.687 (1.081-2.630) 0.021   
Renal 
Impairment* 
1.459 (1.005-2.118) 0.047   
 
* defined as eGFR <60mls/min 
 
Abbreviations; LVF - left ventricular failure. 
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Table 5.6  Cox regression analysis of clinical variables for all cause mortality 
during long term follow-up in peri-operative survivors only 
 
 Univariate Multivariate 
Factor HR (95% CI) p  HR (95% CI) p  
Urgent Surgery 3.336 (2.112-5.268) <0.001 2.573 (1.604-4.127) <0.001 
Anaemia 2.813 (1.810-4.370) <0.001 2.240 (1.419-3.535) 0.001 
History of LVF 2.421 (1.495-3.920) <0.001 2.360 (1.451-3.535) 0.001 
Age >70 years 1.949 (1.260-3.017) 0.003   
Hypertension 1.604 (1.021-2.520) 0.040   
Diabetes 1.576 (0.961-2.584) 0.071   
Cerebrovascular 
disease 
1.626 (0.915-2.890) 0.097   
 
Abbreviations; LVF - left ventricular failure 
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Table 5.7  Cox regression analysis of clinical variables for all cause mortality 
during long term follow-up for patients undergoing elective surgery only 
 
 Univariate Multivariate 
Factor HR (95% CI) p  HR (95% CI) p  
Anaemia 5.081 (2.552-10.117) <0.001 5.228 (2.594-10.540) <0.001 
Age >70 years 2.006 (1.040-3.867) 0.038 2.313 (1.137-4.706) 0.021 
Diabetes 1.901 (0.862-4.192) 0.092 2.948 (1.256-6.916) 0.013 
Hypertension 1.808 (0.912-3.584) 0.090   
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5.3.6 Mutlivariate analysis of clinical variables, BNP and long term 
survival 
When BNP was added to the model, BNP >87.5 pg/ml was predictive of long term 
mortality (HR 4.196, 95% CI 2.870-6.136, p<0.001), and remained significant on 
multivariate analysis (HR 3.173, 95% CI 2.145-4.693, p<0.001) [Table 5.8].  Other 
variables that remained significant in this multivariate model were urgent 
surgery (HR 2.148 , 95% CI 1.408-3.275, p<0.001) and anaemia (HR 1.990, 95% CI 
1.336-2.966, p=0.001).  No ‘traditional’ risk factors for cardiac disease (IHD, 
previous MI, a history of LVF or cerebrovascular disease) demonstrated any 
independent efficacy in the prediction of long term survival. 
The findings were similar when considering only the patients that survived the 
peri-operative period (6 weeks).  Multivariate analysis identified BNP >87.5 
pg/ml (HR 2.658, 95% CI 1.697-4.163, p<0.001), urgent surgery (HR 2.200, 95% CI 
1.368-3.538, p=0.001) and anaemia (HR 2.095, 95% CI 1.329-3.302, p=0.001) as 
independent predictors of long-term mortality.  In addition, a history of LVF was 
significant in this model (HR 1.989, 95% CI 1.219-3.246, p=0.006).    
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Table 5.8  Cox regression analysis of clinical variables and BNP for all cause 
mortality during long term follow-up 
 
 Univariate Multivariate 
Factor HR (95% CI) p  HR (95% CI) p  
BNP >87.5pg/ml 4.196 (2.870-6.136) <0.001 3.173 (2.145-4.693) <0.001 
Urgent Surgery 3.348 (2.236-5.012) <0.001 2.148 (1.408-3.275) <0.001 
Anaemia 2.848 (1.936-4.189) <0.001 1.990 (1.336-2.966) 0.001 
Age >70 years 1.945 (1.329-2.847) 0.001   
Diabetes 1.870 (1.239-2.821) 0.003   
Hypertension 1.732 (1.163-2.580) 0.007   
History of LVF 1.687 (1.081-2.630) 0.021   
Renal 
Impairment* 
1.459 (1.005-2.118) 0.047   
 
 
Abbreviations: HR - Hazard Ratio, BNP – B-type Natriuretic Peptide, LVF – Left 
Ventricular Failure, eGFR – Estimated Glomerular Filtration Rate, CVD – 
Cerebrovascular Disease,  COPD – Chronic Obstructive Pulmonary Disease, IHD – 
Ischaemic Heart Disease. 
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5.3.7 Long term implications of non-fatal cardiac event / cardiac 
injury  
From the group of patients that survived the peri-operative period, 33 patients 
had a non-fatal PMI.  A further 23 patients had an elevated troponin, but did not 
meet the criteria for MI.  Therefore, 56 patients in total had a peri-operative 
troponin rise.  A raised troponin was associated with poorer 1 year mortality 
(25.0% vs. 9.5%, p=0.001) [Table 5.9].  Similarly, patients who suffered a non 
fatal MI had a poorer 1 year mortality rate than patients who did not suffer an MI 
(30.3% vs. 10.2%, p=0.001).  Interestingly, an asymptomatically raised troponin 
without meeting the criteria for MI was not associated with a lower 1 year 
survival.   
Mean (95% CI) survival was shorter in patients who suffered a non-fatal MI (920 
days, 95% CI 706-1132 days) and an asymptomatic troponin rise (931 days, 95% CI 
754-1112 days) than patients with no post-operative cardiac morbidity (1251 
days, 95% CI 1189-1314 days, p=0.002) [Figure 5.4]. 
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Table 5.9  Post-operative cardiac morbidity and 1 year survival after surgery 
 
  n=318 1 year mortality p 
All raised 
troponins 
Yes 56 14/56 (25.0%) 0.001 
No 262 25/262 (9.5%)  
Non-fatal PMI 
Yes 33 10/33 (30.3%) 0.001 
No 285 29/285 (10.2%  
Raised troponin, 
no PMI 
Yes 23 4/23 (17.4%) 0.206 
No* 262 25/262 (9.2%)  
  
*Non-fatal MI patients excluded from denominator 
Abbreviations: PMI - post-operative myocardial infarction 
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Figure 5.4  Kaplan-Meier survival curve according to post-operative 
myocardial infarction or troponin rise 
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5.4 Discussion 
This study shows, for the first time, that preoperative BNP predicts long term 
survival following major non-cardiac surgery, independent of other prognostic 
characteristics. Secondly, we found that the prognostic value of BNP was similar 
in both vascular and non-vascular surgical cohorts, and in the presence and 
absence of ischaemic heart disease.  Thirdly, we extend the findings of other 
smaller cohort studies in this subject, which had shorter follow up periods. 
For the past 20 years, much effort has been spent in devising stratification 
systems to identify patients at higher risk of post-operative mortality.  A point-
of-care test that is easy to perform, cheap and reliably informative has proved 
elusive. Recent interest in the predictive value of a pre-operative BNP has been 
fuelled by a number of studies published in recent years that have shown BNP to 
predict long term outcomes in non-surgical patients with both stable cardiac 
disease and cardiac failure.124,128,215  BNP has also been shown to predict post-
operative MACE and therefore post-operative mortality.11 12   
Few studies have analysed the long term efficacy of natriuretic peptides in the 
prediction of post-operative outcome.  Cuthbertson and colleagues studied the 
medium term follow-up (median 654 days) of 204 patients undergoing major 
non-cardiac surgery at Aberdeen Royal Infirmary and found pre-operative BNP to 
be a significant independent predictor of mortality.133  From the same 
institution, Rajagopalan and colleagues performed medium term follow-up on a 
cohort of 136 patients undergoing major vascular surgery.221  Patients with an 
elevated NT-proBNP had a significantly reduced 2-year survival compared with 
patients who had a non-elevated NT-proBNP (68% vs. 93%, p<0.001).  Likewise, 
Feringa and colleagues pre-operatively measured N-terminal pro-BNP (NT-
proBNP), the inactive precursor of BNP, and found it to predict long term 
mortality in 335 patients undergoing major vascular surgery.222 
This study shows that an elevated pre-operative BNP is associated with a 
reduced long term survival, independent of other factors.  These results appear, 
in this study, to be consistent in both vascular patients in addition to other 
patients groups undergoing major surgery.  BNP was a more accurate predictor 
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of long term survival in vascular patients, which reflects the high incidence of 
cardiovascular disease in these patients.  
Since consecutive patients were included in our study, there is considerable 
heterogeneity in patient characteristics.  Thus, our patients had a broad range 
of concomitant health problems and the surgical problems involved acute illness 
and critical chronic disease, such as due to chronic progressive limb ischaemia.  
While the prognostic value of BNP may be greater in particular subgroups (and 
future studies could address this question), we suggest that the heterogeneity in 
our population may in fact make our results more transferable to ordinary 
clinical practice.  Our follow-up data were obtained in 3 ways: by hospital 
clinicians, by GP contact and by direct patient contact, however since the end-
point was all-cause mortality there is not a risk of bias in the assessment of 
outcomes. 
We found that a BNP level of 87.5 pg/ml provided the best sensitivity and 
specificity for all cause mortality.  Previous studies have identified variable 
levels of BNP that provided the best combined sensitivity and specificity for 
perioperative MACE; Cuthbertson and colleagues concluded that 40 pg/ml 
offered the best ‘cut-off’ point for elective surgery, and 170 pg/ml for 
emergency surgery.12 13  Gibson and colleagues found that a level 108.5 pg/ml 
best predicted the likelihood of perioperative MACE131, and Dernellis and 
colleagues found a level of 189 pg/ml.220  Breidthardt and colleagues 
investigated 270 patients undergoing orthopaedic surgery.223  They observed a 
low (1.5%) post-operative cardiac event rate. ROC curve analysis showed that 
174 pg/ml provided the optimal predictive accuracy.  In all the studies, the 
predictive value of BNP is evident but the best cut-off point is not.      
The predictive value of BNP and NT-proBNP, have been examined in two recent 
meta-analyses.   Karthikeyan et al include nine prospective studies investigating 
the short term peridictive value of BNP (4 studies) and NT-proBNP (5 studies).7  
They conclude that both BNP and NT-proBNP are good independent predictors of 
post-operative cardiac events.  However, due to the small number of studies 
included, they were unable to suggest a threshold value for optimal predictive 
value.  Ryding et al included 15 studies in their analysis (8 relating to BNP, 7 to 
NT-proBNP).142   Similarly, they found that patients with elevated BNP (or NT-
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proBNP) had a significantly higher MACE rate than those without.  A pooled odds 
ratios for MACE of 19.77 (95% CI 13.18-29.65, p<0.0001) was found in patients 
with elevated BNP compared with those that did not.  No study to date has 
directly compared BNP with NT-proBNP in a surgical cohort; however both meta-
analyses concluded that BNP and NT-proBNP are powerful predictors of post-
operative cardiac events. 
This study also identified pre-operative anaemia and urgent surgery as predictors 
of long term mortality and extends the finding that these factors were 
associated with increased peri-operative morbidity and mortality.  The 
significance of these variables are considered in the discussion in Chapter 5 
(5.4.2.2-5.4.2.3)   
Pre-operative risk stratification has become more important in recent years as 
the range of surgical options has increased, and older patients with greater 
comorbidty are being considered for surgical intervention.  Alternatives to 
traditional surgery, such as minimally invasive surgery, endovascular 
intervention and endoscopic procedures, have become commonplace, with a 
corresponding risk reduction in the surgical procedure.  Furthermore 
improvements in intra-operative anaesthetic techniques and post-operative 
critical care in the high dependency setting may also contribute to reduced 
overall risk. These improvements have several beneficial consequences. Firstly, 
since procedure related risk is reduced overall clinical outcomes are improved. 
Secondly, a broader range of higher-risk patients (e.g. increased co-morbidity) 
may be considered for surgery when previously surgery would not have been 
performed. Thirdly, in patients who are identified to be at high risk of 
procedure-related complications, implementation of selected contemporary 
surgical and anaesthetic techniques, could lead to individualised risk reduction.  
Most importantly, since BNP predicts long term prognosis, this information may 
be used to guide surgical management. 
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6 The predictive value of the 12 lead ECG for peri-
operative outcomes  
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6.1 Introduction 
A history of heart disease is associated with a higher rate of peri-operative 
major adverse cardiac events (MACE),224 and peri-operative mortality.4  The 
prevalence of coronary heart disease in 2006/2007 was 4.1% for the West of 
Scotland, compared with a UK mainland prevalence of 3.7%.225  Previous studies 
have shown that the West of Scotland has a high rate of asymptomatic cardiac 
disease.205  In the absence of any clinical symptoms to identify patients with 
ischaemic heart disease (IHD), pre-operative assessment is crucial. 
Cardiac risk assessment is multifactorial.226  Clinical characteristics and 
procedure type have predictive value for post-operative adverse cardiac events, 
especially when combined as risk scoring systems.6  Non-invasive cardiac tests, 
such as stress echocardiography, are fairly sensitive methods for prediction of 
cardiac risk.111  Such tests, however, are not routinely available.  The pre-
operative use of cardiac biomarkers, such as B-type natriuretic peptide, provides 
additional risk stratification in patients with known ischaemic heart disease and 
in the general population.131  Again, these tests have limited availability in the 
National Health Service and further afield. 
A 12-lead ECG is part of the standard pre-operative assessment for patients 
undergoing major surgery. However, new diagnostic technologies (e.g. 
echocardiography) have, arguably, diminished the importance applied to a pre-
operative ECG, which is universally cheap and easily acquired. Furthermore, 
automated analysis is now standard in ECG machines such that an interpretation 
of the ECG is usually provided. The benefit of routinely performing an ECG has 
been questioned,86–89 and the pre-operative ECG is often not examined properly 
prior to surgery.227   
Therefore, we aimed to assess the predictive value of a pre-operative 12-lead 
ECG in patients undergoing major surgery in a population with a high prevalence 
of cardiovascular disease.  
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6.2 Methods 
6.2.1 Patient Selection 
A prospective single centre observational cohort study was performed.   
Consecutive patients undergoing major vascular surgery (aortic surgery, bypass, 
amputation) or laparotomy were selected for inclusion in the study.  All patients 
had standard pre-operative assessment including a 12-lead ECG the day before 
surgery.  Further cardiac assessment was carried out at the discretion of the 
operating team.  The presence of risk factors such as smoking, diabetes, 
hyperlipidaemia, previous myocardial infarction (MI) and chronic obstructive 
airways disease (COPD) were obtained from the patient’s history and medical 
records.  A history of ischaemic heart disease was defined as a previous 
myocardial infarction, a report from a cardiologist describing ischaemia on an 
exercise tolerance test, use of nitrate therapy for angina or the presence of 
pathological Q-waves on ECG.6   Left ventricular failure (LVF) was considered 
present if the patient had a prior hospital admission with heart failure or left 
ventricular impairment on previous echocardiography.  Cerebrovascular disease 
was defined as a previous cerebrovascular accident or transient ischaemic 
attack.  The glomerular filtration rate (GFR) was estimated using the 
Modification of Diet in Renal Disease (MDRD) equation.192  Renal impairment was 
considered present if the estimated GFR was <60mls/min.  A patient was 
considered a smoker if they were smoking at the time of admission for surgery.  
Hypertension was considered present if the patient had a previous medical 
documentation of hypertension and was currently taking antihypertensive 
medication.  The current medication was also recorded, in particular the 
prescription of antiplatelet agents, a statin and beta-blockers.   
Post-operative screening for cardiac events was performed.  This consisted of 
daily clinical assessment and serial ECGs and troponin I measurement on days 2 
and 5 and 6 weeks following surgery.  The primary outcomes were MACE (non-
fatal MI and cardiac mortality) and all-cause mortality within the post-operative 
period (6 weeks).  The definition of a non-fatal MI was that used by The Joint 
European Society of Cardiology/American College of Cardiology Committee:34 a 
typical rise and gradual fall of cTnI with at least one of the following: ischaemic 
symptoms, development of pathological Q waves on the ECG, ECG changes 
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indicative of ischaemia (ST segment elevation or depression) or coronary artery 
intervention.  Cardiac death was defined as death secondary to MI, cardiogenic 
shock or intractable arrhythmia.  Regional ethics committee approval was 
obtained and all patients gave written consent to the study following a verbal 
explanation and written information. 
ECG Analysis 
All electrocardiographs (ECGs) were batch analysed at the end of the study by 
two investigators (general surgeon and cardiologist), blinded to the clinical 
outcomes.  The ECG results were then double checked by a second cardiologist 
and disagreements were resolved by consensus.  ECGs were examined for the 
presence of the following abnormalities; 
 Left ventricular hypertrophy: Sokolow-Lyon voltage criteria (S wave in V1 
and R wave in V5 or V6 > 35mm, or R wave in aVL > 11 mm).194 
 Bundle branch block: The standard morphological appearance of left or 
right bundle branch block, with a QRS duration of >120 ms. 
 Atrial fibrillation: presence or absence. 
 Axis deviation: Using standard QRS axis electrical criteria, left axis 
deviation > -30, right axis deviation > +90. 
 Q-waves: Present of a negative deflection preceding the R wave in two 
contiguous leads with duration of >40ms and amplitude greater than 25% 
of corresponding R wave.   
 Ventricular strain pattern:  Planar ST segment depression ≥ 1mm or T 
wave inversion in V5/V6. 
 Premature ventricular contraction (PVC): presence or absence of broad 
complex ectopic beats.  
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An ECG was considered abnormal if one or more of the above characteristics 
were present.  Cumulative abnormalities on individual ECGs were also recorded. 
ECG findings: heart rate (HR), QRS duration and QTc were recorded directly from 
the automated data display on the ECG.  Tachycardia was defined as HR >100, 
broad QRS complex as >130ms and prolonged QTc as >440ms.      
6.2.2 Statistical Analysis 
Statistical analysis was performed using SPSS (Version 15) statistical software 
package (SPSS, Chicago, Illinois, USA).  A p-value of less than 0.05 was 
considered significant.  Categorical data were compared using the χ2 test or 
Fisher’s exact tests were applicable.  Univariate analyses were performed using 
logistic regression methods.  Only variables with a p-value of less than 0.10 were 
further evaluated with a multivariate logistic regression analysis using a 
backward stepwise selection. 
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6.3 Results 
6.3.1 Patient characteristics 
345 patients were included in the study.  Two hundred and seventy six  (80.0%) 
patients underwent a vascular procedure (aortic surgery 25.8%, lower limb 
bypass 29.0% and amputation 25.2%) and 69 (20.0%) patients underwent 
laparotomy.  The ECGs were obtained on average 1 day (range 0 – 8 days) prior 
to surgery. 
6.3.2 Post-operative outcomes: frequency and associations 
MACE occurred in 46 (13.3%) patients, and 27 (7.8%) patients died in the post-
operative period (within 6 weeks).  The peri-operative MACE rate was higher in 
patients with hypertension (18.4% vs. 6.7%, p=0.002) and those aged ≥ 70 years 
(19.4% vs. 7.8%, p=0.002) [Table 6.1].  Patients with diabetes and renal 
impairment had a higher peri-operative mortality rate than patients without 
these co-morbidities (15.9% vs. 5.8%, p=0.005, and 11.3% vs. 5.4%, p=0.047 
respectively) [Table 6.2]. 
An abnormal ECG was present in 141 (40.9%) patients.  The commonest 
abnormalities were prolonged QTc (19.7%), left ventricular strain (12.5%), 
tachycardia (11.6%), an abnormal axis (10.7%) and LVH (10.1%).   
Patients with an abnormal ECG had a higher incidence of MACE (21.6% vs. 8.3%, 
p<0.001) [Table 6.3].  The individual ECG abnormalities that were associated 
with post-operative MACE were ventricular strain (p<0.001), AF (p=0.016) and 
prolonged QTc (p<0.001).  Patients who died were also more likely to have an 
abnormal ECG than those who survived (63.0% vs. 39.0%, p=0.015) [Table 6.4].   
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Table 6.1  Pre-operative clinical variables and perioperative major adverse 
cardiac event (MACE) 
 
  n=345  
MACE  
n =46 (%) 
p* 
Sex Male 217  30 (13.8%) 0.727 
 Female 128 16 (12.5%)  
Age  ≥ 70 years 165  32 (19.4%)  0.002 
 <70 years 180 14 (7.7%)  
Smoker Yes 145  20 (13.8%) 0.831 
 No 200 26 (12.0%)  
Diabetes Yes 69  12 (17.4%) 0.268 
 No 276 34 (12.3%)  
HTN Yes 196  36 (18.4%) 0.002 
 No 149 10 (6.7%)  
GFR <60 Yes 142  25 (17.6%) 0.051 
 No 203 21(10.3%)  
Hyperlipideamia Yes 110  14 (12.7%) 0.821 
 No 235 32 (13.6%)  
Previous MI Yes 64  11 (17.2%) 0.315 
 No 281 35 (12.5%)  
IHD  Yes 104  16 (15.4%) 0.462 
 No 241 30 (12.4%)  
LVF  Yes 64  11 (17.2%) 0.315 
 No 281 35 (12.5%)  
Cerebrovascular  Yes 43  9 (20.9%) 0.117 
 No 302 37 (12.3%)  
COPD Yes 49  4 (8.2%) 0.180 
 No 296 41 (13.9%)  
 
 
* Chi-squared test unless stated, Fischers exact test  
 
Abbreviations; HTN; hypertension, eGFR; estimated glomerular filtration rate 
(ml/min), MI; myocardial infarction, IHD; ischaemic heart disease, LVF; left 
ventricular failure, COPD; chronic obstructive pulmonary disease, CVD; 
cerebrovascular disease.  
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Table 6.2  Pre-operative clinical variables and peri-operative all cause 
mortality 
 
  Total (%) 
Perioperative 
Death 
n=27 (%) 
p* 
Male Sex Male 217  19 (8.8%) 0.403 
 Female 128 8 (6.3%)  
Age ≥ 70 years ≥ 70 years 165  17 (10.3%) 0.101 
 <70 years 180 10 (5.6%)  
Smoker Yes 145  10 (6.9%) 0.584 
 No 200 17 (8.5%)  
Diabetes Yes 69  11 (15.9%) 0.005 
 No 276 16 (5.8%)  
HTN Yes 196  20 (10.2%) 0.059 
 No 149 7 (4.7%)  
eGFR <60 Yes 142  16 (11.3%)   0.047 
 No 203 11(5.4%)  
Hyperlipideamia Yes 110  10 (9.1%) 0.550 
 No 235 17 (7.2%)  
Previous  MI Yes 64  6 (9.4%) 0.609 
 No 281 21 (7.5%)  
IHD Yes 104  8 (7.7%) 0.952 
 No 241 19 (7.9%)  
LVF Yes 64  2 (3.1%) 0.090 
 No 281 25 (8.9%)  
Cerebrovascular  Yes 43  4 (9.3%) 0.442 
 No 302 23 (7.6%)  
COPD Yes 49  7 (14.3%) 0.069 
 No 296 20 (6.8%)  
 
 
* Chi-squared test unless stated, Fischers exact test  
 
Legend; HTN; hypertension, eGFR; estimated glomerular filtration rate 
(ml/min), MI; myocardial infarction, IHD; ischaemic heart disease, LVF; left 
ventricular failure, COPD; chronic obstructive pulmonary disease, CVD; 
cerebrovascular disease.  
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Table 6.3  ECG abnormalities and peri-operative major adverse cardiac event 
(MACE) 
 
  
Total  
n=345 (%) 
MACE  
n =46 (%) 
p* 
Abnormal ECG Yes 141  31 (22.0%) <0.001 
 No 204 15 (7.4%)  
Abnormal Axis Yes 37  8 (21.6%) 0.116 
 No 308 38 (12.3%)  
LVH Yes 35  6 (17.1%) 0.484 
 No 310 40 (12.9%)  
Strain Yes 43  17 (39.5%) <0.001 
 No 302 29 (9.6%)  
Q-wave Yes 33  6 (18.2%) 0.389 
 No 312 40 (12.8%)  
BBB Yes 14  3 (21.4%) 0.412 
 No 331 43 (13.0%)  
AF Yes 32  9 (28.1%) 0.010 
 No 313 37 (11.8%)  
PVC Yes 21  3 (14.3%) 0.750 
 No 324 43 (13.3%)  
HR >100 Yes 40  6 (15.0%) 0.742 
 No 305 40 (13.1%)  
QRS >130ms Yes 12  2 (16.7%) 0.666 
 No 333 44 (13.2%)  
QTc >440ms Yes 68  19 (27.9%) <0.001 
 No 277 27 (9.7%)  
 
* Chi-squared test unless stated, Fischers exact test  
 
Abbreviations; LVH; left ventricular hypertrophy, BBB; bundle branch block, AF; 
atrial fibrillation, PVC, premature ventricular complex.  
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Table 6.4  ECG abnormalities and peri-operative all cause mortality 
 
  Total (%) 
Perioperative 
Death 
n=27 (%) 
p* 
Abnormal ECG Yes 141  17 (6.3%) 0.015 
 No 204 10 (4.9%)  
Abnormal Axis Yes 37  3 (8.1%) 1.000 
 No 308 24 (7.8%)  
LVH Yes 35  5 (14.3%) 0.133 
 No 310 22 (71.0%)  
Strain Yes 43  6 (14.0%) 0.110 
 No 302 21 (7.0%)  
Q-wave Yes 33  4 (12.1%) 0.310 
 No 312 23 (7.4%)  
BBB Yes 14  2 (14.3%) 0.301 
 No 331 25 (7.6%)  
AF Yes 32  4 (12.5%) 0.297 
 No 313 23 (7.3%)  
PVC Yes 21  2 (9.5%) 0.674 
 No 324 25 (7.7%)  
HR >100 Yes 40  6 (15.5%) 0.072 
 No 305 21 (6.9%)  
QRS >130ms Yes 12  1 (8.3%) 1.000 
 No 333 26 (7.8%)  
QTc >440ms Yes 68  7 (10.3%) 0.398 
 No 277 20 (7.2%)  
 
 
* Chi-squared test unless stated, Fischers exact test  
 
Abbreviations; LVH; left ventricular hypertrophy, BBB; bundle branch block, AF; 
atrial fibrillation, PVC, premature ventricular complex.  
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6.3.3 Clinical variables and ECG abnormalities - multivariate 
predictors of adverse outcomes 
The clinical variables and ECG abnormalities with a p value of <0.10 from 
univariate analysis of peri-operative MACE were entered into a logistic regression 
model [Table 6.5].  The only clinical factors that remained significant on 
multivariate analysis were hypertension and age > 70 years.  From the ECG 
abnormalities, ventricular strain and QTc >440ms remained significant.  An 
abnormal ECG, eGFR <60 ml/min and AF did not remain significant in the model. 
Diabetes, an abnormal ECG, eGFR >60 mls/min, hypertension, COPD and HR>100 
were associated with peri-operative mortality on univariate analysis [Table 6.6].  
However, only diabetes remained significant after multivariate analysis. 
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Table 6.5  Cox regression analysis of clinical variables and ECG 
abnormalities and post-operative major adverse cardiac event (MACE) 
 
 Univariate Multivariate* 
Factor HR (95% CI) p HR (95% CI) p 
Ventricular Strain 6.12 (2.92-12.66) <0.001 4.93 (2.30-10.58) <0.001 
QTc >440ms 3.59 (1.85-6.96) <0.001 2.92 (1.44-5.96) 0.003 
Hypertension 3.13 (1.50-6.53)   0.002 2.79 (1.28-6.01) 0.010 
Age ≥ 70 years 2.85 (1.46-5.57)   0.002 2.26 (1.11-4.60) 0.025 
Abnormal ECG 3.21 (1.73-5.95) <0.001   
AF 2.92 (1.26-6.78)   0.010   
 
 
Abbreviations;  HR - hazard ratio, CI - confidence interval, AF- atrial fibrillation,  
 
 
Table 6.6  Cox regression analysis of clinical variables and ECG 
abnormalities and post-operative mortality 
 
 Univariate Multivariate* 
Factor HR (95% CI) p HR (95% CI) p 
Diabetes 3.08 (1.36-6.99) 0.007 2.56 (1.10-5.95) 0.029 
Abnormal ECG 2.66 (1.18-6.00) 0.018   
eGFR >60 2.22 (0.99-4.93) 0.051   
Hypertension 2.31 (0.95-5.61) 0.065   
COPD 2.20 (0.92-5.77) 0.076   
HR >100 2.39 (0.91-6.32) 0.080   
 
Abbreviations; HR - hazard ratio, CI - confidence interval, eGFR - estimated 
glomerular filtration rate (mls/min). 
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6.3.4 Relationships between a history of IHD and the presence or 
absence of an abnormal ECG 
The relationship between a history of IHD and an abnormal ECG was examined.  
Patients with a history of IHD and a normal ECG had the lowest MACE rate (2.4%) 
compared with no IHD and a normal ECG (8.6%), IHD and an abnormal ECG 
(24.2%) and no IHD and an abnormal ECG (20.3%) (p=0.001).  The preoperative 
prescription of an antiplatelet agent, a statin and a beta-blocker within these 
groups is summarised in Table 6.7.  Patients with known IHD and a normal ECG 
have a significantly higher rate of antiplatelet therapy, statin and beta-blocker 
prescription compared with the other groups.  Multiple ECG abnormalities were 
encountered in 54 (15.7%) patients (37 (10.7%) patients had 2 and 17 (4.9%) had 
3 or more).  The rate of peri-operative MACE was higher in patients with 2 
(35.1%) and 3 or more (23.5%) abnormalities, compared with 1 (16.1%) and a 
normal ECG (7.4%) (p<0.001).  
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Table 6.7  Prescription rate of best medical therapy in patients with or 
without ischaemic heart disease (IHD) and a normal or abnormal ECG 
 
   Normal ECG Abnormal ECG p* 
   
No IHD 
n = 162 (%) 
IHD 
n=42 (%) 
No IHD 
n=79 (%) 
IHD 
n=62 (%) 
 
Antiplatelet 
Agent 
Yes   64 (39.5) 32 (76.2) 44 (55.7) 39 (62.9) <0.001 
No  98 (60.5) 10 (23.8) 35 (44.3) 23 (37.1)  
Statin 
Yes  65 (40.1) 32 (76.2) 41 (51.9) 37 (59.7) <0.001 
No  97 (59.9) 10 (23.8) 38 (48.1) 25 (40.3)  
Beta-
blocker 
Yes  22 (13.6) 25 (59.5) 20 (25.3) 19 (30.6) <0.001 
No  140 (86.4) 17 (40.5) 59 (74.7) 43 (69.4)  
 
* Chi-squared test. 
Abbreviations; IHD - Ischaemic heart disease  
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6.4 Discussion 
This study has two key findings: Firstly, a standard pre-operative ECG has 
stronger predictive value for peri-operative events than clinical characteristics, 
such as IHD.  Secondly, patients with an abnormal ECG, but without a prior 
history of ischaemic heart disease represent an otherwise unrecognised high risk 
group.  This finding is important since this group could potentially be amenable 
to risk reduction intervention. 
Although a number of other studies have examined the relationship between the 
pre-operative ECG and post-operative outcomes, we believe this study has a 
number of strengths.  This was a prospective study in consecutive patients who 
were screened for post-operative cardiac events. The relatively high MACE rate 
may be explained by the fact that ‘all-comers’ were included and no patients 
were excluded on clinical grounds.  By so-doing, we were also able to collect 
information on patients without a prior diagnosis of heart disease 
Noordzij and colleagues retrospectively computer interpreted ECGs from 23036 
patients undergoing non-cardiac surgery.86  Since this study was performed 
retrospectively using cardiac death as their only endpoint, non-fatal cardiac 
events were not included in the analysis.  This may explain their conclusion that 
an ECG is not necessary in lower risk procedures.  Similarly Lui and colleagues 
concluded that the preoperative ECG was of limited value in a prospective study 
of more than 500 elderly patients (aged >70).88  They found a high prevalence of 
ECG abnormalities (75.2%) and concluded that the ECG had no discriminatory 
value.  They did however examine far more ECG abnormalities than in this study 
(22 variables), and this may reflect the reduction in specificity.  Van Klei and 
colleagues examined 2422 patients, enrolled in a previous study, for post-
operative MI and all cause mortality.87  They found that on univariate analysis 
bundle branch block predicted outcome, but was not significant on regression 
modelling.  Again this study was performed retrospectively.  They concluded 
that in their study group an ECG did not improve prediction beyond risk factors 
identified on a careful history.  Landesberg and colleagues carried out a 
prospective study of 405 patients undergoing vascular surgery.90  They carried 
out rigorous post-operative screening for cardiac events (daily cardiac enzymes).  
Despite this, they found a low rate of MACE (4.7%), perhaps reflecting a 
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healthier population.  However they did find that LVH and ST segment 
depression was more predictive of poor outcome than standard clinical 
variables.  Correll and colleagues performed a case-control study comparing a 
cohort of 95 patients with an abnormal pre-operative ECG, matched to 195 
patients without an abnormality.89  They concluded that risk factors obtained 
from a careful history predicted ECG abnormalities and therefore questioned the 
value of the routine ECG. 
With regard to our second key finding, we were surprised to find such a high 
event rate in patients with an abnormal ECG but without a prior history of IHD.  
In fact, the MACE rate in these patients (20.3%) was higher than in patients with 
known IHD and a normal ECG (8.6%), and nearly as high as the MACE rate in IHD 
patients with an abnormal ECG (24.2%).  There may be several explanations for 
this surprising result.  Firstly, the rate of antiplatelet agent, statin and beta-
blocker use was lower in this group.  These drugs improve prognosis after major 
surgery.228  Secondly, since these patients had ECG abnormalities, it seems likely 
that some of them had undiagnosed heart disease.  Thirdly, since these patients 
had no history of IHD, it seems plausible that prior risk assessment, such as 
stress testing or coronary arteriography, would not have been performed.  
Thinking ahead, this group of patients with unrecognised or subclinical cardiac 
illness represent a group who might benefit from a targeted pre-operative 
intervention, such as more aggressive risk assessment and improved best medical 
management.     
One limitation of our study is that the ECGs were assessed by a cardiologist 
which is rarely routinely performed on all pre-operative ECGs.  However, this 
study examined standard ECG characteristics, many of which are routinely 
described in the automated computer report provided on the ECG print-out. 
Therefore, we believe our findings are relevant to everyday practice.   Bedside 
interpretation of the ECG by a non-cardiology trained staff member is standard 
in most settings.  More complex analyses performed in some other studies may 
not allow this relevance.  This study included consecutive patients undergoing 
major surgery in our unit, and reflects the case load we encounter.  The 
heterogeneous nature of our cohort could also be considered as a limitation, 
although we feel this allows the findings to be applicable to general clinical 
practice.  Finally, it is worth remembering that a pre-operative ECG remains the 
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optimal baseline comparison in the event of a post-operative MI, and without it, 
the timely diagnosis of a cardiac event may be hampered. 
In conclusion, we show that in this study group, the ECG remains an important 
tool in the pre-operative assessment of patients undergoing major non-cardiac 
surgery. 
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7 The performance of the Revised Cardiac Risk 
Index (RCRI) in patients undergoing major 
vascular surgery 
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7.1 Introduction 
The pre-operative assessment of the likelihood of a post-operative cardiac event 
is complex229. The Revised Cardiac Risk Index (RCRI) is a commonly used scoring 
system for the stratification cardiac risk of patients undergoing major non-
cardiac surgery.6  The RCRI scores patients according to 6 clinical categories; 
high risk surgery (thoracic, abdominal and supra-inguinal vascular surgery), 
history of ischaemic heart disease, history of congestive heart failure, 
cerebrovascular disease, insulin-dependent diabetes and renal failure.  The RCRI 
defines Class 1 as no factors present, Class 2 as 1 factor present, Class 3 as 2 
factors present and Class 4 as 3 or more factors present.  Results from the 
validation cohort of the original study suggest that the risk of a major adverse 
cardiac event (MACE) in Class 1, 2, 3 and 4 was 0.4%, 0.9%, 7% and 11% 
respectively.   
Since the publication of the original paper in 1999, the RCRI has become a 
widely used stratification tool for cardiac risk.  Indeed the most recent American 
College of Cardiology/American Heart Association (ACC/AHA) guidelines on peri-
operative cardiovascular evaluation for non-cardiac surgery stress the use of risk 
stratification, in particular the RCRI, in its recommendations.69  The RCRI has, to 
date, been cited in over 400 papers, although very few of these papers have 
focused on validating its findings.   
Several attempts have been made to directly validate the RCRI.101,102,230,231  A 
recent meta-analysis has examined the predictive value of the RCRI in these 
studies.103  It concluded that the RCRI performed moderately well at 
discriminating between low and high peri-operative risk.  However the authors 
felt it performed poorly in vascular cohorts, and that the studies included were 
of variable quality.  This report highlights the need for further studies evaluating 
the RCRI.  Therefore, we aim to prospectively assess the predictive value of the 
RCRI in patients undergoing vascular surgery in a West of Scotland setting. 
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7.2 Methods 
7.2.1 Patients Selection 
This is a single centre observational study in patients undergoing major vascular 
surgery.  Consecutive patients undergoing aortic surgery, lower limb bypass 
surgery and amputation were selected for inclusion in the study.  All patients 
had standard pre-operative assessment including a 12-lead ECG.  Further cardiac 
assessment was carried out at the discretion of the operating team.  Ethical 
approval for this study was provided by the West of Scotland Research Ethics 
Committee.  All patients gave written consent to the study following a verbal 
explanation and written information 
The patients were pre-operatively scored according to the RCRI using the 
following criteria.6  High risk surgery was defined as thoracic, abdominal or 
supra-inguinal bypass surgery.  Ischaemic heart disease was defined as a previous 
myocardial infarction, a positive exercise tolerance test, the use of nitrate 
therapy or the presence of pathological Q-waves on ECG.  Previous congestive 
cardiac failure, cerebrovascular disease (stroke or transient ischaemic attack) 
and pre-operative treatment with insulin was noted.  Renal failure was defined 
as a serum creatinine of >2.0mg/dl (176.8umol/l). 
The presence of other risk factors such as smoking, hyperlipidaemia, and chronic 
obstructive airways disease (COPD) were obtained from the patient’s history and 
medical records.  Hypertension was considered present if antihypertensive 
medication was taken.    The glomerular filtration rate (eGFR) was estimated 
using the MDRD equation.192  An eGFR of greater than 60 mls/min was considered 
normal.  This was used as a separate variable from the definition for renal 
failure in the RCRI.  Pre-operative anaemia was defined as a haemoglobin of 
<13.0 g/dl for males and <11.0 g/dl for females.  Operations were recorded as 
elective or urgent (surgery during an unplanned admission).  Patients operated 
as an emergency, within 24hrs of an unplanned admission were excluded.   
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7.2.2 Post-operative Surveillance  
Post-operative screening for cardiac events was performed.  This consisted of 
daily clinical assessment and serial ECGs and troponin I measurement on day 2, 
day 5 and 6 weeks following surgery.  All patients were followed-up for the first 
post-operative year, either at outpatient clinic or with the general practitioner 
(GP).  In the absence of follow-up data, the patient was directly contacted.  The 
primary outcomes were MACE (non-fatal myocardial infarction and cardiac 
mortality), all-cause mortality within the post-operative period (6 weeks) and 1 
year all-cause mortality.  The definition of a non-fatal MI was that used by The 
Joint European Society of Cardiology/American College of Cardiology 
Committee34: a typical rise and gradual fall of serum troponin with at least one 
of the following: ischaemic symptoms, development of pathological Q waves on 
the ECG, ECG changes indicative of ischaemia (ST segment elevation or 
depression) or coronary artery intervention.  Cardiac death was defined as death 
secondary to MI, cardiogenic shock or intractable arrhythmia. 
7.2.3 Statistical Analysis 
Statistical analysis was performed using SPSS (Version 15) statistical software 
package (SPSS, Chicago, Illinois, USA).  A p-value of less than 0.05 was 
considered significant.  Categorical variables are presented with totals and 
percentages, and analysed with chi-squared, Fishers exact test or Mann-Whitney 
test as appropriate.  Receiver operating characteristic (ROC) curves were 
plotted to model the efficacy of the RCRI.  The area under the curve (AUC) was 
calculated. 
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7.3 Results 
A total of 252 patients undergoing major vascular surgery were included in the 
study.  Sixty-five patients underwent aortic surgery (25.8%), 100 had lower limb 
bypass surgery (39.7%) and 87 had a lower limb amputation (34.5%).  Thirty-nine 
patients (15.5%) had a post-operative MACE, and twenty patients (7.9%) died 
within the post-operative six week period.  The one year mortality rate was 
22.6%.   
7.3.1 Utility of Revised Cardiac Risk Index (RCR)I for prediction of 
peri-operative MACE, peri-operative mortality and 1 year 
survival 
Applying the RCRI to the cohort as a whole, the rate of MACE for RCRI class 1, 2, 
3 and 4 was 13.4%, 14.9%, 18.6% and 16.7% respectively (p=0.858) [Table 7.1].  
Similarly, the rate of peri-operative mortality for these groups was 7.3%, 9.2%, 
6.8% and 8.3% (p=0.951).  The one year mortality in each group was 17.1%, 
24.1%, 25.4% and 29.2% (p=0.492).   
Table 7.1 Primary Endpoints by Revised Cardiac Risk Index (RCRI) Class 
 
 n MACE (%) 
Peri-operative  
Mortality (%) 
1 Year  
Mortality (%) 
Total 252 39 (15.5) 20 (7.9) 57 (22.6) 
RCRI Class 1 82 11 (13.4) 6 (7.3) 14 (17.1) 
RCRI Class 2 87 13 (14.9) 8 (9.2) 21 (24.1) 
RCRI Class 3 59  11 (18.6) 4 (6.8) 15 (25.4) 
RCRI Class 4 24  4 (16.7) 2 (8.3) 7 (29.2) 
p-value*  0.858 0.951 0.492 
 
* Chi-Squared Test 
Abbreviations: MACE - Major Adverse Cardiac Event, RCRI - Revised Cardiac Risk 
Index  
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7.3.2 Revised Cardiac Risk Index; individual component analysis 
for endpoints. 
Analysis of the RCRI components revealed that no individual factor predicted 
post-operative MACE after univariate analysis [Table 7.2].  Insulin therapy was 
higher in patients that died in the peri-operative group (18.2% vs. 6.4%, 
p=0.020).  Patients with a pre-operative creatinine >2mg/dl had higher peri-
operative mortality (30.0% vs. 7.0%, p=0.036), and 1 year mortality (60.0% vs. 
21.1%, p=0.004).  Patients undergoing high risk surgery had a significantly lower 
1 year mortality (10.8% vs. 26.7%, p=0.008).  
7.3.3 Operative subgroup analysis and predictive utility of 
Revised Cardiac Risk Index 
The predictive value of the RCRI was then examined within the three individual 
operative groups [Table 7.3].  Due to small numbers, the two highest risk groups 
(class 3 and 4) were combined for analysis.  In no subgroup was the RCRI 
predictive of peri-operative MACE.  The RCRI did stratify 1 year mortality in the 
patients undergoing lower limb bypass surgery; class 1, 2 and ≥3 with mortality 
rates of 9.6%, 18.5%, 33.3% (p=0.049) respectively.  In the amputation group, 
patients in RCRI class 1 had peri-operative mortality rate of 13.3%, compared 
with 17.9% in class 2 and 6.9% in class 3.
Table 7.2  Predictive value of individual RCRI components for peri-operative major adverse cardiac event (MACE), peri-operative 
mortality and 1 year mortality 
 
 n 
Peri-operative 
MACE 
p* 
Peri-operative 
mortality 
p* 1 Year Mortality p* 
High Risk 
Surgery 
Yes 65 9 (13.8) 0.673 3 (4.6) 0.300† 7 (10.8) 0.008 
No 187 30 (16.0)  17 (9.1)  50 (26.7)  
IHD 
Yes 82 12 (14.6) 0.797 7 (7.6) 0.807 23 (28.0) 0.152 
No 170 27 (15.9)  13 (7.6)  34 (20.0)  
CCF 
Yes 57 11 (19.3) 0.364 2 (3.5) 0.263* 17 (29.8) 0.139 
No 195 28 (14.4)  18 (9.2)  40 (20.5)  
CVD 
Yes 38 7 (18.4) 0.586 3 (7.9) 1.000† 12 (31.6) 0.152 
No 214 32 (15.0)  17 (7.9)  45 (21.0)  
IDDM 
Yes 33 7 (21.2) 0.328 6 (18.2) 0.020 11 (33.3) 0.115 
No 219 32 (14.6)  14 (6.4)  46 (21.0)  
Creat  Yes 10 3 (30.0) 0.189† 3 (30.0) 0.036† 6 (60.0) 0.004 
>2 mg/dl No 242 36 (14.9)  17 (7.0)  51 (21.1)  
 
Legend;  
* Chi-Squared Test unless otherwise stated.† Fisher’s Exact Test. 
Abbreviations: MACE - Major Adverse Cardiac Event, IHD – Ischaemic Heart Disease, CCF – Congestive Cardiac Failure, CVD – 
Cerebrovascular Disease, IDDM – Insulin Dependant Diabetes Mellitus. Creat - Creatinine. 
188 
Table 7.3 Predictive value of Revised Cardiac Risk Index (RCRI) Class within Operation Groups 
 
  RCRI Class n  MACE (%)  
Peri-operative 
Mortality (%) 
 
1 Year  
Mortality (%) 
Aortic Surgery 
 
1 0  -  -  - 
2 32  5 (15.6)  2 (6.3)  4 (12.5) 
 ≥3 33  6 (18.2)  1 (3.0)  3 (9.1) 
 p value*   0.683  0.536  0.658 
Bypass 
 1 52  5 (9.6)  2 (3.8)  5 (9.6) 
 2 27  3 (11.1)  1 (3.7)  5 (18.5) 
 ≥3 21  3 (14.3)  3 (14.1)  7 (33.3) 
 p value*   0.846  0.198  0.049 
Amputation 
 1 30  6 (20.0)  4 (13.3)  9 (30.0) 
 2 28  5 (17.9)  5 (17.9)  12 (42.9) 
 ≥3 29  8 (27.6)  2 (6.9)  12 (41.4) 
 p value*   0.644  0.456  0.539 
 
 
* Mann-Whitney test. 
Abbreviations: MACE – Major Adverse Cardiac Event 
7.3.4 Clinical predictors of primary endpoints not included in the 
revised cardiac risk index 
Analysis of other risk factors not included in the RCRI showed that age ≥ 70 years 
(p=0.002), a history of hypertension (p=0.010), pre-operative anaemia (p<0.001) 
and urgent (p=0.024) had a significantly higher rate of post-operative MACE 
(table 4).  Furthermore, age ≥ 70 years (p=0.028), diabetes (type I and II) 
((p=0.013), GFR <60mls/min (p=0.009), COPD (p=0.043), pre-operative anaemia 
(p=0.025) and expedited surgery (p=0.020) were associated with an increased 
rate of post-operative death.  The following factors were associated with lower 
one year survival rates; age ≥ 70 (p=0.024), diabetes (type I and II) (p=0.044), 
hypertension (p=0.023), GFR <60mls/min (p=0.031), expedited surgery (p<0.001) 
and pre-operative anaemia (p<0.001).
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Table 7.4  Patient Characteristics and predictors of major adverse cardiac event (MACE), peri-operative mortality and 1-year 
mortality 
 
Factor 
n (%) 
n=252 
MACE (%) 
n=39 
p* 
Perioperative 
Mortality (%) 
n=20 
p* 
1 year 
Mortality (%) 
n=57 
p* 
Male Sex 166 (65.9) 26 (66.7) 0.909 16 (80.0) 0.165 38 (66.7) 0.886 
Age ≥ 70 135 (53.6) 27 (69.2) 0.002 14 (70.0) 0.028 35 (61.4) 0.010 
Smoker 126 (50.0) 19 (48.7) 0.862 9 (45.0) 0.641 29 (50.9) 0.880 
Diabetes (I and II) 57 (22.6) 10 (25.6) 0.624 9 (45.0) 0.013 18 (31.6) 0.066 
Hypertension 154 (61.1) 31 (79.5) 0.010 16 (80.0) 0.071 42 (73.7) 0.027 
Hyperlipidaemia 82 (32.5) 11 (28.2) 0.530 8 (40.0) 0.458 21 (36.8) 0.431 
eGFR <60mls/min 107 (42.5) 22 (56.4) 0.055 14 (70.0) 0.009 31 (54.4) 0.038 
Previous MI 50 (19.8) 8 (20.5) 0.909 6 (30.0) 0.235 18 (31.6) 0.012 
COPD 46 (18.3) 4 (10.3) 0.160 7 (35.0) 0.043 12 (21.1) 0.534 
Beta-Blocker 68 (27.0) 11 (28.2) 0.852 6 (30.0) 0.751 18 (31.6) 0.374 
Antiplatelet  150 (59.5) 22 (56.4) 0.667 9 (45.0) 0.168 33 (57.9) 0.776 
Statin 139 (55.2) 21 (53.8) 0.858 9 (45.0) 0.341 34 (59.6) 0.438 
Pre-operative Anaemia 116 (46.0) 29 (74.4) <0.001 14 (70.0) 0.025 41 (71.9) <0.001 
Urgent Surgery 153 (60.7) 30 (76.9) 0.024 17 (85.0) 0.020 50 (87.7) <0.001 
Blood loss >500mls 32 (12.7) 7 (17.9) 0.284 2 (10.0) 0.706 5 (8.8) 0.311 
 
* Chi-Squared Test unless otherwise stated. † Mann-Whitney test. 
Abbreviations: eGFR – Estimated Glomerular Filtration Rate, MI – Myocardial Infarction, COPD – Chronic Obstructive Pulmonary Disease. 
191 
7.3.5 Receiver operator curve analysis of the performance of the 
RCRI 
The area under the ROC curve for the RCRI score was calculated for the 
endpoints.  The AUC for peri-operative MACE was 0.538 [Figure 7.1], 0.501 for 
peri-operative mortality and 0.562 for 1 year mortality.  The same analysis was 
performed, amending the RCRI to consider all included vascular operation groups 
as high risk.  The AUCs were not improved for peri-operative MACE, mortality or 
1 year mortality respectively (0.507, 0.473 and 0.525).  However if this category 
in the RCRI was replaced by age ≥ 70 years, the AUCs were improved (0.614, 
0.622 and 0.665). 
Figure 7.1  ROC curve analysis: RCRI and post-operative major adverse 
cardiac event (MACE) 
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7.4 Discussion 
The prediction of post-operative cardiac morbidity is challenging.  Patient co-
morbidity, operation type, peri-operative stress and post-operative factors are 
all influential in the pathogenesis of post-operative MACE.4,232  Extensive 
research has examined a plethora of pre-operative stratification tools.  Many 
cardiac scoring systems have been devised that aim to stratify and quantify 
risk.229  
The RCRI includes patients factors (IHD, cardiac failure, cerebrovascular disease 
and insulin dependent diabetes), pre-operative renal impairment (Creatinine 
>2mg/dl) and type of surgery.  These factors were found to be the most 
significant predictors of post-operative MACE in a derivation cohort of 2893 
patients and the model was validated in a cohort of 1422 patients.  Procedure 
types included thoracic, orthopaedic, vascular and abdominal surgery.  The rates 
of major cardiac morbidity in the derivation and validation cohorts were 2% and 
2.5% respectively.  These rates are considerably lower than in our study group, 
perhaps reflecting the heterogeneous nature of the procedures examined and a 
healthier study population.  
Why then has it performed so poorly in our cohort? Firstly, the RCRI defines high 
risk surgery as, intrathoracic, intraperitoneal and suprainguinal vascular surgery.  
In our cohort, patients undergoing high risk surgery, as defined by the RCRI, had 
a lower MACE rate, improved peri-operative survival and lower 1 year mortality.  
This can be explained as the high risk patients were undergoing elective aortic 
surgery, yet patients undergoing lower limb revascularisation or amputation 
were considered as low risk surgery.  However, removing this ‘high risk surgery’ 
parameter from the model did not improve the predictive efficacy.  Secondly, 
patients with peripheral vascular disease have a notoriously high level of 
subclinical cardiac disease.10  The absence of clinical manifestations of cardiac 
disease may in part be due to their physiological exercise limitations.233   This is 
likely to ‘underscore’ patients with vascular disease, therefore underestimating 
the risks of post-operative cardiac events.   
We did not include patients undergoing endovascular aortic aneurysm repair 
(EVAR) in our analysis.  EVAR is associated with lower post-operative mortality 
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and reduced cardiac event rates,176 however it is uncertain whether these 
patients should still be considered as ‘high risk surgery’.  Archan et al examined 
the predictive value of the RCRI in 225 EVAR patients.58  They found a low 
cardiac event rate (6.2%), and no in-hospital cardiac deaths.  Patients with a 
RCRI Class 4 had a higher cardiac event rate and lower 1 year survival on 
univariate analysis; however this was not the case over the longer follow-up 
periods.  Similarly, patients undergoing other forms of minimally invasive 
surgery, such as laparoscopic colorectal resection have an improved peri-
operative morbidity profile.234  It is unclear if traditional risk assessment tools 
apply to these patients.   
Boersma et al retrospectively analysed the post-operative mortality of over 
100,000 patients undergoing non-cardiac surgery.101  The study cohort included 
orthopaedic (20%), abdominal (15%), ear, nose and throat (14%), gynaecological 
(14%) and urological surgery (10%).  Due to the retrospective nature of the study, 
mortality (1.7%), and in particular cardiac mortality (0.5%) was the primary 
endpoint.  They concluded that the RCRI was “probably suboptimal for 
identifying patients with greater cardiac risk”.  The authors improved the 
performance of the scoring system by adding age to the model.  Welten et al 
retrospectively reviewed the outcome of 2730 patients undergoing open vascular 
surgery (aortic, carotid and lower limb revascularisation).102  They also found 
that the predictive value of the RCRI was improved by an adjustment for age.  
These findings are reproduced in the present study. 
Ford and colleagues have performed a meta-analysis examining the uses of the 
RCRI.103  The majority of the studies included simply use the RCRI as a 
stratification tool to display data.  Only five high quality, prospectively 
performed studies were found that specifically aimed to validate the findings of 
the RCRI.  The authors conclude that the RCRI demonstrated moderate 
performance in differentiating low and high cardiac risk within mixed surgical 
cohorts.  However, a significantly inferior predictive value was found within 
specific vascular cohorts. 
The validation of scoring systems with large cohorts has largely been performed 
retrospectively.  While large numbers of patients are available for analysis, 
accurate end points are difficult.  Boersma and colleagues’ paper examined only 
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cardiac death, as the determination of post-operative non-fatal MI was not 
possible.101  In a recent editorial, Goldman identified a number of limitations in 
the published studies investigating the efficacy of the RCRI.235  These included 
the inability to accurately document pre-existing risk factors on retrospective 
chart analysis, variable post-operative screening for cardiac events and the 
inconsistent end-points used.  He reminds the reader that the RCRI was designed 
to predict only post-operative MACE. 
A limitation of this study is that routine screening for post-operative MI will 
inevitably lead to a higher event rate than experienced in day-to-day practice.  
However, the RCRI index was derived and validated on data extracted from a 
similarly screened population.  In addition, the importance of a silent infarction 
is well recognised.14  Asymptomatic myocardial injury leads to increased 
inpatient complications and reduced survival.32   
The reliance on the RCRI has been questioned in the recently published 
combined European Society of Cardiology (ESC) / European Society of 
Anaesthesiology (ESA) guidelines on the preoperative cardiac risk assessment and 
for patients undergoing non-cardiac surgery, due to its ‘suboptimal’ performance 
in patients with multiple risk factors.180  With this in mind, we conclude from our 
prospectively gathered cohort study, that the RCRI performs poorly in predicting 
post-operative cardiac morbidity and mortality following vascular surgery.  The 
inclusion of an age category improves efficacy.  Caution should be used when 
applying this index to vascular patients. 
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8 Discussion 
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8.1 Cardiac risk assessment in patients undergoing 
major non-cardiac surgery (NCS) 
The assessment and prediction of cardiac risk during and after non-cardiac 
surgery is multi-factorial.  There is no simple and universally available 
assessment technique that is effective for all surgical populations.  Ultimately, 
grouping clinical factors and assessment measures together as an easy to use 
scoring system should be superior to using individual factors in isolation.  
Identification of both simple to perform and easy to interpret tests are crucial.  
With this in mind, the studies presented in this thesis have several important 
findings; 
8.1.1 BNP is a powerful predictor of peri-operative cardiac 
morbidity, mortality and long term survival 
This study shows that an elevated pre-operative BNP is associated with an 
increased peri-operative MACE rate, increased peri-operative mortality and a 
reduced long term survival, independent of other factors. The short-term 
findings reported in this thesis are supported by several trials published 
subsequently132,203,204,220,223.  The long-term outcome study represents the 
longest follow-up data available in the literature.   
BNP appears to be a surrogate marker for a number of medical co-morbidities; 
however BNP has a far superior predictive value than the individual factors 
alone.  What then are the predictive strengths of BNP?  While patients with an 
elevated BNP have a high chance of an adverse outcome, patients with a 
‘normal’ BNP have an extremely low chance of an adverse event.  For example, 
over 40% of patients with an elevated BNP in our study had a MACE and 18% died 
in the peri-operative period.  The negative predictive values for MACE and 
mortality were 96% and 97% respectively.  Thus, these studies demonstrate that 
BNP is a predictor of adverse outcomes; however, of greater importance, a low 
BNP is highly indicative of an uneventful post-operative period.  This finding of a 
high NPV is supported by meta-analysis of other published studies.216      
We found that a cut-off BNP level of 88 pg/ml provided the best sensitivity and 
specificity for peri-operative MACE, 107 pg/ml for peri-operative mortality and 
87.5 pg/ml for all cause long-term mortality.  It is difficult to extract a 
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consensus regarding the optimal BNP cut-off point from the existing literature.  
Although several studies have been published examining the relationship 
between BNP and peri-operative MACE rate, there is considerable variation in 
study population and methodology.  The cut-off points derived from the 
individual studies range from 39-174 pg/ml.132,136,203,204,223  Studies from non-
surgical populations have demonstrated 100pg/ml as a suitable cut-off point and 
the various analyses in this thesis would support the adoption of this cut-off 
point for the purposes of surgical risk stratification.217,218          
8.1.2 Traditional cardiac variables perform poorly in prediction of 
peri-operative and long term mortality 
With the exception of a history of hypertension, none of the recorded cardiac 
variables predicted an adverse short-term post-operative outcome.  Likewise, 
with the exception of a history of LVF in a sub-group analysis of peri-operative 
survivors only, none of the cardiac variables predicted long-term survival.  
Therefore, neither IHD nor a history of a previous MI had any predictive value in 
the various analyses presented in this thesis.   There are several possible reasons 
for this.   
The first reason may be the influence of best medical therapy prescription in 
patients with a past cardiac history.  Patients with known stable heart disease 
are likely to be receiving optimal medical therapy.  The use of APAs, statins and 
beta-blockers are associated with reduced peri-operative MACE and mortality in 
patients undergoing major NCS.45,78,143,144,155  Secondly, the presence of 
subclinical heart disease may explain the lack of difference of MACE rate 
between patients with cardiac risk factors and those without.  A high rate of 
asymptomatic LVSD has previously been demonstrated in the general population 
in the West of Scotland.205  Therefore, some patients in our cohort will present 
for surgery with ‘latent’ CAD or LVSD.  Also, a proportion of our cohort was 
undergoing vascular surgical procedures.  This group has a notoriously high 
prevalence of CAD, of which a subgroup will have asymptomatic disease.10   
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8.1.3 Anaemia and urgent surgery are strong predictor of adverse 
outcome 
Pre-operative anaemia and urgent surgery, defined as surgery performed during 
an unplanned admission, were both significant predictors of peri-operative MACE 
on multivariate analysis.   
 Pre-operative anaemia has been identified as a predictor of poor post-operative 
survival.  Large database analyses (>200,000 patients) have also shown pre-
operative anaemia rates of up to one third, and a significant association with 
peri-operative mortality.213,214  In light of the considerable limitations of 
retrospective database analyses and the insufficient data we collected regarding 
the aetiology of anaemia, it remains unclear if anaemia represents a modifiable 
variable or simply acts as an indicator of other chronic diseases.   
Urgent surgery is also known to predict adverse outcome from previous 
studies.39,47  Although urgency of surgery proved a powerful predictor of both 
reduced short and long term survival, the opportunities for optimisation and 
intervention are more limited than in patients undergoing elective surgery and 
therefore these patients pose a particular challenge.  In these studies, we 
defined urgent as requiring non-elective surgery during an unplanned admission.  
Patients who underwent surgery within 24hrs of an unplanned admission were 
excluded.  Therefore, these patients had a minimum of 24hrs in hospital prior to 
surgery and in some cases several days of in-patient care preceding surgery.  
This period should allow adequate risk assessment and at least a short period of 
optimisation before surgery.  Risk stratification may also guide appropriate 
modifications in surgical or anaesthetic techniques and in certain cases, 
consideration of alternatives to operative intervention. 
8.1.4 ECG is a better predictor than traditional cardiac variables 
The results of this research demonstrate that, in this cohort, a standard 12-lead 
ECG has a superior predictive utility for peri-operative cardiac events than 
standard cardiac characteristics.  This study also highlights a sub-group of 
patients who have an abnormal ECG, but no known history of heart disease that 
is at particularly high risk of cardiac morbidity and may potentially benefit from 
risk reduction intervention. 
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8.1.5 The revised cardiac risk index performed poorly in the 
vascular sub-group analysis  
The Revised cardiac risk index is a commonly used assessment tool and is 
recommended in the American College of Cardiology/American Heart Association 
(ACC/AHA) guidelines on peri-operative cardiovascular evaluation for non-
cardiac surgery.6,179  Analysis of the vascular group of patients showed that the 
RCRI offered no predictive accuracy for peri-operative MACE, mortality or 1 year 
survival.  This confirms concerns regarding the use of this scoring system in 
vascular patients.103  Despite the poor performance in our vascular cohort, the 
RCRI remains a well validated tool for the stratification of risk in the non-
vascular setting.  The RCRI is simple to use, and is certainly the best currently 
available scoring system.  However, there appears to be a ‘gap in the market’ 
for a scoring system derived from, and validated entirely in, a vascular-only 
cohort. 
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8.2 Study Strengths and Limitations  
This was a prospective study in consecutive patients who were screened for 
post-operative cardiac events.  This resulted in a high yield of peri-operative 
cardiac events.  The study was performed in a single centre by a small group of 
investigators to limit bias and variation.  All the long term follow-up was 
performed by a single investigator. 
Since consecutive patients were included in our study, there is considerable 
heterogeneity in patient characteristics.  Thus, our patients had a broad range 
of co-morbidities and the surgical problems involved acute illness and critical 
chronic disease, such as that due to chronic progressive limb ischaemia.  While 
the prognostic value of BNP may be greater in particular subgroups, we suggest 
that the heterogeneity in our population may in fact make our results more 
transferable to ordinary clinical practice.   
We used all-cause mortality, rather than cardiac death and non-cardiac death, 
as the endpoint for analysis of our long-term results.  All-cause mortality was 
chosen as it was not possible to obtain accurate ‘cause of death’ for all patients, 
particularly when the death occurred in the community.  Nor was it possible to 
adjudicate on these events.  However, we feel that ‘all cause mortality’ is a 
very robust endpoint.  Arguably, knowledge that BNP predicts death in any form 
in the longer term after surgery represents ‘the bottom line’, and perhaps this 
result above all is most important if our research with BNP (and work done by 
others) is to be translated into clinical practice.  
During analysis of the database for this thesis, I encountered several data points 
that I considered inadequate to perform secondary post-hoc analysis.  If I were 
to repeat this study I would improve recording of the following variables; 
 Smoking status.  We recorded only for presence or absence of smoking at 
the time of admission for surgery.  I would like to have recorded packs 
smoked per day or prior smoking history.  However, self reporting of 
cigarette use is notoriously inaccurate and additional data collected may 
be inaccurate. 
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 Status of previous MI.  We recorded a history of MI as a dichotomous 
variable; we did not record specific data regarding timing of MI in relation 
to surgery or the use of coronary angiography at the time of MI. 
 Improved data collection for anaemia. As previously mentioned, the 
identification of anaemia as a powerful predictor of MACE and long-term 
mortality was not anticipated as a major finding of this study.  Therefore, 
no specific data was collected other than pre-operative haemoglobin.  In 
retrospect, data about chronicity of anaemia, categorisation of anaemia 
(i.e. haematinic assessment) or previous investigations for anaemia would 
be helpful. 
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8.3 Implications for care of patients undergoing major 
non-cardiac surgery (NCS) 
It is clear from the review of current literature and the results presented in this 
thesis that risk stratification based on standard clinical variables collected at 
pre-operative assessment alone is unsatisfactory.  Likewise, the utility of scoring 
systems, such as the RCRI, in certain circumstances is questionable.  
Identification of high-risk patients, with the use of cardiac biomarkers or by 
other techniques, allows targeted pre-operative assessment and appropriate risk 
modification.   
8.3.1 Multidisciplinary approach 
A multidisciplinary team (MDT) approach to the management of many 
conditions, such as cancer, is now routine.  A multidisciplinary approach 
standardises investigation, intervention and follow-up of such patients.  
Standardisation of the very same steps (investigation, intervention and follow-
up) seems crucial for improved care of high risk patients undergoing major 
surgery.   
A similar multidisciplinary approach to such patients would have a number of 
likely benefits.  Firstly, the patient would be offered evidence-based 
optimisation of co-morbidities by informed clinicians and the patient would have 
timely access to appropriate cardio-respiratory investigations. 
Secondly, a patient-centred MDT decision regarding progression to surgery in 
high risk patients would have the ‘corporate backing’ of the combined team in 
the event of an adverse outcome.  This should be useful for clinicians, surgeons 
and anaesthetists alike; particularly as individualised mortality figures are 
shortly to become publicly available, as they currently are in cardiac surgery.  It 
should reduce the occurrence of an inappropriate patient undergoing a surgical 
procedure based on a single clinician’s assessment.  Therefore, it is good for 
patients, good for individual clinicians and good for healthcare providers.   
With ongoing controversy regarding the role of non-invasive cardiac imaging, 
peri-operative beta-blockers and dual-antiplatelet therapy and the constantly 
evolving field of peri-operative medicine, these decisions should be made by an 
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experienced team of clinicians equipped with the current best evidence in the 
field of cardiac risk modification.   
8.3.2 Bundle of Care for High risk patients 
‘Bundles of care’ have become popular in several areas of medicine.  Enhanced 
recovery after surgery (ERAS) is an example of this.165  While individual 
components of the ERAS protocol are ‘unproven’ to improve post-operative 
outcomes after surgery, when examined in its entirety, the ERAS bundle has 
been shown in numerous trials to significantly improve outcome.166–168  The 
surviving sepsis bundle is another example of standardising the assessment and 
treatment of a clearly defined population, with an easy to follow pathway that 
has demonstrated improvements in patient outcomes.236 
Pathways, checklists and bundles are helpful tools for the standardisation of 
care.  Pre-operative assessment and risk stratification should lend itself to this 
approach.  Accordingly, a simple evidence-based care pathway, specifically for 
patients at higher than normal risk of cardiac morbidity, should be investigated 
with prospective clinical trials.   
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8.4 Areas for Future Research 
8.4.1 Natriuretic peptides 
While our study agrees with several other studies in demonstrating natriuretic 
peptides as powerful predictors of MACE and mortality, there is currently no 
consensus regarding which marker to use (BNP or NT-proBNP), or which cut-off 
point to use.141,142  Hopefully, the ongoing Vascular Events In Noncardiac Surgery 
Patients Cohort Evaluation Study (VISION) will answer these questions.  This 
ambitious multicentre project intends to recruit 40,000 patients undergoing 
major NCS.237  The study aims to document MACE rates in this large prospective 
cohort and identify predictors of adverse outcome.  The utility of BNP is one of 
the objectives of the study. 
8.4.2 Improved risk prediction scoring system 
This thesis questions the utility of the most commonly used risk prediction 
scoring system, the revised cardiac risk index (RCRI), within the vascular group.  
However, the concept of an easy to use scoring system containing several 
simple-to-record variables remains attractive.  The cohort described in this 
thesis could be used as a derivation cohort to construct a new scoring system.  A 
further observational study would be required to validate these findings. 
8.4.3 Risk reduction with High Risk Bundle 
The development of a high risk bundle or care pathway, that would require the 
multi-disciplinary involvement of various specialties, is discussed above.  The 
efficacy of such an approach, particularly with the likely increased costs 
incurred per patient would require a randomised clinical trial in order to 
establish its role in peri-operative medicine. 
8.4.4 Management of Peri-operative Myocardial Infarction 
Finally, in the absence of prospective trials examining the management of PMI, 
there is an opportunity to perform a study that would inform clinicians regarding 
the management of PMI in an evidence based fashion.  When combining MACE 
and asymptomatic troponin rise, 1 in 5 patients in our cohort had a cardiac 
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injury.  High event rates such as this, within a large centralised surgical service, 
would allow a prospective trial to be performed.  Furthermore, until such a 
study is performed, the management of asymptomatic troponin elevation 
remains unclear.     
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8.5 Conclusion 
Accurate and individualised cardiac risk stratification remains an elusive goal.  A 
single pre-operative blood test to measure BNP offers valuable information in 
the prediction of peri-operative adverse outcomes and long-term survival after 
surgery.  The predictive value of BNP appears to be superior to the traditional 
cardiac variables examined in this thesis.  The presence of anaemia at the time 
of surgery and urgency of surgery also predict adverse outcome.  However, the 
exact role of anaemia in this population requires more research.   
The continued value of the pre-operative ECG has been demonstrated in this 
cohort, and an abnormal ECG predicts adverse outcome compared with standard 
cardiac risk factors.  The presence of an abnormal ECG in patients with no 
history of heart disease may help identify a high risk group who would benefit 
from medical optimisation.   
The exact course of action to pursue after identification of a patient who is at 
higher than normal risk of cardiac morbidity is unclear.  However, further 
assessment followed by medical optimisation with anti-platelet agents, statin 
and cautious beta-blockade should be considered.  Alterations of surgical 
approaches or anaesthetic techniques, as well as an improved level of care after 
surgery are additional measures that may further reduce risk of cardiac 
morbidity.   
Finally, as surgeons, we are very focused on clear documentation of the surgical 
risks of individual procedures.  Quantification of these risks has become routine 
in the informed consent process.  More accurate assessment of the non-surgical 
complications should be included in this process in order to allow patients to 
make a truly informed decision about proceeding to or declining major surgery.  
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